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INTRODUCTION 
1.1 Rationale 
In a letter I received from Dr Morris J. Brown he wrote 'As regards 
the pathogenesis of hypertension ... I am becoming firmly of the 
view that the study of established hypertension is akin to studying 
the stable after the horse has bolted. Somehow we have to derive 
methods for studying patients while the hypertension is still 
developing'. In these two sentences Dr. Brown has formulated the 
basis of this thesis. 
At least three characteristics of "primary hypertension" make 
the study of this condition in epidemiology highly attractive and 
profitable. Firstly, hypertension is no disease in the classical 
sense, but a risk indicator for cardiovascular morbidity and 
mortality.{!) Secondly, and in close combination with the first 
characteristic, hypertension is defined by an arbitrary deviation 
from a norm, a quantitative rather than a qualitative phenomenon.(2) 
These two notions provide the opportunity . to investigate 
determinants of elevated blood pressure in relation to blood 
pressure distributions as observed in the population. Moreover, 
dynamic characteristics and responses of blood pressure to 
intervention may be studied in subjects not yet eligible for 
pharmacologic treatment of high blood pressure by conventional adult 
clinical standards, or even in normotensive individuals. Thirdly, 
the concept of an elevated blood pressure is not limited to a 
certain age group. Indeed, evidence is accumulating that the 
development of primary hypertension is the consequence of a process 
that starts early in life.{3) Therefore, the use of epidemiological 
methods, i.e., aiming at the study of health and illness in 
populations,(4) in young subjects with an increased risk of 
developing frank hypertension in the future, may clarify mechanisms 
involved in the pathogenesis of hypertension and may direct ways of 
intervention on elevated blood pressure at an early stage. 
The studies presented in this thesis were conducted on the basis 
of this reasoning. The subjects that participated in the 
investigations were characterized by a blood pressure level 
persistently in the upper part of the blood pressure distribution 
for their age group. In addition, for a number of variables they 
were compared with normotensive youngsters derived from the same 
population, and thus sharing the same environment and background. 
This was made possible by the unique availability of data on blood 
pressure and related characteristics from a cohort of 1,597 children 
and young adults living in Zoetermeer, who took part in a follow-up 
study comprising yearly examinations since 1975 (the EPOZ study). 
!2 
1.2 Structure of the report 
The main investigations of this thesis are presented in chapter 6. 
They are formed by two randomized trials on the effect of sodium 
restriction, potassium supplementation and calcium supplementation 
on the blood pressure of young subjects with mildly elevated blood 
pressure. Apart from the evaluation of the efficacy of the 
intervention, the objectives of these studies were to provide 
further insight in mechanisms involved in the association between 
dietary electrolytes and blood pressure. rn chapter 2, some 
methodological concepts of intervention studies, in particular of 
randomized trials, are discussed. Chapter 3 and 4 comprise brief 
reviews on aspects of 
hypertension, and the parts 
the pathogenesis 
played by sodium, 
of early primary 
potassium and calcium. 
some observations on differences in variables potentially associated 
with elevation of blood pressure between hypertensive and 
normotensive subjects, are presented in chapter 5. Finally, chapter 
6 will deal with theoretical and practical aspects of 
non-pharmacologic intervention on high blood pressure in childhood. 
13 
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Chapter 2 
THE RANDOMIZED TRIAL IN EPIDEMIOLOGICAL RESEARCH 
methodological aspects 
!5 
2.1 INTRODUCTION 
This chapter will deal with methodological aspects of randomized 
trials. Randomized trials are referred to here, as experiments 
involving human subjects. In a way the randomized trial is a cohort 
study, from which it differs with regard to the planned nature of 
the intervention. A second characteristic of the randomized trial is 
that the effect(s) of the intervention are 
intervention group to another group 
evaluted by comparing the 
of subjects to whom 
no-intervention or alternative intervention is given: the 
control- or reference-group. Randomized trials are sometimes called 
randomized controlled trials, but in our view the addition of the 
word "controlled" does not add to a better understanding of what 
kind of study is indicated. It is hard to see how a randomized trial 
could be conducted "uncontrolled". 
Although randomized trials can be applied to patients as well as 
to any other group of human subjects this particular type of study 
is in general known as the "clinical trial". This term is, however, 
a misnomer, as trials, like the ones discussed in chapter 6, may 
well be conducted in a non-hospitalized population, and may concern 
subjects without any known disease and thus are not "clinical" in a 
strict sense. 
Trials come in many forms but, in the present context, they have 
one single necessary attribute in common: the element of 
randomization.(!) We will briefly discuss the role of randomization 
in trials, different classifications of trials, the advantages of 
blinding procedures, aspects and implications of patient selection 
and compliance, and finally 
experimental methods in 
some problems inherent 
humans. The statistical 
to the use of 
methods and 
techniques available to evaluate the hypothesis under study will not 
be discussed here, as a number of excellent reviews provides the 
necessary details.(2-6) 
2.2 THOU SHALT RANDOMIZE 
Uncontrolled trials have the potential to give a very distorted view 
of the efficacy of a therapy or any other intervention. The use of a 
control, or reference, group permits an internally valid evaluation 
of a treatment by limiting the possibility that confounding factors 
may account for the observed effect. In addition, to attribute an 
(enhanced) effect observed in a trial to the intervention applied, 
it is essential to take any possible measure to ensure that the two 
or more groups of subjects undergoing different intervention 
regimens, i.e., intervention and control 
in any relevant characteristic other than 
16 
groups, are not different 
the treatment(s) received. 
This basic principle of the conduct of trials aims at guaranteeing 
the internal validity of a study. 
Attempts to evaluate therapeutic procedures can be traced back 
to prehistoric times.(7) Most early medical experiments are, 
however, more appropriately named quasi-experiments.{8) In 
quasi-experiments interventions are tested but the experimental or 
comparison group is not predesignated. Although the quasi-experiment 
may provide valuable information and still has a place in medical 
research, a major problem is formed by its high liability to be 
affected by bias as will be discussed below. It is mainly in the 
second part of this century that the concepts and scientific 
foundations of trials, have experienced increased attention and have 
shown an impressive growth. Pre 20th century medicine was largely 
based on uncontrolled observations, though some early attempts to 
change this attitude have been made.(7,9-ll) Lind, in 1753, 
conducted a comparative trial of the most promising treatment of 
scurvy.(l2)Twelve patients received six different treatments and 
after only six days a remarkable effect of oranges and lemons was 
observed. Although the statistical power of this study is without 
doubt rather limited, it was the first known example of the use of 
concurrent control subjects receiving alternative treatments, and 
the efficacy of the use of oranges and lemons in treating scurvy has 
been firmly established since. 
One of the first approaches developed to reduce the 
possibilities of major differences in treated patients and control 
subjects was the procedure of assigning two treatments to alternate 
patients. This 
serum against 
was applied by Fibiger 
diphteria.(13) Belmont 
in a trial 
suggested 
of therapeutic 
to allocate each 
group to one treatment by casting lots.(14) Here a random act was 
introduced to form one or more groups. Amberson and coworkers 
divided twenty-four patients into two groups "individually matched" 
by the flip of a coin.(lS) There are, however, disadvantages to this 
method as indicated by Armitage.(l6) First, the two groups, however 
carefully matched, may differ substantially in some important 
characteristics which were ignored in the matching. Secondly, there 
is no way of measuring the relevant random error, since we cannot 
tell by how much the responses in the two groups might have differed 
if the treatments had been identical: there is inadequate 
replication. 
The first genuine 
and MacKenzie in 1923 
randomization procedure was applied by Fisher 
in agricultural experiments evaluating the 
effect of manure on th~ crops of different potato varieties.{17,18) 
The first randomized trial to evalute a medical intervention in 
human subjects was 
the efficacy of 
conducted by the Medical Research Council to test 
streptomycin in the treatment of pulmonary 
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tuberculosis.(l9,20) The design of this study forms a landmark in 
the evolution of the randomized trial. In particular the 
contribution of Sir Austin Bradford Hill, member of the scientific 
committee that was responsible for the conduct of this trial, needs 
to be mentioned.(!) Several methods have since then been developed 
to carry out random assignment. Which procedure is chosen largely 
depends on the design of the trial.(16,21) 
The principal advantage of the use of randomly selected control 
subjects over a non-randomized control 
guarantee of internal validity of a 
group in 
study by 
a trial is the 
the act of 
randomization. { 22) Randomizat·ion can 
bias. The intervention(s) studied 
avoid systematic error, i.e., 
will be compared with no or 
another intervention under broadly similar circumstances. 
The potential of randomization as a means of controlling 
confounders is accentuated in the study of intended effects, as are 
most intervention studies including the ones presented in chapter 6. 
According to Miettinen,(23) perceived risk or poor prognosis 
provides an indication for intervention. Therefore the mere act of 
selecting subjects for a particular study constitutes a confounder. 
Indication is by definition a correlate of the determinant under 
study, and thus a determinant of the null outcome. 
It is often suggested that due; to randomization, groups become 
"equal" or "similar". This is in general not true. Unless very large 
numbers are included, certain dissimilarities in the distributions 
of baseline characteristics will inevitably occur, due to random 
variation. It is, however, unlikely that these will affect in 
particular those characteristics potentially associated with a 
response to 
from biased 
Accordingly 
treatment. Moreover, these differences are not resulting 
allocation, but stem from a stochastic procedure. 
valid ~omparability is assured. The argument for 
randomization is not that no truths can emerge without it, but that 
without it moderate biases can easily arise. 
Although not an advantage of randomization per se, in a 
randomized controlled design masking of the identity of treatment or 
the use of placebos is made more feasible, both on ethical and 
practical grounds, than when a predesignated reference group is 
used. As will be discussed later, blinding of both participants and 
investigators studies with blood pressure as the outcome variable is 
a prerequisite to reliably assess intervention efficacy. 
Since the early work by Hill and others in the trials of Medical 
Research council, the concept of randomization has been firmly 
established as part of the scientific basis of clinical trials. 
There remains, however, debate about the necessity of randomization. 
Various alternatives, in particular the use of historical controls, 
have been suggested.(24,25) Part of this controversy is based on the 
I8 
question whether randomization is 
already some evidence suggesting 
intervention studied. Strictly 
ethically justified when there is 
that subjects may benefit from the 
spoken the ethical basis of the 
randomized trial depends upon the absence of convincing data about 
the relative merits of a planned intervention, but in general there 
are at least indications from previous animal or non-experimental 
observations that subjects on intervention will do better than 
controls.{26) Therefore, to quote Hill •a trial should be begun at 
the earliest possible opportunity, before 
though suggeslive evidence of the value 
there is inconclusive 
of treatment. Not 
infrequently, however, clinical workers publish favourable results 
on three or four cases and conclude their article by suggesting that 
this is the method of choice, and that what is required now is a 
tri·al on an adequate scale. They do not seem to realize that by 
their very publication they have vastly increased the difficulties 
of that trial or, indeed, made it impossible' .{20) 
Another situation in which the use of randomized concurrent 
controls may be difficult is when a trial is used for a very rare or 
severe disease and the numbers of eligible patients available are 
small.(27) A clinical trial using historical controls will require a 
smaller sample size to test the null hypothesis with equivalent 
statistical power.(28) 
On ethical grounds, and to overcome some of the difficulties 
mentioned above, it is most important to inform the subjects 
eligible for a study as extensively as possible before they enter 
into the trial. The legal basis for this so-called "informed 
consent" varies in different _countries, and differences in practical 
implementation may be possible, but it has to be guarded as a 
leading principle in experimental medicine.(29) 
2. 3 DIVERSITY IN UNIFORMITY 
Characteristics as diverse as purpose, 
and a number of others have been used to 
duration, inference, design 
classify randomized trials. 
Although often arbitrarily, some of these classifications are useful 
in interpreting findings of trials with different designs and 
composition of study groups. In the follo~ing paragraphs an attempt 
will be made to inventory the main distinctions that can be made 
between different types of trials. 
2.3.1 Diversity due to the purpose of the trial. 
Three major groups can be distinguished according to the purpose of 
the trial: 
1. The efficacy of a certain therapeutic interventiot1 like a drug, 
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a surgical procedure, or a change in diet is compared with 
either no intervention at all, or with another type of 
therapeutic intervention. The participants are, in general, 
patients having a certain well-defined disease, and the 
end-points used to evaluate the intervention effect are such as 
prolongued life expectancy or a change in natural history of 
the disease studied. 
2. The assessment of intervention aiming at primary or secondary 
prevention through risk factor modification. The participants 
in this type of trial may belong to a defined population or are 
characterized by certain individual behaviors, biological 
factors, or aspects of the environment. Endpoints to evaluate 
the value of the intervention may be indicators of reduced 
risk, i.e., reduced incidence of the disease, or a reduction in 
mortality. Also, a change in the level of a risk factor may be 
used to evaluate the intervention. These studies are sometimes 
referred to as prophylactic trials or field trials. 
3. The randomized trial can be used to identify causal or 
pathogenetic mechanisms involved in the aetiology of a disease 
or an increased risk. The experiment enables a maximum of 
control by the investigators over the study situation 
permitting to isolate the effect of one single factor on a 
defined condition. It is a very powerful tool in the study of 
causality. This type of study can be conducted in patients as 
well as in normal healthy subjects, depending on the questions 
under study. 
Obviously, type 1 and type 2 studies can provide type 3 information. 
A trial can, however, be planned exclusively to assess and quantify 
the relation between a certain factor, like the intake of 
sodiumchloride, and another variable, like blood pressure. The 
intervention studies presented in chapter 6 show a combination of 
type 2 and type 3 purposes. By measuring not only the change in 
blood pressure, but also a number of outcome characteristics as 
indicators of mechanisms involved in blood pressure regulation, an 
attempt has been made to clarify the way whereby certain 
electrolytes may affect blood pressure. 
2.3.2 Diversity due to the inference of the trial. 
Another distinction, originally made by Schwartz and Lelouch,(30) 
primarily concerns type 1 and 2 trials. They propagated the concept 
of nexplanatory" and "pragmatic" approaches. The explanatory trial 
seeks to determine whether one treatment is more effective than 
another or no treatment, while the objective of a pragmatic trial is 
to demonstrate which of two treatments, when administered in the 
population at large, will give better results. In other terms, the 
first approach aims at understanding, while the second aims at 
decision-making. Consequently, treatment may be defined in two ways. 
Either ordinary current practice may be adhered to ("normal" 
conditions}, or else more 
which could only be met 
exacting conditions 
in the course of a 
may 
trial 
be introduced 
{"laboratory" 
conditions}. The implications of this distinction will be observed 
not only in the form in which a certain intervention is applied. 
Also, it may affect the selection of participants invited to enter 
the trial. In a pragmatic trial the study groups may need to reflect 
the whole spectrum of patients expected to be eligible for 
treatment. In an explanatory study, as in a type 3 study, one may 
select subjects expected to respond andjor comply well to a certain 
intervention.(3ll This concept has been extended by Feinstein.{32} 
In his view the two approaches may have differences in impact, not 
only on policies aiming directly at answering the questions raised 
by practicing clinicians or workers in basic medical research, but 
also on the way in which the trial is designed and how the data are 
analyzed, in a manner that will yield unbiased results. Therefore 
Feinstein, somewhat sceptically, proposed to use the term 
"fastidious" 
Miettinen has 
instead of explanatory. 
suggested to describe 
Within this same framework 
the objective of a trial as 
"premise" or "practice" evaluation.(33) 
2.3.3 Diversity due to the stage of an investigation. 
A third classification is the proces of the 
development and testing 
Phase I trials. The 
of 
in particular used in 
a new drug:(21) 
fir,st experiments with 
of this type of study 
a new drug in humans. 
is to evaluate the The main purpose 
clinical pharmacology and toxicity of a drug. Participants are 
volunteers and in general randomization procedures are not 
used. 
Phase II trials. These studies are conducted as an initial 
clinical investigation 
numbers of patients are 
to assess the treatment effect. Small 
closely monitored. Here also in general 
no randomization is carried out. 
Phase III trials. These trials are randomized clinical trials, in 
a strict sense, with purposes as summarized for type 1 trials. 
Participants in these studies are randomly allocated to one of 
two or more treatment groups. 
Phase IV trials. This term is used for postmarketing 
surveillance, moni taring of side effects, as well as for 
marketing and promotion activities itself. 
This classification involves four types of so-called trials but only 
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one of these (phase III) can be regarded as a genuine randomized 
trial. Moreover, explanatory aspects most clearly form the basis for 
phase I and II trials, while phase IV is in general entirely 
pragmatic. The terms are, however, frequently used and they are not 
necessarily restricted to trials involving new pharmaceutical 
products. 
2.3.4 Diversity due to duration of the trial. 
Yet another classification of subtypes of experiments was made by 
Kleinbaum et al.(34) They defined three groups of trials based on 
the approximate duration of the study and the selection of subjects: 
1. The laboratory experiment. This type of experiment has the 
shortest duration, hours to days, and is used to estimate acute 
biological or behavioural responses 
believed to be indicative of risk 
to a certain intervention, 
for a disease. The study 
population is seldomly representative of the target population 
and may indeed be very, highly restricted. 
2. The "clinical" trial. This type has a longer duration, from 
days to years, and is usually restricted to a selected 
population, such as a group of screened subjects, diagnosed 
patients or other volunteers. 
3. The community intervention trial. This type of intervention 
study has a long duration, at least six months, and is 
conducted within a particular sociopolitical context of a 
naturally formed population (community). These studies are 
predominantly dealing with aspects of primary prevention by 
intervention on single or multiple risk factors. 
2.3.5 Diversity due to the design of a trial. 
The parallel-group design. 
In the discussion on randomization in the previous paragraphs the 
element of comparison was based on comparisons between subjects. The 
subjects that are compared are randomly allocated to one, or more, 
treatment and reference groups. This method of conducting trials is 
called a "parallel-group" design, and it has implicitely been used 
as "the" example of a randomized trial in the two introductory 
paragraphs of this chapter. 
The crossover trial. 
As subjects tend to express a wide variation in response to 
treatment and the efficacy of most interventions is only moderate, 
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substantial numbers of participants are needed to reliably assess 
treatment effects in conventional parallel group studies.(35} This 
phenomenon has resulted in recent years in a number of very large 
multicentre randomized trials.(36) However, under certain conditions 
it is possible to apply two or more types of intervention, e.g. two 
types of drugs, to one subject over several equal periods of time. 
The advantages of within-subject comparisons were already 
appreciated in the second half of the nineteenth century, when 
Claude Bernard conducted his first experiments in physiology by 
comparing the effects of successive treatments applied to one 
preparation.(37} The crossover study was introduced in medicine in 
1950, when Quin and coworkers performed a trial on the effects of 
various agents on rheumatoid arthritis. 
Within subject comparisons have several advantages over between 
subject comparisons. The influence of patient characteristics that 
determine the general level of response can be "subtracted out" of 
the treatment comparison. Biologic variation within an individual 
can, of course, not be removed, but if within subject variability is 
small relative to between subject variability, a crossover design 
based on a small sample of subjects can provide the same statistical 
power as a much larger parallel study.(38,39) Therefore, research 
questions may potentially be answered with the use of relative small 
groups, and;or the same study group may be used to answer multiple 
questions. This is illustrated by the crossover intervention study 
on sodium, potassium and blood pressure reported in chapter 6. 
Crossover trials have besides advantages also some serious 
disadvantages, which 
attractive.(39,40} The 
but one 
make their use in many 
main problem is, that one may 
studies 
compare 
less 
the 
wants to compare "similar" baseline same subjects 
states.(32) If a patient receives one treatment for two weeks and a 
second treatment in the next two weeks, one must be assured that he 
has the same baseline state at the inception of both treatments. 
This condition may be affected in two ways. Firstly, serial changes 
resulting from either changes within an individual (like a reduction 
of symptoms}, or from environmental changes (like seasonal 
influences}, may make the first baseline status different from the 
second "baseline" status. Secondly, a particular treatment may have 
carry-over effects which influence the second period. As a remedy 
for the latter phenomenon a wash-out period, with no effective 
treatment, is sometimes used. Both the magnitude of serial and of 
carry-over effects can be tested by statistical methods. Moreover, 
various statistical techniques allow adjustments for trends and 
carry-over effects.(41} However, when the results of a trial suggest 
a definite interaction between treatments and periods, a treatment 
comparison should be based on the first period alone. A potential 
hazard is, that tests lack sensitivity to adequately establish 
definite interaction, 
study is based on 
mainly because 
the purpose of 
the statistical power of the 
assessing treatment, not 
interaction, effects. 
A special type of carry-over effect may occur when the treatment 
applied affects a deficiency resulting from long-term relative 
shortage of a certain factor, e.g. vitamin B-12 in pernicious 
anemia. In these instances, removal of the underlying cause of 
disease by eliminating the deficiency may seriously disbalance 
treatment periods. 
As a general rule, as long as the existence and magnitude of 
carry-over effects of a certain intervention are not yet firmly 
established a crossover design should not be the first choice. This 
reasoning made us to conduct the 
crossover design, whereas for the 
design was used (paragraph 6.2). 
sodium-potassium trial 
calcium trial a parallel 
in a 
group 
The effects of serial changes on the study outcome may be 
eliminated by an equal distribution of possible sequences of 
intervention between groups of equal number. This is realized by the 
randomization procedure commonly applied in crossover studies. 
Participants who enter into the trial are randomly allocated to one 
of the possible sequences (two sequences in a two-period crossover 
study and six in a three-period crossover study etc.). 
Crossover trials are very powerful in the evaluation of small 
effects in groups of limited size. However, although the crossover 
design has the potential advantage of economy and of providing a 
direct comparison of intervention within the same subject, the 
parallel group design allows a more straightforward data-analysis, 
and its efficacy is less dependent on assumptions about the process 
of the disease or condition under study. 
2_4 BLINDING PROCEDURES 
Confounding bias has already been mentioned as a serious threat of 
the internal validity of a study. A problem that may, however, 
effectively be reduced by randomization procedures. Another source 
of bias encountered in the conduct of a trial is "information bias" 
or "assessment bias". Blinding of participants, investigators, or 
both, for the treatment ~applied in a trial may minimize the 
distortion that 
whether a certain 
group. The use 
may. occur when either of these groups is aware 
participant is in the treatment or the reference 
of placebos, an inert and innocuous substance or 
situation closely resembling the treatment employed in a study, may 
provide a possibility to make blinding practicable. The word and 
concept of a "placebo" were first used in a medical trial by Diehl 
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and coworkers, using a saline solution as a control treatment versus 
prophylactic vaccinations against colds.(42) 
of blinding procedures in trials has been 
although still many research workers as 
Since then, the value 
widely recognized, 
well as practising 
clinicians question the need of blinding as a conditio sine qua non 
in evaluating treatment effects. As indicated in the previous 
paragraphs, randomization is a safeguard against sources of bias 
potentially affecting treatment evaluation. one might wonder whether 
this is not enough of a guarantee to obtain unbiased results. There 
remain, however, ways in which bias may occur, when everyone 
involved in the trial is aware of which treatment each patient is 
receiving. The problems that may give rise can be summarized by the 
categories of participants in the trial:(21) 
The subjects undergoing treatment. When a subject is aware 
whether he receives the intervention or the control 
treatment, this notion may affect the outcome of the 
intervention by psychological mechanisms. For example, 
subjects changing their dietary habits in a randomized 
trial studying dietary effects on elevated blood 
pressure, may also try to more lose weight or increase 
physical activity, in contrast to a reference group 
receiving no intervention at all. Obviously, the extent 
to which these factors are of relevance in a particular 
study is depending on the nature of the intervention and 
the type of endpoints used to evaluate treatment 
efficacy. Also, knowledge of the intervention may affect 
a subject's attitude towards compliance, attendance for 
evaluation etc., resulting in increased numbers dropping 
out in one of the groups or an unequal distribution of 
compliance across intervention groups. 
The treatment team. Those involved in the practical conduct 
of the study, 
assistants or 
for example 
dieticians, form 
physicians, research 
the treatment team. 
Knowledge of intervention status of the subjects in the 
study groups by members of the treatment team may affect 
the outcome of the study in particular when decisions 
must be made on dose modification, frequency of 
evaluation, need for additional treatment, or adjustment 
of the diet during the trial. Also, subjects known to 
receive a new and promising treatment might be monitored 
more closely than those on a control treatment. Indeed, 
for several reasons, physicians in these situations may 
inadvertently treat control subjects as a second class 
group.(43) 
Those performing the evaluation. One key is that those 
responsible for assessing patient outcomes are as 
objective as possible. There is potential danger that 
evaluators will err towards more favourable responses on 
the new treatment. Assessment bias may occur in 
particular when the evaluation of the response is based 
on subjective criteria involved in clinical judgement. 
the Medical Research This concept was emphasized 
Council's first randomized 
in 
trial on streptomycin in 
pulmonary tuberculosis: 
X-ray shadows was 
the extent of improvement 
determined independently 
of 
by 
individuals, ignorant of the treatment schedule.(19) To 
reduce assessment bias in the measurement of study 
endpoints, it is also possible to 
objectivity of the data derived from 
increase the 
certain devices 
used to measure these. For example, the London School of 
Hygiene and Random Zero sphygmomanometers were developed 
to reduce observer bias in blood pressure 
studies.(44,45) The latter of these devices was used 
throughout the studies presented in this book. 
To achieve blinding of either of these groups for intervention 
status, several methods have been developed. According to which of 
these groups is blinded a trial is classified single or double 
blind. Stricktly spoken, as three groups are involved, a trial could 
be triple blind. In general, those carrying out the trial in 
practical terms are often also performing the evaluation of the 
results and the latter term is never used. 
There are some additional 
may avoid 
subject is 
advantages of blinding in a randomized 
interference with the randomization 
liable to refuse cooperation after 
trial. Blinding 
process if a 
discovering that the undesired treatment was allocated. Furthermore, 
blindness may prevent individual ethical qualms when a potential 
effective agent is being compared with a control treatment. The ways 
in which the process of double blinding may be checked have been 
reviewed by investigators of the Aspirin Myocardial Infarction 
Study.(46) A special method of achieving blindness that is often 
applied is the use of a placebo. A placebo can be any type of 
treatment, exactly 
any known effect. 
psychotherapy, but 
the same as the true intervention, but lacking 
This may be a placebo· drug, or a placebo 
also a placebo "reduced sodium intake" as shown 
in the sodium-potassium trial presented in paragraph 6.1. It is, 
however, not necessarily true that a placebo has no effect on the 
condition under study when no rationale exists for therapeutic 
efficacy of the placebo given. The mere act of providing for example 
placebo pills may well affect subjective, or even objective, aspects 
of disease or feelings of well being, the so-called "placebo 
effect".(47,48) Therefore it may be an advantage as well as a 
problem to exclude any placebo effects by using placebos as a 
control treatment, since a placebo can without doubt have beneficial 
properties. This may be dependent on the ultimate goal of a trial in 
analogy with the differences in approach between explanatory and 
pragmatic trials. Placebo effects must either be equalized between 
the two groups (explanatory approach), or included within the "true" 
effect (-pragmatic approach). ( 30) 
Apart from the value of blinding procedures in intervention 
studies, these may also evoke Specific problems. A main problem may 
arise when efforts to preserve double blindness affect the original 
design or protocol of the study. The investigators may be forced to 
modify the intervention originally planned when it appears that 
blinding is not feasible. In a 
placebos may be unavailable. 
rather trivial situation, adequate 
This happened, for example, in the 
calcium study presented in chapter 6. At first it was decided to use 
calcium tablets permitting a single dose daily. The company 
producing these tablets had, however, major problems in creating 
placebo tablets with the same organoleptic characteristics as the 
vera tablets. Therefore it was decided to use calcium citrate 
powders in a dosage of nine a day. This did, according to our 
impression, affect compliance and resulted in the cessation of use 
of powders during the trial by some, and a reduction in overall 
effective dosage for the total group 
Furthermore, a particular placebo 
qualified subjects to participate 
towards the end of the study. 
intervention 
in the 
may 
trial. 
distract 
In the 
sodium-potassium trial (paragraph 6.1) the notion that, during part 
of the study, the effort put in reducing sodium intake would be 
counteracted by the concurrent use of sodium tablets, made several 
subjects decide not to participate. Other problems associated with 
blinding may result from ethical considerations. As stated in a 
Lancet editorial, patients in randomized, trials might be 
"deceived".(49l Furthermore, it may be ethically unjustified to 
assign a subject to placebo intervention when an alternative 
standard therapy with established efficacy is available.(43,50,51) 
Finally, for some interventions appropriate blinding by placebo 
maneuvers is virtually impossible to achieve. An example of this is 
provided by the difficulties in assessing the effects of alcohol on 
blood pressure in a double blind fashion.(52) In conclusion, where 
randomization is a basic characteristic of the trial, the extent to 
which and the procedures whereby blinding must be achieved is 
depending on the nature of the intervention, the condition to which 
intervention is applied, the methods to assess efficacy, and the 
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type of endpoint studied. With regard to intervention aiming at a 
response in blood pressure, in our opinion, 
This may be illustrated by a comparison of 
restriction and blood pressure as presented 
blinding is crucial. 
studies on sodium 
in chapter 4 (4.1}. 
Blinded studies showed an overall 40% lesser response in systolic 
blood pressure to intervention than open studies suggesting that 
knowledge of intervention status may substantially affect the 
results. 
2.5 SELECTION OF PARTICIPANTS AND GENERAL APPLICABILITY OF FINDINGS 
A precise definition of which patients are to be included in the 
trial is essential whatever type of trial is planned. When a type 1 
or 2 study is conducted from a pragmatic point of view, the subjects 
included need to be representative of the future population to whom 
the intervention, if effective, is going to be applied. Therefore, 
one must try to include as large as 
subjects satisfying the entry criteria 
possible a 
for the 
proportion of 
study. If not, 
general recommendations based on the results of the study may be 
spurious or, in other words, the external validity of the trial is 
reduced. For an explanatory trial, or an intervention study designed 
to give information on aetiological aspects, it may be important to 
select subjects in whom the maximum benefit, as indicated by the 
objectives 
is aimed 
of the study, can be expected. 
at scientific understanding. 
The explanatory approach 
In these instances, 
representativeness for a larger group of subjects or general 
applicability of the intervention procedure is of lesser importance. 
Due to the strict protocol and the planned character of the 
intervention applied in the trial, in combination with randomization 
and possibly the use of a placebo or other measures to blind those 
in the trial for the intervention, a substantial number of potential 
participants may drop out even before the study has started. The 
number of subjects entered into the trial is liable to be dependent 
on a "filtration proces". As in any cohort study the filtration 
proces eventually resulting in the study groups can be cited 
according to eight different populations:(32) 
1. The target population. Essentially, these are the people to whom 
the results of trial will presumably apply when generalized. 
This population consists of all subjects sharing a particular 
condition to which the intervention maneuver is assumed to be 
directed. 
2. The available group. This group consists of those individuals 
belonging to the target population that are part of the 
population or group in which a particular group of researchers 
is working and planning to conduct the trial. 
3. The candidate group. These are those members of the available 
group that come to the attention of the investigators. For 
example, when a study is going to be performed within a cohort 
study that has already started, some members of this cohort 
may temporarily or definitely have ceased to participate or 
attend certain examinations. 
4. The eligible group. Those members of the candidate group that 
fulfill the criteria to be entered into the trial are eligible 
for the study. These criteria may be of very different nature, 
like a set of diagnostic criteria, age or living distance from 
the research centre. 
5. The qualified group. This group consists of those eligible that 
are not to be excluded because of certain exclusion criteria 
like the use of a certain drug or pregnancy. 
6. The receptive group, is formed by those that are qualified and 
thereby willing to participate according to the protocol. The 
act of randomization, or the use of a placebo as well as the 
necessity to undergo a certain intervention, like a reduction 
in sodium intake, may well prevent people to join the study 
group. 
7. The admitted group. The receptive group forms in general the 
group that can enter the study and is then called the admitted 
group. When the receptive group is too large to be studied in 
a certain protocol, 
selecting an admitted 
the number may be reduced by randomly 
group from the receptive group. This 
group is then randomized into one or more intervention and 
control groups, or intervention sequences in case of a 
crossover study. 
8. The counted group. Some subjects may drop out just before 
intervention starts, but after randomization. This can result 
from a variety of causes ranging from the participant changing 
his mind, to an adverse drug reaction. 
In any of the phases of the filtration process the number of 
subjects forming the next group will reduce. For most studies it 
will be difficult or impossible to accurately establish to what 
extent all these different steps have contributed to the overall 
reduction. It may follow, therefore, that any discussion on general 
applicability of the results of the trial is arbitrary to begin 
with. The aim of the study, explanatory or pragmatic, therapeutic or 
aetiologic, will determine how much effort is to be put in getting, 
and keeping, all eligible subjects into the trial. This may even 
affect the design of the trial or prompt the investigators to alter 
the protocol of the study. However, in face of external validity of 
a study, it is important to report the number of eligible subjects 
and, when possible, indicate reasons why this number is different 
from the number of participants, when the results of a trial are 
presented. 
2.6 BENEFITS AND COSTS 
The randomized trial is one of the most powerful tools in 
epidemiological research. 
unequivocally the efficacy 
deliberately altered factor 
It provides the only way to establish 
of intervention, or effect of any other 
on a given condition. The randomized 
trial may be used to evaluate pharmacologic and non-pharmacologic 
treatment, to establish the value of prophylactic measures and to 
test a hypothesis of causality. 
The conclusions drawn from randomized trials stemm from 
comparisons between or within subjects. The basic methodological 
concept underlying these comparisons is randomization. The 
randomization procedure forms a safeguard against unspecified 
disturbances affecting the internal validity of a study, in 
particular selection bias and confounding, by assuring that any 
dissimilarities between study groups is solely due to random 
variation, i.e., to chance. 
Randomization creates, however, also problems in handling 
differences in baseline characteristics between groups. These 
problems are 
characteristics 
aggravated when differences 
potentially associated with 
ace 
the 
observed in 
outcome of the 
intervention applied, which constitutes confounding by definition. 
Probabilistic statistical methods cannot be used to test any 
baseline differences because, due to randomization, the 
null-hypothesis that any unequal distribution of characteristics 
between groups is only due to chance is invariably true. one can 
even calculate the distributions of differences between baseline 
variables 
of times. 
particular 
higher in 
It is 
when randomization should be performed an 
What then should be done when, for 
study baseline blood pressure_ levels are 
infinite number 
example, in a· 
substantially 
the group receiving a placebo than in the treatment group? 
conceivable that this would erroneously lead to an 
overestimation of treatment effects as there was a difference 
between groups to begin with. When, however, adjustments are made 
for baseline d"ifferences in blood pressure, for example by comparing 
change in blood pressure rather than difference in blood pressure on 
intervention, bias may be introduced because of the selective 
adjustment of a variable potentially associated with the 
intervention and the outcome. Moreover, this will deliberately 
affect the baseline state and thus could be seen as an elegant way 
to spoil the randomization. Therefore, in a strict 
is between either no adjustments at all, or 
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sense, the choice 
adjustment for 
differences in all variables of which, nonetheless, only a limited 
number are included in the study. The latter might be achieved by 
calculating the coefficients of multiple regression between all 
baseline variables and the achieved blood 
intervention in the control group, and use these to 
in blood pressure in the treatment group. Thus, the 
pressure under 
adjust changes 
choice would be 
between a multivariate analysis or just comparing means of the 
outcome variable. As an alternative approach the use of a confounder 
score, made up of several potential confounding variables, for which 
multivariate adjustments are made, has been suggested.{33) This, 
however, seems a compromise that is not easily justified, as it may 
even increase the arbitrary nature of the adjustment. In practice, 
for only the 
one, 
quantitative 
or for all 
difference in outcome when adjustments 
baseline variables are made, will presumably in 
general 
kind of 
be limited. Nevertheless, this is largely dependent on the 
intervention and outcome, on the condition or disease 
studied, and on the number of subjects included. 
In conclusion, it may seem that, due to the solid methodological 
foundation of the randomized trial, everything is under control. 
This apparent control, however, may also induce serious analytical 
problems. The highly structured nature of the randomized trial forms 
both the power and the weakness of this type of research. Apart from 
the great advantages summarized in the previous parts, the apparent 
rigidity of the design implies that, for example, more complex 
associations and 
impossible, to 
procedures pose 
multiple 
study. 
ethical 
interventions are rather difficult, if not 
Moreover, randomization and blinding 
problems to the study of certain 
interventions and may impair compliance. The way in which balancing 
costs and benefits will affect the nature and design of a study is 
determined by the scientific question posed, but also by practical 
considerations of resources, both in terms of funding and 
participation. 
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Chapter 3. 
SOME ASPECTS OF THE EARLY PATHOGENESIS OF PRIMARY HYPERTENSION 
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3.1 Introduction 
This chapter provides a short treatise of the pathogenetic 
mechananisms that have been described in primary hypertension, and 
in particular of those mechanisms that may 
phase. There is a substantial literature 
play a part in its 
on this subject to 
early 
which 
reference will be made when appropriate. The scope of this chapter 
is, however, to place the data provided in the following chapters in 
a pathophysiological perspective and no effort is made to give an 
extensive review of the work accomplished in this area. Although 
hypertension is commonly classified into primary ("essential") 
hypertension and secondary hypertension with a known pathological 
cause,(l) elevation of blood pressure whatever its cause inevitably 
results from alterations in one or more of the systems that regulate 
arterial pressure.(2) Changes in pressure regulating systems and the 
resulting rise 
disturbances,(3) 
in blood pressure are not necessarily 
as they may serve a defined purpose. In these 
instances high blood pressure may be seen as a side-effect, be it 
harmful, of a homeostatic response. For example keeping the renal 
blood flow intact behind a stenosis. In primary hypertension, 
however, the physiologic value of the increased systemic pressure is 
unclear and what remains are the defenite effects of high blood 
pressure on cardiovascular morbidity and mortality. Because of this 
notion, use of the term "essential" hypertension should be omitted, 
as this term suggests that the elevated pressure is of importance or 
even indispensable in an individual. In 
some remarks will be made on the 
hypertension. In addition, the promises 
measurement of catecholamines in the 
the next three paragraphs, 
haemodynamics of early 
and difficulties of the 
study of elevated blood 
pressure will be discussed. These notions serve as an introduction 
to chapter 5, paragraph 5.1. 
3.2 Haemodynamics in hypertension 
Under normal circumstances, at rest as well as during various 
stressful conditions, the blood pressure in the systemic circulation 
is kept within certain limits. The circulation may be regarded a 
system of "fluid" running through "tubes".(4) The relation between 
the total blood flow (cardiac output) and the total peripheral 
resistance is constantly regulated and a rise in blood pressure will 
essentially be determined by a rise in either of these factors or in 
both. This notion can, according to Poiseuilles law, be 
mathematically described by the function MAP~f(CO,TPR) (MAP: mean 
arterial pressure, CO: cardiac output, TPR: total peripheral 
resistance) .(5) Notwithstanding that, strictly spoken, this function 
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is only valid for a laminar flow it satisfactorily describes the 
physiological basis for a deviation of systemic blood pressure from 
its normal range. 
The haemodynamic mechanisms behind increased pressure vary. 
Firstly, they depend on on the cause of hypertension. For primary 
hypertension it is generally been accepted that the main 
haemodynamic characteristic in adults is an increase in total 
peripheral resistance, with cardiac output being usually lower than 
in normotensive subjects of the same age.(6,7) Central haemodynamics 
in primary hypertension may, however, be different at different 
ages.(6-12) As has been mentioned, a change in blood pressure 
results either from a change in cardiac output and/or from an change 
in total peripheral resistance. Both these two determinants may 
represent functional modifications in the contractile state of heart 
or vessels, or relate to structural alterations in these organs. In 
this chapter we will discuss the evidence relating cardiac output 
and total peripheral resistance to elevated blood pressure in the 
young. 
3.3 Haemodynamics in the onset of primary hypertension 
There is a ongoing debate on the haemodynamics in the course of 
elevated blood pressure in childhood. Two hypothesis compete.(8) The 
first hypothesis states that primary hypertension in its early state 
is characterized by high cardiac output which, as a secondary 
phenomenon, initiates a rise in peripheral resistance. The 
importance of the elevated cardiac output then gradually decreases 
and finally hypertension is maintained solely by raised peripheral 
resistance. According to the second hypothesis, elevated blood 
pressure at all ages is related to an increase in peripheral 
resistance. 
The concept of elevated cardiac output leading to elevation of 
arterial blood pressure was put 
1914, and further elaborated 
forward by Patterson and Starling in 
by Borst and Borst-de Geus in 
1963.(13,14) In this concept, increased cardiac output leads to 
hyperperfusion of the tissues, and as an autoregulatory response 
vasoconstriction will result. There is considerable confusion about 
the use of the term "hyperkinetic circulation" in this respect.(l5) 
It appears, however, appropriate to apply this term to the proposed 
elevated cardiac output in the initial state of elevated blood 
pressure. The characteristics of the subjects in which the 
haemodynamics of early hypertension have been studied vary markedly, 
as do the methods used to assess cardiac output.(S) In some studies 
a debatable definition of the stage of hypertension, "labile" or 
"borderline", was used as an indicater of early hypertension, while 
in other studies the age of the subjects, i.e., young subjects with 
elevated blood pressure, determined the existence of early 
hypertension. Essentially, two different approaches have been used 
in determining cardiac output, the first being invasive, the second 
non-invasive by means of echocardiographic methods. 
The haemodynamic abnormality in prolongued primary hypertension 
rests in an elevation of peripheral resistance. According to a 
number of studies, in hypertension in its early phase cardiac output 
is elevated in combination with a normal total peripheral 
resistance.(5,6,15-20) In these studies invasive methods were used 
to evaluate cardiac output in young subjects and hypertensive 
subjects classified as labile or borderline. Observations in young 
hypertensive subjects using echocardiographic methods to measure 
cardiac output have, however, not confirmed these findings.(21-24) 
The study presented in chapter 5 of this thesis also is at variance 
with earlier findings which have suggested elevated cardiac output 
in early hypertension. In our study, although a substantial 
difference in blood pressure between the two groups was present, 
cardiac output and cardiac index was similar in hypertensive and 
normotensive subjects. 
Findings in studies using invasive methods to determine cardiac 
output may record a different haemodynamic response to the stress 
evoked by the method applied, in hypertensive as compared to 
normotensive youngsters, and may thereby present an epiphenomenon of 
the procedure. 
At present, evidence for a hyperkinetic or high-cardiac output 
state in early hypertension is unconvincing,(8) and appears to favor 
the concept that primary hypertension from its early phase is 
characterized by elevated total peripheral resistance. 
3.4 Catecholamines in hypertension 
Most of the haemodynamic characteristics of both early and 
established hypertension may be explained by 
sympathetic nervous system.(25) When some 
participation of the 
fifteen years ago 
catecholamines became sensitive 
available, 
techniques for 
and evidence 
measuring 
increased 
plasma 
that those levels reflect 
study of this relationship in 
At one time it was thought that 
characterized by sympathetic 
sympathetic neural activity, the 
hypertension became feasible.(26) 
all hypertensive subjects were 
overactivity.(27,28) This could not 
conducted thereafter.{29) Still, 
be confirmed by 
there may be a 
most studies 
subgroup of 
hypertensive individuals with elevated catecholamine levels. In 
particular, studies in children and young adults showed a consistent 
pattern of higher noradrenaline levels in hypertensive subjects than 
• 
in normotensive subjects.(30) Findings concerning plasma adrenaline 
levels are less conclusive, and a limited number of studies on 
plasma dopamine were all showing nonsignificant differences between 
normotensive and hypertensive groups.(30) 
Several methodological difficulties may explain the inconclusive 
findings. The use of plasma levels of catecholamines, and in 
particular of noradrenaline, has been criticized by some authors in 
that its use may provide only a crude index of sympathetic nervous 
system activity, and lack sensitivity.(31) In addition, it has been 
suggested that, when overall sympathetic activity in hypertensive 
subjects turns to be similar to normotensives, regional differences 
in organ-specific sympathetic nervous tone could eventually reflect 
the role of the autonomic nervous system in the elevation of blood 
pressure.(32) 
Nevertheless, even though these considerations may account for 
some of the negative findings in studies reporting catecholamine 
levels in hypertension, they do apply less to studies in which 
sutstantial differences in one or more plasma catecholamine levels 
were observed. Furthermore, although techniques are developed to 
more specifically 
they still are of 
measure regional sympathetic nervous activity, 
limited practical use in the study of larger 
groups of subjects. Also, these methods are usually based on the 
infusion and measurement of isotope labelled catecholamines, which 
may disturb any physiological associations that exist between 
various catecholamines. 
Goldstein, in his review of studies on sympathetic nervous 
activity in hypertensive and normotensive subjects, has pointed at 
another source of difficulties that may account for the inconclusive 
findings in a number of studies.(30) In particular differences 
between hypertensive and normotensive groups with regard to source 
population (for example, hypertensive patients compared with 
laboratory personnel serving as a reference group), age 
(hypertensive patients were often older, and plasma noradrenaline 
levels may rise with age), and a number of other factors, may lead 
to spurious results. 
that when patient 
However, Goldstein in the same review concludes 
age and other factors were considered 
simultaneously, virtually all studies of young, established 
hypertensives were positive with respect 
A third remark that may be made 
to plasma noradrenaline. 
on the interpretation of 
differences in catecholamine levels between hypertensive and 
normotensive groups is that these reflect 
between these subjects.(31) The discomfort 
increase catecholamine levels more in 
differences in arousal 
of venipuncture may 
hypertensive subjects. 
Although an interesting observation by itself, this would indicate 
that basal sympathetic activity need not be altered in hypertension. 
This suggestion calls for the need of an indwelling catheter when 
obtaining plasma samples in this type of study as a partial remedy. 
In the comparative study presented in chapter 5.3, an attempt 
has been made to take the aforementioned issues into account. 
Hypertensive and normotensive subjects were selected from the same 
population and were all within a narrow, young, age group. Moreover, 
an indwelling venous catheter was used to obtain blood samples and 
hypertensive and normotensive subjects were all studied according to 
the same strictly standardized protocol. This led us to conclude 
that not only average plasma noradrenaline levels may be elevated in 
young hypertensive individuals, but also substantial differences may 
be observed in plasma adrenaline and dopamine levels. The latter 
finding is of particular interest, since attention has recently been 
raised for a putative role of dopamine in a number of renal and 
cardiovascular mechanisms that may be associated with blood pressure 
regulation.(33,34) Dopamine may have hypotensive properties, for 
example by counteracting some of the blood pressure raising effects 
of noradrenaline. Finally, interrelationships between catecholamines 
were studied, and the observations were suggestive of altered 
associations between the various catecholamines in hypertensive 
subjects compared to the normotensive reference group. A 
differential arousal between these groups seems unlikely, as no 
significant differences in pulse rate were observed. 
Definite conclusions about the part played by the sympathetic 
nervous system in elevated blood pressure can not be made at 
present. However, the observational evidence favours the assumption 
that the autonomous nervous system may be altered in hypertension. 
In addition, theoretical considerations have pointed at the 
plausibility of initiation and aggravation of high blood pressure by 
sympathetic (over-) activity.(2,12,35,36) 
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Chapter 4 
ELECTROLYTES AND BLOOD PRESSURE 
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4_1 INTRODUCTION 
The blood pressure level of an individual is the result of an 
interaction of both genetic and environmental factors, of an 
interplay between nnaturen and nnurture"-(1,2) Nurture includes a 
variety of factors of which some dietary constituents have been most 
extensively studied-(3,4) Although the magnitude of the effect of 
dietary factors, relative to other environmental influences, is not 
yet clearly established,(S) the role played by the diet, in 
particular by dietary electrolytes, in the pathogenesis of high 
blood pressure has become increasingly clear. In this chapter we 
will briefly discuss observational and experimental evidence that 
links three major dietary electrolytes, sodium, potassium and 
calcium, to blood pressure. In addition, an attempt has been made to 
indicate possible pathogenetic mechanisms that may explain the 
putative role played by these dietary constituents in blood pressure 
regUlation. The considerations expressed in these reviews played a 
part in the design of the intervention studies presented in chapter 
6, and some of the questions put forward by the current theories 
have been addressed in these experiments. One of the reasons that 
the diet has gained great attention in hypertensiology is that it 
may provide an attractive means of influencing blood pressure 
levels, either at the individual level or on a population scale. The 
potential of dietary intervention in the young will be discussed in 
chapter 7. 
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4.2 SODIUM AND BLOOD PRESSURE 
4~2.1 Introduction. 
A classical work on medicine by the chinese "yellow" emperor 
comprises the first written indication of an association between 
sodium and blood pressure in stating that high salt intake makes 
"the pulse hard".{!) This may be seen as the start of an ongoing, 
and by times heated, discussion about the role of sodium intake in 
the aetiology of primary hypertension, leading to the general 
opinion that sodium has indeed "something" to do with hypertension, 
but to less unanimity as to what extent and in what range of intake 
this relation is apparent, and much controversy about the efficacy 
of sodium reduction in hypertensive subjects.{2-ll) 
We will briefly review the evidence regarding the various 
components of the putative association between sodium and blood 
pressure, referring to some of the numerous reviews on this subjects 
when appropriate. The vast amount of data from animal studies, in 
which hypertension is produced by salt-loading and related 
procedures, will not be discussed here. 
the available data from trials studying 
In the subsequent paragraph 
the effects of a reduction 
in sodium intake on blood pressure will be analysed. 
4.2.2 Sodium intake and blood pressure. 
Inter population studies 
The collective results of a great number of, mostly anthropological, 
studies describing sodium intake and blood pressure levels in 
different populations show, when combined, a highly significant 
association between systolic and diastolic blood pressure and sodium 
intake (or excretion) in both men and women, as reviewed by Meneely 
and Dahl,(l3) and more recent extensively by Gleiberman and Simpson 
{Figure 4.2.la, 4.2.lb).{l4,15) 
These findings are influenced by the inclusion of several 
populations having a diet virtually lacking sodium and almost no 
cases of hypertension, like the Yanomano Indians of Brazil and 
tribes living in the Solomon Islands, and populations using 
extremely large amounts of sodium like in some regions of 
Japan.{l6,17) Obviously, these people are different in many more 
ways from people living in Europe or the USA, than with respect to 
sodium intake alone. This indicates an important source 
comparing different populations according to 
of bias when 
a certain 
characteristic, like sodium intake, which is sometimes referred to 
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as the "ecological fallacy". Several differences exist between most 
low-sodium/low-blood pressure societies, and westernized societies 
where average sodium intake and blood pressure are higher. In more 
primitive societies people lose weight with age, in the western 
world they gain weight with age. Furthermore, people in primitive 
societies tend to be more physically fit, a factor that has been 
associated with blood pressure level.(l8) Also, between populations 
dietary habits, not only differ in sodium intake, but also in other 
factors that may affect blood pressure level, like potassium. 
Finally, low-salt communities tend to be small, and live in relative 
isolation under stable conditions unexposed to the turbulence and 
physical and emotional stress inherent to westernized societies. 
In addition, many of the interpopulation studies suffer from 
methodological shortcomings in data collection and handling, and 
this makes a comparison even more difficult. Data on body weight and 
dietary factors other than sodium are often lacking, and 
blood pressure measurements of sodium intake and excretion and of 
are far but standardized. 
In 
studies 
conclusion, however, the evidence from 
is suggestive that at least a very low 
interpopulation 
and a very high 
sodium intake are associated with a relative low and high prevalence 
of high blood pressure. A large and thoroughly standardized 
interpopulation study is currently being conducted under auspices of 
the council on epidemiology of the International Society and 
Federation of Cardiology, the INTERSALT project. Although one might 
be sceptical with regard to yet another study because some problems 
can never be totally solved, this study can perhaps provide us with 
some clear data on the extent to which sodium intake is related to 
blood pressure between populations. 
Intra population studies 
Contrary to the findings in inter-population studies, in most 
withinpopulation studies no relationship between an individuals 
sodium intake and blood pressure has been observed.(l9,20) Several 
factors may explain difficulties in finding an association within a 
population. 
Firstly, most intra-population studies use a single 24 hour 
urine specimen to estimate sodium excretion. In western societies 
sodium intake is highly variable, and it is notoriously difficult to 
characterize an individual on this basis. Liu and coworkers 
suggested that a series of seven 24 hour urine samples may be needed 
to adequately estimate an individual's sodium intake,(21) and 
Simpson calculated that twelve samples would be required to 
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characterize the sodium output of an individual subject with 95% 
accuracy.(22) A single estimation of urinary sodium output in a 
population appears to give a reliable value for mean sodium output, 
but it characterizes the individual poorly. Watt and Fay estimated, 
that in order to have a 90% chance of detecting a regression slope 
of 0.1 mmHgjmmol Na (the strength of association observed between 
populations and used to approximate the effect 
sodium intake on blood pressure), 5,720 subjects 
each provides only one 24 hour urine sample.(23) 
Secondly, even when a person's sodium intake 
reliably, this can only indicate current sodium 
necessarily relate to the sodium intake over the 
his life. 
of a reduction in 
are required if 
could be assessed 
use which does not 
remaining part of 
Thirdly, the association between sodium intake and blood 
pressure may be nonlinear, implying that a certain threshold level 
exists beyond which the association is no longer apparent. This 
so-called saturation phenomenon has first been suggested by Meneely 
and Batterbee.(24) According to some authors, at an intake of about 
70 mmol sodium per day a threshold level would exist, above which no 
clear effect of sodium on blood pressure would be detectable.(25) 
Indeed, when communities are studied where the range of sodium 
intake is wider and intra-individual variation in sodium intake is 
less, direct relationships between blood pressure levels and sodium 
excretion have been shown.(26,27) 
The obvious alternative explanation for the lack of a 
sodium-blood pressure relationship within western communities is, 
however, that no relationship exists between sodium and high blood 
pressure. 
A different concept might be that the sodium-blood pressure 
association 
population. 
aetiology of 
only applies to certain susceptible subgroups within a 
As genetic factors appear to be involved in the 
hypertension,(28) inherited differences in sodium 
sensitivity may affect blood pressure in 
positive family history for hypertension 
certain individuals. A 
could be a factor 
distinguishing salt-sensitive from non salt-sensitive subjects.(29) 
However, this could not be established in a recent double-blind 
study by watt and coworkers.(30) Also, age may modify the response 
of blood pressure to sodium intake.(31) This would implicate that 
susceptibility to dietary sodium is an acquired rather than an 
inherited characteristic. This is in agreement with an analysis of 
the data from thirteen randomized trials of sodium restriction on 
blood pressure, which showed reduction of sodium intake to be more 
effective in older subjects (Chapter 4.3). 
Analyses from data obtained in the Health and Nutrition 
Examination 
much to the 
association 
Survey 
present 
between 
(HANES) by MacCarron and coworkers have 
controversy.(32) They reported an 
dietary sodium intake and absolute 
added 
inverse 
blood 
pressure level as well .as prevalence of hypertension (Figure 4.2.2). 
Propor110n of Pooulat1on with Systolic Blood 
Pressure <:.160 mmHg based on Sodium Intake 
0.13 
0.11 
o. 09 
0. 07 
0. OS 
0. 03 
0. 01 
Sodium Consumption mg/day 
Figure 4.2.2. Prevalence of hypertension in the National Health 
and NutritiOn Examination Survey, 1971-1974, for different strata of 
sodium intake. Reproduced from 32. 
This study has been subject to much debate and a second analysis of 
the same data by Harlan et al. did not confirm the first report in 
all aspects.(33) The findings of MacCarron and his group are, 
however, in agreement with data from the Ten State Survey, where 
groups of subjects consuming more sodium, showed lower prevalences 
of hypertension.(34) 
No definite conclusions can be drawn on the basis of the 
combined intrapopulation studies conducted thus far. Moreover, 
intrapopulation studies are in part conflicting with, and on the 
average not confirmative of, findings of studies compari'ng different 
populations. These latter studies, however, are hampered by a number 
of methodological and statistical difficulties, which may invalidate 
the judgement based on their findings. 
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4.2.3 Studies on the effect of sodium restriction on blood pressure. 
The evidence of a blood pressure lowering effect of moderate sodium 
randomized trials on a reduction of sodium intake in subjects of 
varying age and different levels of blood pressure (paragraph 4.3). 
One study needs to be mentioned separately. Hofman and in 
coworkers, a double blind randomized trial, have reported a 
reduction of rate of increase in blood pressure in newborns fed with 
a low sodium baby-food formula.(74) This provides the only evidence 
at hand that sodium intake may be 
elevated blood pressure. As has 
associated with the aetiology of 
been mentioned, this finding does 
not necessarily imply that a reduction of sodium intake may be used 
to reduce a blood pressure level that is high already. 
4.2.4 Pathophysiological aspects of the sodium-blood pressure 
relationship. 
Several theoretical concepts have been developed to connect dietary 
sodium intake and blood pressure. Three hypotheses have obtained 
particular attention. 
The autoregulation theory 
Borst and Borst-de Geus postulated that an increase in cardiac 
output, leading to hyperperfusion of the tissues,{35) and resulting 
vasoconstriction and increased peripheral 
responsible for sodium induced elevation of 
in autoregulatory 
resistance, might be 
blood pressure. In 
hypertension would be a 
this concept, 
renal defect 
the primary abnormality of 
leading to sodium and water 
retention, increased venous return and elevated cardiac outPut. This 
was extensively studied by Guyton and coworkers.(36,37) Doubt 
remains however, whether an increase in cardiac output is a common 
characteristic of early primary hypertension, and whether 
autoregulatory responses can be chronically maintained.(38) 
Although the initial enthousiasm for this theory has somewhat 
declined, it is likely that abnormal renal sodium handling is 
involved in primary hypertension. { 39.) Moreover, kidney 
cross-transplantation experiments in inherited hypertension in rats 
have been strongly suggestive· that the kidney is implicate in the 
aetiology of high blood pressure.(40) 
The natriuretic hormone/Na+-Ca2+ exchange/hypertension hypothesis 
The second hypothesis is based on the initial suggestion by ?ahl 
and coworkers that a circulating factor, or hormone, is present in 
hypertensive animals, which is capable of inducing natriuresis in 
other animals.(41) Haddy and Overbeck(42) and Blaustein(43} 
subsequently applied 
Blaustein suggested a 
transport inhibitor 
this theory to volume expanded hypertension. 
mechanism whereby a raised level of a sodium 
could increase vascular reactivity by slowing 
down sodium-calcium exchange across arteriolar smooth muscle cell 
membranes. (44) 
According to Dewardener and MacGregor,(45) those who will 
develop primary hypertension may have an inherited reduced ability 
of the kidneys to excrete the dietary sodium load normally 
encountered in westernized societies. This would result in an 
initial slight increase in blood volume, stimulating the release of 
natriuretic hormone to restore sodium balance back to normal. The 
combined results of the natriuretic factor on the kidney and on 
smooth muscle cells would result from inhibiting Na-K-ATPase, 
leading to natriuresis in the kidney, and to increased contractile 
tone in the arteriolar wall, by reduced transcellular membrane 
sodium-potassium pump activity (Figure 4.2.3). This theory has 
gained much support, although only limited experimental evidence is 
available thus far to provide the necessary empirical foundation 
(See Swales(46)). 
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Figure 4.2.3. Sequence of events to explain a postulated defect 
in the kidney's ability to excrete sodium, leading to a rise in the 
concentration of a circulating sodium transport inhibitor, and a 
rise in peripheral resistance in primary hypertension. Adapted from 
MacGregor GA, Hypertension 1983;5 (supp III) :80. 
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There is circumstantial evidence for the existence of a 
natriuretic hormone, as reviewed by De wardener and Clarkson,(47) 
but the molecular structure of the hormone is still obscure, and 
attempts to purify a peptide with natriuretic and Na-K-ATPase 
inhibiting properties have not yet yielded clear results. After 25 
years, only one possible relevant substance, the Atrial Natriuretic 
Factor (ANF), has been identified.{48,49) This peptide, however, 
decreases vascular reactivity and lacks an effect on Na-K-ATPase. 
Recent evidence suggests that circulating atrial natriuretic 
peptides are raised in adult hypertensive subjects and this finding 
has been interpreted as sUpportive of the view that the ability of 
the kidney to excrete sodium is reduced in primary hypertension.{50) 
From a theoretical point of view, the possibility that inhibition of 
Na-K-ATPase activity increases vascular reactivity has encountered 
little objection. The postulated resulting natriuresis is, however, 
still subject to debate. Therefore, the natriuretic hormone and the 
factor inhibiting Na-K-ATPase may well turn out to be two or more 
distinct substances. Moreover, inhibition of the red cell 
sodium-potassium pump has been observed in a number of conditions 
not associated with hypertension, as in hypothyroidism, uraemia, and 
obesity. (46) 
Finally, although abnormalities of the ouabain sensitive, i.e., 
Na-K-ATPase dependent, sodium-potassium pump have been the subject 
of many investigations both in humans and rats, the results are 
equivocal. Findings of reduced sodium pump activity mainly concern 
leucocytes.(51,52) This was also observed in normotensive relatives 
of hypertensive patients which may indicate that reduced Na-K-ATPase 
activity is at least not the sole determinant of elevated 
pressure.(53) Alternatively, impaired sodium-potassium transport may 
be an early indicator of primary hypertension before the elevation 
of blood pressure level has become apparent. 
Altered cellular membrane function as the source of hypertension 
An impressive amount of data has accumulated during recent years 
to support the hypothesis that one or multiple alterations of 
cellular membrane function may play a part in the development of 
primary hypertension (For a more 
Swales(46}, Postnov{54), Tosteson{55), 
extensive discussion see 
Parker(56,57), Garay(58), de 
Wardener(59) ). The view that disturbances in cellular electrolyte 
handling are in some way associated with elevated blood pressure is 
founded on the concept that any rise in peripheral resistance due to 
enhanced vascular smooth muscle tone must result from raised 
intracellular calcium levels (For theoretical considerations see 
paragraph 4.4.5). 
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The basis for studying intracellular sodium and other 
electrolyte concentrations in hypertension, was laid by the initial 
observations of Tobian and Binion of elevated sodium and water 
content in the arterial wall of hypertensive subjects.(60) Losse and 
coworkers were the first to report increased intracellular sodium 
levels in red blood cells of patients with primary hypertenson.(61) 
They extended their observations by demonstrating increased net 
sodium flux across the red cell membrane.(62) In a group of 90 young 
untreated subjects with persistently mildly elevated blood pressure 
levels, we observed a significant positive association between intra 
erythrocyte sodium concentration and systolic blood pressure (b • 
2.4, SE - 1.2, p = 0.05), and a negative association between intra 
erythrocyte potassium concentration and systolic blood pressure (b = 
-0.7, SE 0.3, p ~ 0.03). This suggests that either red cell 
permeability to sodium was raised in these hypertensive youngsters, 
or sodium extrusion mechanisms were reduced. 
The main transport mechanisms involved in cellular sodium 
handlin are shown in Figure 4.2.4. Extracellular sodium 
concentration is higher, and potassium concentration lower, than 
intracellular sodium and 
gradients drive Na+ and 
potassium concentration. Electrochemical 
K+ across the cell membrane in opposite 
directions. Intracellular Na concentration tends to rise by passive 
permeability and by the anion-carrier [1][2]. The stationary 
intracellular sodium concentration is maintained by the ATPase 
dependent Na-K pump, exchanging internal Na+ for external K+ [3], 
and to a lesser degree by the chloride-dependent Na+-K+ 
co-transport system [4]. The physiological role of the Na+-Na+ 
countertransport system [5], exchanging intra- and extracellular Na+ 
on a one-to-one ratio is still unclear. The co-transport can be 
inhibited by furosemide. The counter transport is measured by 
preloading erythrocytes with lithium and comparing its extrusion 
into solutions that contain physiological concentrations of sodium, 
or no sodium at all. This method has led to the more common name of 
"sodium-lithium" countertransport for this transport system. An 
alternative way for sodium to be extruded from the cytosol is by the 
energy dependent Ca+-Na+ pump (the "calcium pump", see figure 
4.5.3). This transport system exchanges three Na ions for one Ca 
ion. Garay and coworkers, in 1979, reported a reduction in net 
Na+-K+ fluxes in erythrocytes of hypertensive patients.(63) In a 
subsequent study they attributed this observation to reduced 
activity of the Na+-K+ co-transport.(64) Furthermore, while Na+-K+ 
co-transport appeared to be reduced in hypertensive patients and 
part of their offspring, there was no overlap for values between 
subjects with essential and secondary hypertension.(65} In the same 
year, Canes sa and collaborators observed high Na+-Li+ 
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countertransport fluxes in essential hype~tensive 
Since then, a series of studies, including a 'combined 
patients.(66J 
study by the 
groups of Garay and Canessa,(67) has been conducted. The studies 
involve different groups of patients and the use of several 
biochemical methods. Moreover, they focused on erythocytes as well 
as on a number of other cell types. 
Figure 4.2.4 Compilation of postulated membrane transport 
mechanisms involved in cellular sodium and potassium homeostasis. 
The results from 
discrepancies, making 
disturbances in sodium 
these investigations 
any definite conclusions 
transport mechanisms 
have 
on the 
in 
shown major 
pattern of 
hypertensives 
difficult. (68) Several factors may explain these inconclusive 
findings. Differences in patient selection may account for some of 
the dissimilarities. Most studies provide limited data on the way 
control groups were obtained. Furthermore, as hypertensive subjects 
tend to be more obese, and obesity has been associated with 
alterations in cellular sodium handling,(69) this may induce 
differences between groups. 
treatment may affect study 
Also, race, age, and anti-hypertensive 
outcomes. Anti-hypertensive drugs may 
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influence sodium efflux rate,(70) but almost all studies have been 
conducted in previously treated patients, in which medication had 
been stopped for a varying period before the study. Alternatively, 
differences in biochemical methods and in sampling and storage of 
cells, could in part be responsible for the different findings. At 
the very least, there appears to be a substantial heterogeneity in 
disturbances in cellular electrolyte handling in primary 
hypertension. On the basis of the findings thus far, one could 
suggest a number of subgroups of hypertensive patients, in some of 
which intracellular sodium is elevated due to a membrane leak for 
sodium; in some an apparent leak is compensated by enhancement of 
one, or more, transport mechanisms; in still others reduced 
extrusion forms the main determinant of increased intracellular 
sodium content; and finally in some no clear alteration of 
intracellular sodium handling is present. 
It remains insufficiently clarified how these disturbances in 
sodium handling can lead to elevation of pressure. Indeed, it is 
still not clear whether these alterations are at all implicated in 
the pathogenesis of high blood pressure. As indicated at the 
beginning of this paragraph, eventually the mechanism(s) involved 
should lead to elevation of intracellular calcium. A plausible 
explanation has been provided by Blaustein in relation to the 
concept of a natriuretic hormone (see previous paragraph and 
reference 44). In this hypothesis the effects of Na+-K+-ATPase 
inhibition might be replaced by oth er factors resulting in raised 
intracellular sodium levels and, thereby, in activation of the 
calcium pump. However, the alterations in sodium transport 
mechanisms observed in some hypertensive patients and in 
normotensive relatives of hypertensive subjects, may also reflect an 
epiphenomenon related to another primary defect rather than being 
causally related to the elevation of blood pressure. 
Following this reasoning, some workers have postulated a genetic 
membrane defect in primary hypertension. These alterations of the 
cell membrane function might affect a variety of membrane 
characteristics, including cation transport, passive electrolyte 
movements, and intra- and extra-cellular Ca+ binding. Some of these 
phenomena are discussed in more detail in paragraph 4.5. There is 
substantial evidence for decreased calcium binding by cell membranes 
of hypertensive humans and rats.{71) It is conceivable that the 
primary abnormality of the cell membrane would reside in the 
phospholipid component 
theory this could, by 
handling of sodium and 
Na+ - K+ pump, as 
as well as the glycoprotein structure.(54) In 
destabilization of the cell membrane, affect 
potassium, in particular permeability and the 
a secondary phenomenon.(46) The final 
consequence would then be an increased concentration of free calcium 
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in the cytosol of contractile cells, and also in other tissue 
involved in blood prPssure regulation, like the sympathetic nervous 
system. 
The existence of a widespread alteration in membrane function is 
compatible with the notion that the rise in peripheral resistance as 
observed in primary hypertension 
vascular beds but may involve the 
the veins.(72) In this view, the 
is not clearly limited to specific 
whole vascular system, including 
kidney resets to avoid salt and 
water loss due to increased pressure, i.e., operates with the renal 
function curve shifted with respect to systemic blood pressure.(54) 
4.2.4 Conclusion. 
There are numerous data indicative of a role for sodium in the 
aetiology of primary hypertension. The magnitude of the association 
between sodium and blood pressure, as well as the mechanism(s) 
inv0lved, are still unknown. 
At a time that the contribution of a number of other dietary and 
non-dietary factors in determining blood pressure level has become 
increasingly clear, it may be questioned whether the attention paid 
to a solitary role of sodium salts in blood pressure elevation is 
justified. It is conceivable that the relatively simple way of 
determining sodium intake (by urinary sodium excretion) has 
stimulated this great interest.(73) Moreover, sodium is one of the 
few dietary constituents that enters our daily food almost entirely 
artificially, either in the household (30%) or in manufacturing 
(30%), and sodium intake is therefore easily 
also influence the choice for a reduction 
manipulated. This may 
of sodium intake in 
assessing the hypotensive properties of dietary changes. 
TWo ways whereby sodium intake may affect blood pressure have 
been suggested. Firstly, a high sodium intake may induce 
of blood pressure. Secondly, a reduction of sodium intake 
Furthermore, either 
elevation 
may lower 
of these an already elevated blood pressure. 
actions may apply to certain subgroups of normotensive or 
hypertensive subjects susceptible to sodium. It is important to note 
that these two phenomena are not necessarily linked. It is 
conceivable that sodium intake determines blood pressure levels, but 
that changing sodium intake does not affect the level of blood 
pressure already achieved, or vice versa, 
may be implicated in the aetiology 
i.e, different mechanisms 
and the treatment of 
hypertension. In other words, sodium intake may be related to high 
blood pressure as a "clue" or as a "cure". 
Data on the first effect stem predominantly from interpopulation 
studies, but these findings have not been convincingly confirmed by 
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studies within populations. The latter type of study is less liable 
to confounding by other factors. 
methodological difficulties may 
results. The only experimental 
However, as has been pointed out, 
also account for the inconclusive 
study conducted thus far on the 
effect of sodium on rise of blood pressure,{74) conducted in Dutch 
newborns, has indicated that a higher sodium intake may indeed 
increase the slope of blood pressure in the first years of life. 
This finding calls for confirmation by further intervention studies. 
The hypotensive property of large reductions of sodium intake to 
levels below 20 mmol/day is generally accepted. This type of dietary 
intervention has, however, serious drawbacks. Most obviously because 
severe sodium restriction is unpalatable and is likely to result in 
significant loss of compliance when implemented for a longer period 
or outside the clinic. In addition, a sodium restriction that i3 
this drastic may pose medical risks. 
changes in dietary sodium intake, to 
less well documented. 
The efficacy of less great 
levels of about 80 mmol/day is 
It appears that moderate sodium restriction is predominantly 
effective in older patients with moderate to severe hypertension. 
rhese patients, however, are likely to be eligible for treatment 
with drugs. This notion may raise questions to the usefulness of 
widespread reductions of sodium intake as part of public-health 
measures or intervention programs to shift the blood pressure 
distribution of a whole population to lower levels. Although it may 
seem acceptable to disencourage the overenthousiastic use of sodium 
during the preparation of food, a more aggressive "low-salt for all'' 
campaign appears at present not to be sufficiently justified. 
Finally and unfortunately, no definite criteria are available at 
the moment to detect those at increased risk to respond to a high 
sodium intake with blood pressure elevation, or those most liable to 
show a fall in blood pressure on sodium restriction. Although the 
available evidence is suggestive of marked heterogeneity in the 
response to sodium in both normotensive and hypertensive subjects, 
further studies are clearly indicated. 
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4.3 DOES SODIUM RESTRICTION LOWER BLOOD PRESSURE? 
Data from thirteen randomized trials 
Introduction 
The merits of sodium restriction in primary hypertension are subject 
to an ongoing and sometimes heated debate. Although important pieces 
of evidence have been derived from observational studies, most would 
agree that the ultimate test for the effect of a reduction in 
dietary sodium on blood pressure is the experiment. We reviewed 
thirteen randomized trials of sodium restriction on blood pressure, 
with special reference to the question which variables predict the 
effect of sodium restriction on blood pressure. 
Methods 
Data from trials 
The data of twelve studies, comprising thirteen randomized trials, 
were used.(l-12) From these studies the following characteristics 
were recorded (Table 4.3): 
1- The design of the study. Whether a study was performed in 
parallel-group 
a 
whether a or blinded or open fashion, and 
crossover design was employed. 
2- The number of parti·cipants of whom complete data sets were 
study groups, and the duration of obtained, the mean age of the 
the intervention period. 
3- The initial systolic and 
Readings in supine position 
diastolic blood pressure 
were used when provided. 
levels. 
when the 
study comprised a lead-in period, the blood pressure measured at 
the start of the intervention period was used. 
4- Daily sodium and potassium intake, based on the 24 hour urinary 
electrolyte excretion. When no data on urinary sodium were 
included, the intake was based on an estimate of the sodium 
content of the diet.{lO) Some reports did not provide data on 
potassium intake or excretion.(l,2,9) 
5- The maximum achieved reduction in sodium intake and the change in 
potassium intake during intervention. 
6- The change in systolic and diastolic 
intervention. Depending on the design of 
between intervention and control 
blood pressure during 
the study the difference 
period (crossover 
studies),(l,3,4,6,8,10-12) or the difference in change of blood 
pressure from baseline between the intervention and the control 
group (parallel-group design),(2,5,7,9) was used. 
7- The statistical significance of the results. In most studies a 
t-test for unpaired or paired observations was performed. Results 
W"ere considered significant when a two-sided p-value was less 
than 0.05. 
8- The year the study was published. Although studies on sodium 
restriction in individuals have been conducted since the 
beginning of this century, studies before 1970 often were very 
small, and frequently did not match current criteria for design 
and data analysis.(13) Therefore only studies published from 1970 
to 1985 were included. From one study unpublished data were 
used. ( 12) 
Table 4.3. Compilation of data from the studies included in the analysis 
Ref T 
1 0 
2 0 
3 0 
4 1 
5 0 
6 1 
7 0 
8 0 
9 0 
10 0 
11 1 
11 1 
12 1 
Index 
Ref 
T 
D 
p 
N 
D p N A Sys Dia Na K dNa dK dSys 
2 28 22 41 175 112 191 -98 -6.7 
1 730 62 60 163 97 191 -38 -2.0 
2 14 20 23 125 73 210 71 -170 -6 -2.7 
2 28 19 49 154 97 162 65 -76 -6 -10.0 
1 84 90 49 141 87 150 77 -113 +3 -5.2 
2 28 18 52 137 83 143 54 -56 +3 -0.5 
1 365 28 55 163 99 149 60 -21 +5 -8.7 
2 35 12 40 150 92 210 55 -100 +8 -5.2 
1 28 94 46 157 101 130 -58 -3.0 
2 24 113 16 103 61 113 49 -70 +16 -0.6 
2 28 31 23 111 64 128 64 -60 -1 -0.5 
2 28 35 22 114 63 131 61 -74 -6 -1.4 
2 42 40 24 137 73 129 77 -72 -3 -0.8 
to the table: 
reference number. 
type of study: 0 ~ open study, 1 = double-blind study. 
design: 1 m parallel-group, 2 = crossover. 
duration of period of sodium restriction (days). 
number of participants. 
mean age (years). 
initial mean systolic blood pressure (mmHg). 
initial mean diastolic blood pressure (mmHg). 
dDia p 
+3.2 1 
-7.0 1 
-3.0 0 
-5.0 1 
-3.4 0 
-0.3 0 
-6.3 0 
-1.8 0 
-2.5 0 
-1.4 0 
+1.4 0 
+1.2 0 
-0.8 0 
y 
73 
78 
81 
82 
82 
83 
83 
84 
84 
84 
85 
85 
A 
Sys 
Dia 
Na 
K 
dNa 
dK 
dSys: 
dDia: 
p 
mean sodium intake during the control period or at baseline (mmol/24h). 
mean potassium intake during the control period or at baseline {mmolj24h) . 
change in sodium intake during intervention (mmolj24h). 
change in potassium intake during intervention (mmol/24h). 
change in systolic blood pressure during intervention (mmHg). 
change in diastolic blood pressure during intervention (mmHg). 
statistical significance of the results: 0 = ns, 1 =sign. (< 0.05). 
y year of publication. 
Data analysis 
Although substantial differences between the s~udies exist, they 
were accorded equal weight. The data analytic approach was two-fold. 
First, predictors of the fall in blood pressure during sodium 
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restriction were studied in simple linear and multiple linear 
regression analysis, in which the fall in blood pressure was the 
outcome variable and its potential predictors were entered as 
determinants in the model. Second, studies were grouped on the basis 
of their design and on the statistical significance of the results, 
and differences between the groups were tested using a t-test for 
unpaired observations. The results of statistical tests are 
expressed as two-sided p-values. 
Results 
General aspects 
The studies included in this analysis are summarized in the table. In 
all of them a fall in systolic blood pressure during sodium restriction 
was observed, with an average of 3.6 mmHg, ranging from 0.5 mmHg to 
10.0 mmHg. Diastolic blood pressure showed on the average a fall of 
2.0 mmHg. However, although ten studies showed a fall in diastolic 
blood pressure, ranging from 3.0 mmHg to 7.0 mmHg, in three studies 
diastolic blood pressure rose, ranging from 1.2 mmHg to 3.2 mmHg. 
Only three studies showed a statistically significant fall in 
systolic blood pressure during reduction of sodium intake. Five 
studies were performed double-blind, and all of these date from the 
last three years. Six studies had an intervention period of four 
weeks or shorter, three were five to twelve weeks, and two took one 
year or more. A total of 584 subjects participated in the trials, 
with a mean age of 38.5 years, the average age by study ranging from 
16 to 60 years of age. Five studies were conducted in adolescents or 
young adults. The average sodium intake in the trials combined was 
157 mmol/24 hour, and average potassium intake was 64 mmol/24 hour. 
No significant associations between initial blood pressure level and 
sodium or potassium intake were found. There is a tendency for 
initial sodium intake to fall with year of publication of the study. 
This association, which remained after adjustment for age {b • -5.1 
mmol/yr, SE • 2.4, p- 0.05), may indicate an overall downward trend 
in sodium consumption in the Western world. The achieved reduction 
in sodium intake ranged from 26 to 170 mmol/24 hour (mean 78 mmol/24 
hour)_ 
Which variables predict a fall in blood pressure? 
The fall in systolic blood pressure on sodium restriction increased 
with initial blood pressure level (Figure 4.3.1). For diastolic 
blood pressure the association did not reach statistical 
significance. Also, the fall in systolic as well as diastolic blood 
pressure increased with age. This finding was more prominent for 
diastolic pressure (Figure 4.3.2). After adjustment of initial blood 
pressure level for age and vice versa neither of the associations 
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did reach statistical significance. No apparent relationship was 
observed between the fall in blood pressure and initial sodium or 
potassium intake, nor was the fall in blood pressure related to 
achieved reduction in sodium intake. No associations were found 
between duration of the trial and the number of subjects included. 
Fall in Systolic Blood Pressure (mmHg) 
12~---------------------------, 12~-----------------------------, 
r=0.54 (p=0.009) 
to b=0.08 {SE=0.03,p=0.02) 
r=0.47 (p=0.07) 
"10 b=0.09 (SE=O.OS,p=O.lO) 
8 
4 
2 
~+,~,~~--~,~2~,-------,~.~,-------,-,~,-------,~., .· 
10 30 so 
Initial Systolic Age (Years) 
Blood Pressure 
(mmHg) 
Figure 4.3.1. Fall in systolic and diastolic blood pressure 
during sodium restriction by initial blood pressure level. 
Fall in Diastolic Blood Pressure (mmHg) 
70 
•.--------------------------, 
r=O.Jt (p=0.25J 
•,-----------------------, 
r=O.SS (p=0.02) 
b=O. 05 ( SE=O. OS, p=O. 29) b=0.11 (5E=O.OS,p=0.04] 
·. ·. 
-2 -2 
-•+-----------------~----~--~ -4 +---------------------------~ 
60 80 100 120 
Initial Diastolic 
8 Jood Pressure 
(mmHgl 
10 30 50 
Age (Years) 
Figure 4.3.2. Fall in systolic and diastolic blood pressure 
sodium restriction by age. 
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Open and blinded studies 
Blood pressure is very liable to be affected by a variety of other 
factors apart from a reduction in sodium intake. Therefore, 
uncontrolled and open studies may show a fall in blood pressure over 
and beyond the effect of sodium restriction. Blinded studies (n • 5) 
were in general of shorter duration than open studies (n • 8). In 
open studies baseline sodium intake was higher: 168 mmolj24h (SE 
13) in open, and 139 mmolj24h {SE 6) in blinded studies (p-
0.07). The fall in systolic and diastolic blood pressure observed in 
open studies tended to be greater. The average fall in systolic 
blood pressure was 4.3 mmHg (SE ~ 0.9) in open and 2.6 mmHg (SE 
1.8) in blinded studies, and for diastolic blood pressure these 
figures were 2.8 mmHg {SE 1.1) and 0.7 mmHg (SE ~ 1.2), 
respectively. 
significance. 
These differences failed to reach statistical 
"Positive" and "negative" results 
Only three studies reported a statistically significant "positive" 
result. Positive studies were more often not-blinded, tended to 
include less women, and the subjects in these trials were older. 
Baseline sodium intake was higher in positive studies (181 mmol/24h, 
SE 10) than in negative studies (150 mmolj24h, SE = 11) (p 
0.06), but the average achieved reduction of sodium intake was 
similar: 71 mmol/24h (SE = 18) in positive and 80 mmolj24h {SE = 13) 
in negative studies. 
Discussion 
This analysis of thirteen studies on the effect of sodium 
restriction on blood pressure supports the general hypothesis that a 
reduction in sodium intake may lower blood pressure. The hypotensive 
action of sodium restriction appears to be largely restricted to 
systolic blood pressure and is small, ranging from 0.5 to 10.0 mmHg, 
with an average fall of 3.6 mmHg. The fall in blood pressure appears 
to increase with the level of initial bloo_d pressure and with age. 
This suggests that sodium restriction is of limited 
subjects, and in patients with mild hypertension. 
our analysis it is impossible to say whether age 
value in young 
On the basis of 
or 
hypertension 
restriction. 
is a better predictor of the effect 
degree of 
of sodium 
To appreciate these observations, some issues need to be 
addressed. Only three studies showed a statistically significant fall 
in blood pressure during sodium restriction. Moreover, as the 
present analysis is necessarily based on a small sample size, some 
predictors of lesser magnitude may not have been detectable due to 
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the limited statistical power. This suggests that any 
generalizations from the literature might be hazardous. However, a 
separate analysis, including three trials which did not have a 
control group,(l4-16) supported the present findings in almost every 
respect. In all studies that comprised a lead-in period, blood 
pressure tended to fall in this period without any planned 
intervention. Accordingly, blood pressure levels at the first 
screening are hi~her than at the start of the intervention. In this 
analysis the latter of these blood pressure readings was used. In 
comparison with the first reading, our interpretation of "initial" 
blood pressure may overestimate the association between initial 
blood pressure level and fall in blood pressure on 
restriction. 
sodium 
The specific 
vary. This is 
objectives of the studies included in the analysis 
reflected in the procedures used to select 
participants. In some studies, subjects were selected from a general 
population,(12) whereas in other studies only patients attending an 
hypertension clinic,(4) or sharing genetic predisposition for high 
blood pressure(ll) were eligible. Moreover, in most studies, due to 
the nature of the intervention, several potential participants 
refused to be included. This implies that general applicability of 
the results may be limited.(17,18) 
Obviously, no conclusions can be drawn from this analysis 
cegarding an additive effect of sodium restriction to 
antihypertensive medication. Moreover, the type of studies dicussed 
here give primarily information on the hypotensive potential of 
sodium restriction, not on a role for dietary sodium in the 
aetiology of 
trials will 
high blood pressure. It remains doubtful whether more 
give more "positive" information. we observed a a 
negative association between year of study since 1980 and net fall 
in systolic and diastolic blood pressure on sodium restriction: b -
-1.2 mmHg/year (SE = 0.8, p 0.08) for systolic, and b = -1.2 
mmHg/year (SE • 0.4, p ~ 0.02) for diastolic blood pressure. This 
finding may, of course, result from differences in case selection in 
more recent trials, but it may also be associated with the observed 
downward trend in sodium intake in the last decade. 
A question as yet insufficiently answered is whether a subgroup 
exists in which sodium restriction may be most effective. The 
findings in the present analysis suggest that sodium restriction may 
lower blood pressure predominantly in older patients with relatively 
high blood pressure levels. Genetic factors have also been 
implicated in the response of blood pressure to sodium restriction. 
From a recent report by Watt and coworkers a positive family history 
for hypertension appears not to be related to sodium 
susceptibility,(ll) but the findings in an open study by Skrabal et 
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al. suggest the opposite.(3) Initial plasma catecholamines, in 
particular dopamine may be associated with the fall in systolic 
blood pressure on sodium restriction.(12) The value of plasma renin, 
prostaglandins, cellular electrolytes, and circulating natriuretic 
factors in discriminating sodium sensitive and non-sensitive 
hypertensive patients needs further consideration. The smaller net 
changes in blood pressure observed in blinded as compared to open 
studies once again suggest that blindness is a _prerequisite for 
trials in blood pressure research. 
In conclusion, this meta-analysis suggests that sodium 
restrictio may reduce blood pressure, but that the effect is small 
and largely restricted to systolic blood pressure. The fall in blood 
pressure seems to increase with initial blood pressure level and 
age. This implies that sodium restriction may, unfortunately, be of 
limited use in those who are appear to be most eligible for 
non-pharmacological treatment, namely young patients with mild 
hypertension.(19,20) 
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4.4 POTASSIUM AND BLOOD PRESSURE 
4.4.1 Int~oduction. 
The evidence that the dietary intake of potassium 
as well as the evidence 
is associated with 
that potassium blood pressure, 
supplementation may lower elevated blood 
limited and fragmentary than for sodium. 
data obtained in observational surveys 
we 
pressure, is much more 
will briefly review the 
and intervention studies in 
humans on the 
Part of this 
relation between potassium intake and blood 
review is based on discussions of the 
Dustan,(l) Langford,(2) Meneely and Battarbee,(3) 
Tannen,(5) and Treasure and Ploth.(6) 
4.4.2 Potassium intake and blood pressure. 
Inter-population studies 
pressure. 
subject by 
Simpson, ( 4) 
The interest in potassium intake as a factor involved in the 
grown in the shadow, and 
payed to dietary sodium. 
chapter 
aetiology of elevated blood pressure has 
somewhat as a consequence of the attention 
As discussed in the previous parts of 
evidence for a role of sodium in the aetiology 
studies. ( 7) pressure comes from 
sodium intake is by 
inter population 
4, the strongest 
of high blood 
However, a low 
far not the only difference between populations 
with a high and a low prevalence of hypertension.(8) In general, low 
sodium intake is accompanied by a high potassium intake. A low 
potassium intake may therefore be considered as a silent conspirator 
i"n hypertension. Moreover, as first suggested by Friddle and further 
elaborated by Meneely and Ball,(9,10) it might not be the level of 
sodium intake per se that determines the level of blood pressure, 
but rather the ratio of sodium to potassium could be of importance 
mediating the effect of sodium on blood pressure.(ll) This 
hypothesis was based on observations of a protective effect of 
potassium supplementation in animals fed toxic amounts of sodium 
chloride.(12) Froment and coworkers showed a high-order correlation 
between populations, of the urinary sodium/potassium ratio with 
blood pressure.(13) 
Intra-population studies 
The majority of studies on potassium intake and blood pressure has 
been conducted within populations. The first report on a relation 
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between blood pressure level and potassium intake stems from Sasaki 
and collaborators in 1959.(14) They observed a difference in average 
blood pressure levels of the inhabitants of two villages in northern 
Japan, while sodium intake appeared to be similar. Yet, those living 
in the village with the lower blood pressure had a much higher 
potassium intake. A study in 104 young black females participating 
in a school survey showed no correlation between sodium excretion 
and blood pressure. 
association between 
sodium/potassium ratio 
There was, however, a significant positive 
blood pressure level and urinary 
(r • 0.34, p • 0.02).(15) This finding was 
confirmed in a subsequent report on another group of females of the 
same age.(16) Sever and coworkers reported higher blood pressure 
levels in members of an urban living African tribe, than in members 
of the same tribe living in a rural environment.(!?) Although 
potassium excretion was the same in both groups, sodium intake was 
higher in those living in the urban setting, resulting in an urinary 
sodium/potassium ratio that was almost doubled in the urban group. 
In a large study of a Japanese population, blood pressure rose with 
decreasing urinary potassium excretion and with increasing urinary 
sodium/potassium ratio.(l8) A study performed in the Belgian army 
failed to demonstrate a significant association between 24 hour 
potassium (and sodium) excretion and blood pressure.(19) However, 
the same investigators observed a decrease in blood pressure with 
increasing 24 hour potassium excretion in a Korean population.(20) 
It was calculated that a 100 mmol/24 hour increase in potassium 
excretion was associated with a systolic blood pressure that was on 
the average 6.4 mmHg lower.(21) In another Belgian study in 528 
adults this figure was even higher: 12 mmHg/lOOmmol/24 hour for 
systolic and 6 mmHg/100mmol/24 hour for diastolic blood pressure 
after adjustments for body weight and age. In the same paper no 
significant associations between 
were reported in 160 youths, aged 
electrolytes 
10-19 years. 
and blood pressure 
In conclusion, there appears to be growing evidence that 
potassium intake is inversely associated with 
and/or that the sodium/potassium intake 
blood pressure levels, 
ratio is positively 
associated with blood pressure levels, within populations. 
4.4.3 Studies on the effect of potassium supplementation on blood 
pressure 
The experimental data on the hypotensive properties of potassium in 
humans are limited, although studies on the effect of potassium 
supplementation on blood pressure have a long history. In 1928 
Addison placed five hypertensive subjects on a low sodium diet and 
supplemented this diet with either sodium or potassium salts.(22) 
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supplementation with sodium resulted in a rise in blood pressure, 
whereas blood pressure decreased on potassium salts. In other early 
studies by Thompson and McQuarrie and associates, blood pressure in 
hypertensive children rose on a high sodium intake and this rise was 
attenuated when potassium chloride was added to the diet.(23,24) In 
this respect, it must be emphasized that the Kempner diet, often 
used to demonstrate the efficacy of sodium restriction in 
hypertension, not only lowers the intake of sodium enormously but 
also leads to a considerable increase in potassium intake.(25,26) 
This diet may reduce the sodium/potassium ratio by 99%.(6) 
The evolution of idears and experiments on diet and blood 
pressure in general and of sodium and potassium in particular has 
been reviewed by Chapman and Gibbons until! the 
nineteen-fifties.(27} In recent times a series of studies has 
renewed the interest in the effects of potassium supplementation on 
blood pressure, either on a normal-, a high-, or a low-sodium diet. 
Luft and coworkers studied six normotensive subjects on a very high 
(1500 mmol/24 hour} sodium diet with and without potassium 
replacement.(28} Sodium loading in these subjects resulted in a 
small rise in blood pressure and a marked urinary potassium loss. on 
a high sodium diet with extra potassium, blood pressure was elevated 
to a lesser degree and a greater natriuresis appeared, than when no 
extra potassium was added to the diet. In another study in 20 
normotensive subjects, a low sodium/high potassium diet for two 
weeks resulted in a statistically non-significant drop in systolic 
pressure of 2.3 mmHg and of 3.2 mmHg diastolic blood pressure.(29} 
Moreover, on this diet an average reduction of blood pressure rises 
induced by mental stress or noradrenaline infusion of 10 mmHg was 
observed (p < 0.001). In a study by Iimura and associates, 
supplementation with 10 mmol potassium per 24 hour for two weeks in 
20 hypertensive patients lowered the mean arterial pressure by 11 
mmHg.(30) This reduction in blood pressure was accompanied by 
decreases in body weight and body fluid volume. 
The first double blind trials studying the effect of potassium 
supplementation on blood 
Thom,(31} and MacGregor 
pressure were conducted by Khaw 
and coworkers,(32) in normotensive 
and 
and 
hypertensive subjects, respectively. Potassium was supplemented by 
64 mmol/ 24 hour during two weeks in normotensives and four weeks in 
hypertensives. In both studies diastolic blood pressure fell 
significantly, 2.4 mmHg and 4.0 mmHg respectively. Systolic blood 
pressure showed a significant 7.0 mmHg fall in hypertensive 
subjects, and a non significant 1.1 mmHg fall in normotensives. In 
two subsequent open studies, small groups of hypertensive patients 
were put on diets containing 64 mmol potassium per 24 hour for eight 
days and 200 mmol potassium per 24 hour for four weeks respectively. 
Only slight and statistically nonsignificant alterations 
pressure were observed.(33,34) Furthermore, another 
in blood 
study by 
MacGregor and associates failed to show an effect on blood pressure 
when potassium was added to a sodium restricted diet.(35) Contrary 
to this, in fourty young mildly hypertensive subjects participating 
in a randomized crossover trial,{36) a significant fall in systolic 
blood presure was observed after six weeks of a combination of 
sodium restriction and supplementation with 72 mmol potassium per 24 
hour. Moreover, the fall in blood pressure was accompanied by a 
significant fall in cardiac output. 
These findings put forward the question whether the hypokalemia 
that frequently accompanies the use of diuretics in the treatment of 
hypertension, may also have a bearing on the achieved reduction of 
blood pressure 
study, Kaplan 
in these patients.(37,38) In a double-blind crossover 
and coworkers administered potassium (60 mmol/ 24 
hour) for six weeks to 16 hypertensive patients who had 
diuretics-induced hypokalemia and who continued to take a constant 
amount of diuretics.(39) In association with an average rise in 
the mean blood serum. potassium concentration 
pressure fell by an average of 
To summarize, the findings 
far are inconclusive, but the 
of 
5.5 
0.56 mmol/1, 
mmHg (p = 0.004). 
on potassium 
weight of the 
and blood pressure thus 
evidence is suggestive 
of an antihypertensive action of potassium. This effect may be more 
pronounced in hypertensive subjects, which may indicate that 
potassium supplementation interferes with the pathophysiologic 
phenomena resulting in increased blood pressure.(S) The way whereby 
potassium may affect blood pressure is still unclear, and potential 
mechanisms will be discussed below. In our study, however, potassium 
supplementation appeared to reduce cardiac output, a finding which 
is compatible with a direct effect of the cation on the cardiac 
muscle cell. 
4.4.4 Pathophysiological aspects of the potassium-blood pressure 
relationship. 
The role of potassium in blood pressure regulation fits, in part, in 
the mechanisms involved in sodium-related blood pressure elevation 
as discussed in chapter 4 paragraph 2. The theoretical basis for a 
link between blood pressure and potassium is, nonetheless, much less 
well developed than for sodium. Although the evidence is far from 
conclusive, the following ways whereby potassium may influence blood 
pressure have been proposed.(6) 
1. Modification of neural regulation of blood pressure by affecting 
turnover and storage of central or peripheral catecholamines. 
Evidence has accumulated that increased sympathetic nervous 
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system activity is associated with the early phase of primary 
hypertension.(40-43) Enhanced autonomous nervous system activity 
may set the stage for chronic elevations of blood pressure 
maintained by the kidney.(44) Elevations in serum potassium may 
reduce vascular sensitivity to circulating catecholamines.(45) 
There is also evidence that re-uptake of noradrenaline by 
sympathetic nerve terminals is influenced by the relative 
external concentration of sodium and potassium.(46) Dahl and 
coworkers reported reduced pressor and heart rate responses to 
intravenous noradrenaline in subjects on a high potassium 
diet.(47) Moreover, normotensive humans on a high potassium diet 
show less rise in blood pressure in response to mental 
stress.(29) Varying effects of potassium supplementation on 
plasma noradrenaline have been reported. In some studies a rise 
was observed,(30) whereas in others plasma noradrenaline 
fell.(48,49) We observed no significant changes in plasma 
noradrenaline, adrenaline, and dopamine in fourty subjects after 
six weeks of daily supplementation with 72 mmol 
potassium-chloride.(36) 
It appears that the extent to which potassium may modify 
neural mechanisms involved in the pathogenesis of hypertension 
is, as yet, not sufficiently clarified to justify definite 
conclusions. 
2. An effect of potassium on a number of other pressor mechanisms 
has been suggested. Most prominent are observations that 
potassium may 
acutely,(SO,Sl) 
suppress renin secretion rates either when given 
or chronically.(52) The site of inhibition of 
renin secretion by potassium appears to be at the macula 
densa.(53) In general, it seems that inhibition of plasma renin 
activity is most likely to occur when a high potassium intake is 
combined with sodium restriction.(S) However, during six weeks of 
potassium supplementation combined with a reduction in sodium 
intake we did not observe any change in plasma renin activity in 
young mildly hypertensive subjects.(36) As will be discussed 
below, potassium 
natriuresis which 
plasma renin.(54) 
supplementation 
may give rise to a 
This could imply 
may result 
paradoxical 
that the net 
in a marked 
increase in 
result, of a 
combined direct inhibition of renin secretion by potassium in 
combination with a renin secretory stimulus by volume 
contraction, would be no change at all. Apart from its effects on 
renin secretion, potassium may alter the responsiveness of the 
resistance vasculature to angiotensin II.(30) Evidence is 
conflicting, since no-change, as well as increased and 
sensitivity to the pressor effect of angiotensin II 
potassium intake have been reported.(S) Finally, in a 
decreased 
on a high 
study by 
Zinner and collaborators, urinary kallikrein excretion rose with 
increasing urinary potassium 
Elliott and Nuzum reported 
hypertensive individuals.(56) 
kallikrein-kinin system in the 
is still uncertain.(57) 
excretion.(55) As early as 1934, 
reduced urinary kallikrein in 
The significance, however, of the 
aetiology of high blood pressure 
Data on the effects 
angiotensin, and other 
equivocal. Therefore, at 
drawn. 
of potassium supplementation on renin, 
pressure regulating systems are still 
this moment, no clear conclusions can be 
3. The natriuretic properties of potassium are known since Thomas 
Willis advocated its use for the treatment of dropsy in 1679.(58) 
since the first half of the twentieth century a more systematic 
study of the natriuresis produced by potassium supplementation 
has started.(59) A high potassium intake may increase renal blood 
flow,(60) but the natriuretic effect of potassium does not appear 
to be related to alterations in renal haemodynamics.(50) There is 
considerable debate concerning the precise nephron site where a 
high potassium level inhibits sodium 
Natriuresis induced by potassium has 
hypertensive patients.(30) In a 
reabsorbtion.(61,62) 
been 
study 
observed in 
on potassium 
supplementation, in combination with sodium restriction in young 
mildly hypertensive subjects, no clear natriuresis was observed 
as judged by the body weight.(34) This is in agreement with 
findings in other studies.(32,48,49) Part of this may be 
explained by an associated increase in aldosterone levels.(63) 
In conclusion, the significance of natriuresis in relation to 
the antihypertensive properties of potassium supplementation 
remains to be elucidated. 
4. An alternative way whereby potassium may affect peripheral 
resistance and thereby blood pressure, is by direct effects on 
the arteriolar smooth muscle cell. A vasodilatory effect of 
potassium on resistance vessels has been observed at plasma 
levels well in the range found in subjects on a high potassium 
intake.(64,65) Potassium induced vasodilation may be blocked by 
ouabain, indicating that the effect is mediated by the ATPase 
dependent sodium-potassium pump (for details on cellular sodium 
and potassium transport systems see figure 4.2.4).(66)" Moreover, 
an acute reduction of serum potassium level has been shown to 
reduce Na-K-ATPase activity and to increase the contractile 
activity of cardiac and arterial smooth muscle.(67) It has been 
suggested by Blaustein,(68) and De Wardener an MacGregor,(69) 
that a circulating natriuretic substance leading to an increased 
intracellular sodium concentration and subsequently to increased 
intracellular calcium levels, elevated smooth muscle tone, a rise 
in peripheral resistance and thus to high blood pressure, might 
be reponsible for primary hypertension related to a high sodium 
intake (see figure 4.2.3). The proposed natriuretic factor would 
act by inhibiting Na-K-ATPase activity.(70) An increased 
potassium intake may counteract this mechanism by stimulating the 
sodium-potassium pump. A hypotensive action of potassium could 
thus be explained by altered vascular smooth muscle tone, but the 
same mechanism might also affect the sympathetic nervous 
cell.(71) In rats it has been shown that partial replacement of 
sodium by potassium in 
the sympathoneural and 
discussed in chapter 
the diet leads to a reduced stimulation of 
sympathoadrenal system by cold.(72) As is 
4, paragraph 2, it is possible that 
inhibition of the sodium pump in hypertension is secondary to a 
primary disturbance of membrane structure leading to increased 
intracellular sodium and, eventually, calcium levels.(73,74) 
However, irrespective of the primary mechanism leading to altered 
intracellular electrolyte handling, by stimulating Na-K-ATPase 
potassium may act against these disturbances. Although no changes 
in various pressor systems were observed in a study of combined 
sodium restriction and potasssium supplementation for a period of 
six weeks, systolic blood pressure fell significantly, and this 
was accompanied by a fall in cardiac output of 0.4 
ljmin/m2 BSA.(34) In agreement with this Omvik and 
Lund-Johanssen, after moderate sodium restriction in 19 mildly 
hypertensive patients for six month, observed a fall in cardiac 
output that significantly correlated with the achieved fall in 
sodium;potassium ratio.(75) 
In conclusion, the available evidence is suggestive of a 
direct effect of potassium on the arterial and cardiac cell. This 
effect may account for the hypotensive potential of potassium 
supplementation. 
4.4.5 Conclusion. 
Evidence is accumulating, from both inter, and intra population 
studies that a high potassium intake and/or a low sodium/potassium 
ratio are associated with lower blood pressure levels. Potassium 
supplementation may lower blood pressure in normotensive and, more 
clearly, in hypertensive subjects. Moreover, potassium 
supplementation in patients treated with diuretics may not only 
prevent hypokalemia, but also add to the antihypertensive treatment. 
Most studies on the effect of a high potassium diet on blood 
pressure aimed at an increase in potassium intake of approximately 
60 mmol/24 hour. Depending on initial potassium intake, this 
79 
supplementation resulted in an average daily potassium intake of 
about 130 mmol/24 hour. 
A potassium intake of this magnitude 
subjects with normal kidneys, but might pose a 
compromised renal function.(S) Therefore, 
is not hazardous in 
risk in patients with 
some authors have 
expressed their concern about these risks, and also about the 
doubtful cost/benefit ratio of potassium therapy.(76-78) However, 
the potential hypotensive effect of potassium would not imply that 
'whole nations are to be put on potassium pills'_ On the contrary, 
as needs to be further clarified, it may well be that not potassium 
per se but a low dietary sodium/potassium ratio is the primary 
determinant of blood pressure level. In this regard, it is 
interesting that while the dietary sodium/potassium ratio is about 2 
to 4 in Westernized societies,(2) it has been estimated that the 
diet of our paleolithic ancestors had a sodium/potassium ratio 
between 0.01 and 1.0.(79) Moreover, the effect on blood pressure may 
be associated with the relative contributions of other dietary 
components, like calcium and magnesium, or even non-dietary 
environmental variables. Also, an increase in dietary potassium can 
be achieved in alternative ways, for example by replacing common 
table salt by potassium containing "low salt" mixtures.(80) 
In conclusion, there are great attractions in the concept of a 
low sodium/high potassium diet as an additive or even alternative to 
antihypertensive treatment,(81) and more studies of longer duration 
including larger numbers of participants are needed to evaluate the 
benefits and confirm the safety of these dietary changes. 
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4.5 CALCIUM AND BLOOD PRESSURE 
4.5.1 Introduction. 
The main characteristic of primary hypertension is an increase in 
peripheral resistance resulting from increased vascular smooth 
muscle tone.(1,2) Although structural changes in the vascular wall 
may add to the rise in vascular resistance observed during the 
development of high blood pressure, these changes are not likely to 
initiate the rise in blood pressure, nor to account fully for its 
haemodynamic profile.(3,4) It is well established that rapid changes 
in intracellular ionized calcium (Ca++l levels play a central role 
in the regulation of contractile activity of muscle cells.(S) Any 
condition associated with an increase in the strength of contraction 
of vascular smooth muscle must either alter the intracellular Ca++ 
level itself, change the response of the contractile apparatus to 
Ca++, or exert both effects.{6) 
Apart from its role in the contraction of vascular and cardiac 
smooth muscle, Ca++ is a major intracellular messenger in the 
response to noradrenaline, adrenaline, and angiotensin, the release 
of noradrenaline, the rate of secretion of aldosteron by adrenal 
glomerulosa cells, and probably the release of renin from 
juxtaglomerular cells.(7) Furthermore, many vasodilatory and other 
antihypertensive agents exert 
calcium dependent mechanisms, 
their effects by interference with 
or by reduction of intracellular 
calcium concentration.(S-10) The way whereby calcium participates in 
these phenomena, however, goes beyond the scope of this review and 
will not be discussed here. 
Whatever mechanisms are involved in the pathogenesis of primary 
hypertension the final consequence must be, in all likelyhood, a 
disorder of cellular calcium mechanism or, more specifically, in the 
functioning of the cell membrane.(!!) In recent years a variety of 
disorders of cellular calcium metabolism involving cellular calcium 
concentration, membrane binding, and transport kinetics, have been 
described in subjects with hypertension and in animal models. Also, 
several reports suggest that general calcium handling may be altered 
in primary hypertension.(l2-14) These findings indicate a putative 
role for the calcium ion in the pathogenesis of primary 
hypertension.(l4a) 
we will briefly review the evidence that disorders of calcium 
handling are implicated in primary hypertension. The structure of 
the review will be somewhat different from the previous parts of 
chapter 
blood 
4. contrary to the discussion on electrolyte intake 
pressure in the reviews on sodium and potassium, 
and 
in 
considering data on calcium and blood pressure we will extent this 
part by also addressing points raised regarding calcium excretion, 
and plasma calcium levels in relation to blood pressure. The role of 
cellular calcium handling in hypertension will be discussed 
separately, 
pathogenetic 
though in 
mechanisms 
combination with 
that may explain 
speculations 
the relation 
on the 
between 
altered calcium metabolism and blood pressure 
subsequent paragraph attention is payed to the 
parathyroid gland in hypertension. 
elevation. In a 
part played by the 
4_5_2 General calcium handling. 
Calcium intake: inter- and intra-populationstudies. 
The therapeutic properties of natural mineral waters have already 
been recognised by the ancient Egyptians, the Greeks and the Romans. 
In the sixteenth century Paracelsus was among those who stimulated 
the public interest in the healing properties of mineral springs and 
watering places.(15) At the end of that century some early 
biochemical analysis were carried out using water from the Epsom 
spring and attention was focused at the salt content of the water as 
a potential source of the purgative virtue described to the well. In 
recent 
between 
reported 
times Kobayashi 
drinking 
higher 
water 
mean 
was the first to suggest an association 
and cerebrovascular mortality.(16) Stitt 
blood 
towns as 
pressure 
compared 
levels 
with 
in inhabitants of 
those in a soft-drinking 
hard-drinking 
water 
water area.(17) The same was observed 
living 
in the MRC 
Twelve Towns study, the most marked difference being in casual 
diastolic 
cornfirmed 
blood pressure.(18) However, 
by some other studies and 
these findings were not 
remained subject to much 
debate.(19) In the late sixties Langford and Watson suggested that 
the combination of a low calcium intake and high sodium consumption 
might represent a hypertensiogenic situation.(20) 
evidence has come from a series of observational 
More convincing 
studies relating 
dietary calcium intake to blood 
hypertension.(21-29) Although 
pressure level and the prevalence of 
the assessment of dietary calcium 
intake is difficult a rather consistent pattern emerges, suggesting 
that calcium intake is inversely associated with both prevalence of 
hypertension and level of blood pressure. This observation is one of 
the very few examples of an association between a nutritional marker 
and blood pressure within populations. 
In conclusion, the evidence that a (relatively) low calcium 
intake increases the risk of developing high blood pressure is 
strong. The mechanism whereby low calcium intake induces 
88 
quite 
blood 
pressure elevation is, however, less clear. As will be discussed 
later, a low calcium intake may influence serum calcium levels and 
stimulates the release of parathyroid hormone I. This may, either 
direct or indirect, affect cellular calcium homeostasis and 
peripheral resistance. 
Calcium excretion 
Increased urinary calcium excretion 
hypertensive patients, and in several 
significant 
calcium and 
positive correlation was 
blood pressure.(30-33) In 
has been demonstrated in 
large population studies a 
observed between urinary 
some, but not all, studies 
serum calcium levels and calcium intake were studied concurrently 
and the elevated calcium excretion appears to be unrelated to 
alterations in these factors. 
Differences in the intake of dietary sodium are known to affect 
calcium transport on a tubular level.(34) In particular, dependence 
of renal calcium clearance on sodium clearance might imply that 
increase in calcium excretion is merely the result of changes in 
renal sodium handling.(35) 
and sodium excretion were 
calcium to sodium ratio 
However, in two studies urinary calcium 
studied simultaneously and the urinary 
was also found to be increased in 
hypertensive patients.(30,32) These 
existence of a renal calcium "leak" 
findings are suggestive of the 
in hypertensive subjects. The 
partly confirmed by animal observations in humans are 
studies.(36-38) In spontaneously hypertensive rats (SHR), however, 
hypercalciuria was found to be dependent on food or calcium intake, 
and no detectable net renal calcium loss was present.(39) Definite 
answers to these questions can only be derived from balance studies 
carried out in a metabolic ward. 
conclusions can be made. 
Plasma calcium levels 
At present no unequivocal 
There are several reports on plasma calcium concentration in 
relation to blood pressure levels, the results, however, being 
inconclusive. This may, in part, be due to differences in calcium 
determination. Plasma calcium is present as protein-bound calcium, 
complex bound calcium, and free calcium ions (Figure 4.5.1).(40) 
Total calcium can be measured accurately by atomic absorbtion 
spectometry and other methods, but may not give a reliable 
indication of the biologic active calcium fraction as the proportion 
ionized is affected by variations in the concentration of serum 
protein, 
derived 
particularly albumin, and blood pH.(41) No algorithm 
to adjust total calcium values for the effects of protein 
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Figure 4.5.1. The calcium fractions of blood plasma. Reproduced 
from 41. 
binding seems to predict adequately the physiologically important 
free calcium.(42) The roost widely used direct way to measure ionized 
calcium is by the use of an ion-selective electrode.(43) Although 
the interpretation of the values observed by this method is still 
subject of controversy, the importance of measurement of ionized 
calcium apart from total calcium in order to estimate the 
individual's calcium status appears to be well established.(44) 
Recently, attention has been focused on the more easily measurable 
dializable calcium as an alternative.(45) Bulpitt et al. were the 
first to observe a positive relation between serum total calcium and 
systolic blood pressure.(46) These findings were confirmed in a 
large study in Belgian men, and by several other 
investigators.(30,47,48) Others observed a negative association 
between both serum total calcium and phosphorus, and systolic blood 
pressure in hypertensive subjects.(31) Decreased serum total calcium 
levels were observed in a group of mildly hypertensive youngsters, 
compared to age matched controls from the same population (Paragraph 
5.3). In a study by Erne and coworkers serum total calcium levels 
were lowest in established hypertensive patients, highest in 
normotensives, and intermediate in borderline hypertensive 
90 
subjects.(49) Serum ionized calcium levels were reported to be 
reduced,{50) increased,(Sl) or equal(52) in hypertensive subjects 
compared with normotensive subjects. Interestingly, most 
case-control comparisons 
levels where data from 
show reduced serum total or ionized calcium 
Alternatively, 
patients with 
cross sectional studies are 
ionized calcium may be selectively 
low-renin hypertension.(53) In 
equivocal. 
reduced in 
genetically 
hypertensive rats both reduced serum total and ionized calcium 
levels have been reported.(54-S6) salivary ionized calcium levels 
were found to be decreased in hypertensive subjects.(57) Moreover, 
reduced serum phosphate levels have been related to high blood 
pressure.(58,59) 
There are several explanations for the conflicting findings in 
different studies. Serum total calcium levels may be affected by 
haemoconcentration as observed in hypertension.{60) Also, the 
positive relation between serum total calcium and blood pressure was 
observed in large normal populations, and these studies do not 
exclude the possibility that a subgroup exists combining high blood 
pressure with low calcium levels.(l3) Moreover, since age is 
inversely related to serum total calcium levels the association 
between calcium and blood pressure may be different in different age 
groups.(61) Differences in selection of patients may account for 
certain discrepancies. 
especially diuretics, 
concentration.(62) 
For example, antihypertensive drugs, and 
tend to increase serum ionized calcium 
At this time no firm co~clusions can be drawn linking serum 
total and ionized calciumlevels to blood pressure, although there 
appears to be at least a subgroup of hypertensive patients in which 
serum total and/or ionized calcium levels are reduced. 
4.5.3 Cellular calcium handling. 
Intracellular calcium levels 
Techniques for intracellular calcium determination have only 
recently been developed and various biochemical approaches are used. 
Calciumlevels in the extraCellular fluid are much higher than 
intracellular levels (Figure 4.5.2). The resting (or basal) 
concentration of free intracellular calcium varies between 10 -8 
and 10 -7 mol/1. Changes in intracellular free calcium can be 
derived from either extracellular or intracellular sources. 
Calcium may enter the cell from the extracellular fluid by at 
least three different influx pathways: voltage dependent (or 
potential-operated) channels, receptor operated channels, and the 
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Figure 4.5.2. Schematic representation of cellular calcium 
metabolism, emphasizing the roles of the plasma and mitochodrial 
membranes in the maintenance of a low calcium concentration in the 
cell cytosol. Reproduced from 11. 
so-called Na+ channel(ll) (Figure 4.5.3). It has been suggested that 
calcium is transported from the cytosol to the extracellular space 
predominantly by two mechanisms. 
calcium pump, or Ca2+-Mg2+-ATPase. 
Firstly, by the energy requiring 
Secondly, by the Na-ca exchange 
pathway which is driven by a Na gradient maintained by the Na-K pump 
(Figure 4.5.3) The exchange of calcium between cytosol and calcium 
pools of cellular organelles constitutes an alternative way whereby 
cellular free calcium level is determined.(!!) 
In hypertensive subjects increased intracellular free calcium 
levels have been reported in erythrocytes, platelets and 
adipocytes.(49,63-65) Moreover, a close correlation between platelet 
calcium and arterial pressure has been observed.(49,66) 
Calcium binding and membrane transport 
By far the greatest proportion of intra- and extracellular calcium 
is bound to anionic sites on plasma protein and membrane-associated 
phospholipids. Membrane-bound calcium represents approximately 95% 
of nonskeletal calcium, and includes besides the cell membranes also 
the membranes of intracellular organelles like the mitochondria and 
the endoplasmatic reticulum.(67,68) Several groups have studied 
inner and outer cell membrane binding in hypertensive humans and 
animals. Bound calcium influences membrane function in several ways. 
There are binding sites for calcium on the inner and the outer sides 
of the cell membrane. A number of disturbances of membrane calcium 
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binding have been put 
resulting in elevated 
contributing to elevation 
forward in hypertension, all 
intracellular calcium levels 
eventually 
and thereby 
of blood pressure (Figure 4.5.4). 
The outer side of the cell membrane contains both high and low 
affinity binding sites. On the outer aspect of the cell membrane it 
can be shown that calcium is able of inhibiting its own influx and a 
decrease in the (fast) component of the smooth muscular contractile 
response.(69,70) Total removal of calcium from extra-cellular fluid 
results in a marked increase in permeability to the ion. This is 
impressively demonstrated in a phenomenon called "calcium paradox": 
massive inward movement of calcium ions in cardiac muscle cells 
occurs when extra-cellular calcium concentration is restored after a 
short period of perfusion with a calcium-free solution.(15) The 
mechanism whereby outer membrane-bound calcium exerts its effect on 
the calcium influx remains to be elucidated. A specific inactivation 
of potential operated calcium channels has been postulated.(l4) 
Complete or near 
fluid of smooth 
complete removal of calcium from extra-cellular 
muscle cells and erythrocytes also increases 
permeability for potassium and other monovalent cations.(72,73) 
Calcium binding to the outer side of the cell membrane is reported 
to be reduced in spontaneously hypertensive rats when compared with 
normotensive controls.(74,75) There is some evidence that reduced 
outer surface calcium binding also exists in hypertensive 
patients.(72,75,76) 
Figure 4.5.3. Compilation of postulated membrane transport 
mechanisms involved in cellular calcium homeostasis. 
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Figure 4.5.4. Effects of changes in inner and 
membrane calcium binding on intracellular sodium, 
calcium concentration. 
outer plasma 
potassium and 
The calcium binding to the inner side of the cell has been 
assessed by studies in human and rat cells. Due to the relatively 
low ionic calcium concentration within the cell, inner calcium 
binding sites involve high affinity binding. Erythrocytes of 
hypertensive patients show a substantial decrease in the amount of 
calcium bound to the inner side of the cell membrane.(77) Reduced 
calcium binding to inner side binding sites has been observed in 
erythrocytes of spontaneously hypertensive rats as compared with 
normotensive controls.{78) A similar reduction has been reported in 
fat, heart, liver and neural cells from hypertensive rats.(79,80) 
Decreased inner membrane-bound calcium has been linked to inhibition 
of Na-K-ATPase activity, leading to increased intracellular sodium 
concentration. Elevated intracellular sodium levels may result in 
reduced calcium transport out of the cell, and thus to raised 
intracelular free calcium levels (for details see paragraph 
4.2.4) .(81,82) The observation in red blood cells and Purkinje 
fibers that increased inner membrane calcium binding leads to 
hyperpolarisation may suggest 
favours depolarization and 
channels.(83,84) 
that impaired inner membrane binding 
activation of potential operated 
Evidence is accumulating that many calcium dependent effects are 
mediated by binding to, and activation of, the intracellular calcium 
binding protein calmodulin.(85) Calmodulin (18,000 molecular 
weight), has four calcium 
capable 
binding sites and no intrinsic enzymatic 
of interacting with other proteins to activity, but is 
modify their function in a variety of ways. No clear changes in 
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cellular calmodulin content in hypertension have been reported. Yet, 
in hypertensive subjects both affinity for calcium by the calcium 
plump, and the maximum activity of the calcium pump appear to be 
reduced and these characteristics of the pump are mainly controlled 
by calmodulin.(86-88) An alteration of the inner membrane 
calcium-calmodulin binding kinetics leading to impaired calcium pump 
function may be responsible for these findings. 
In conclusion, the existence of changes in both inner- and 
outer-membrane calcium binding in hypertension has been observed in 
a series of studies. 
the smooth muscle 
to cell membranes in Deficient calcium binding 
cells could account for a greater 
agents.(89) 
membrane 
Also, lability and sensitivity for vasoactive 
alterations in membrane function may lead to an increase in 
intracellular free calcium and thereby influence the state of tonic 
contraction of contractile tissue. Together with reports of 
increased intracellular free calcium levels these findings support 
the view that altered cellular calcium metabolism is implicated in 
the pathogenesis and/or aetiology of primary hypertension. 
4.5.4 Parathyroid hormone in hypertension. 
The first suggestion of an association between hypertension and 
parathyroid gland activity stemms from Helstrom and coworkers 
reporting that hypertension is frequently observed in patients with 
hyperparathyroidism.(90) This observation has been confirmed by 
several authors, and according to Lafferty hypertension is twice as 
common in hyperparathyroid patients as in the general 
population.(94) Furthermore the occurence of hyperparathyroidism 
closely follows the pattern of the occurrence of primary 
hypertension in Western society i.e., a greater prevalence of 
hypertension in hyperparathyroid patients that are older and in 
blacks.(59,91-94) Moreover, the incidence of primary 
hyperparathyroidism in patients with hypertension is about eight 
times higher than average.(92) 
In 1980 the first, preliminary, data 
that parathyroid gland activity is 
were presented indicating 
enhanced in primary 
hypertension.(31) These findings were confirmed by Strazzullo and 
coworkers.(32) No differences in serum calcium were observed, but 
renal calcium excretion was elevated in hypertensive patients. Both 
studies are based on the determination of total immunoreactive 
parathyroid hormone in plasma. This not only represents the intact 
hormone, amino acid sequence 1-84, but includes all fragments 
derived either from peripheral metabolism of the active molecule or 
degradation of precursors of the hormone within the parathyroid 
reported in patients with hyperparathyroidism but not in subjects 
with elevations in serum calcium secondary to other causes.(l13) By 
contrast, hypertensive subjects with primary hyperaldosteronism show 
frank elevations of parathyroid hormone levels, in the absence of 
clear alterations in serum ionized or total calcium and combined 
with suppressed plasma renin activity.(l14) It is conceivable that 
in these 
tendency 
patients parathyroid 
of calcium loss 
levels were raised secondary to a 
mineralocorticoid resulting from 
excess. (115) 
Alternatively, sodium volume expansion may trigger parathyroid 
gland activity. It has been demonstrated that both exogenous and 
endogenous parathyroid hormone decrease renal proximal sodium 
reabsorbtion leading to increased sodium excretion.(ll6,117) The 
observation of natriuretic properties attributed to parathyroid 
hormone, might provide a rationale for a role of this hormone in the 
sodium, calcium and blood pressure interrelationships as suggested 
by DeWardener and Blaustein.(ll8,119) 
It is, as yet, unclear whether the association between the 
parathyroid gland activity and blood pressure is more pronounced in 
the early pathogenesis of primary hypertension. In our studies it 
appeared that plasma parathyroid hormone levels are more clearly 
elevated in young hypertensives than in older subjects.(98) In 
experiments in spontaneously hypertensive rats, Schleiffer and 
coworkers observed a permissive role for the parathyroid gland in 
blood pressure rise.(l20) Parathyroidectomy in young animals, while 
a delay of the rise in 
observed when this 
keeping serum calcium normal, resulted in 
blood pressure for 42 weeks. No effect was 
procedure was performed in adult rats. The 
parathyroid gland activity and/or parathyroid 
association between 
hormone and blood 
pressure might be different in different age groups. Levels of 
parathyroid hormone have been shown to change markedly during 
life.(121) Also, during pregnancy, a state associated with increased 
risk of developing high blood pressure, parathyroid hormone levels 
progressively increase in combination with elevations in serum 
ionized calcium indicating that a different "setpoint" appears to be 
opet"ative.{l22) 
In conclusion, parathyroid gland activity appears to be 
associated with elevations of blood pt"essure. There are indications 
that parathyroid hormone itself may affect blood pressure. This 
could result from modulation by parathyroid hormone of the rate of 
transmembrane calcium fluxes in vascular smooth muscle cells, 
thereby increasing intracellular free calcium levels and ultimately 
leading to increased peripheral resistance. More evidence is clearly 
needed, and in particular methods for measurement of intracellular 
calcium levels may provide valuable additive information. 
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4.5.5 Studies on the effect of calcium supplementation on blood 
pressure. 
There is limited published evidence for an antihypertensive effect 
of oral calcium loading either in normotensive or hypertensive 
subjects. This is in appar~nt contrast with the increasing evidence 
that reduced dietary calcium intake is associated with elevation of 
blood pressure. The first observation of a blood pressure lowering 
action was reported by Belizan and coworkers from a controlled trial 
of oral. calcium against placebo in 57 young normotensive subjects 
for 22 weeks.(123) The calcium supplemented group showed a 
significant decrease in diastolic blood pressure amounting a 
reduction of 5.6% and 9% from the initial values, for women and men 
respectively. Preliminary data from a randomized trial on calcium 
supplementation in hypertensive 
lower blood pressure in some 
plasma renin levels.(l24,125) 
patients suggest that calcium may 
but not all patients, dependent on 
In a randomized crossover study by 
McCarron and coworkers, supplementation with one gram of calcium for 
eight weeks resulted in a fall in blood pressure in hypertensive, 
but not in normotensive subjects.(l26) In a 4-year clinical trial to 
assess age-associated bone loss in women, aged 35 to 65 years, 
calcium suppletion decreased systolic blood pressure in hypertensive 
women on medication, but not in normotensive women.(l27) 
Calcium supplementation of 2 gram daily was reported to lower blood 
pressure in normal pregnant young women.(l28) Preliminary data from 
a study by Strazzullo and coworkers of a placebo controlled 
crossover trial in eightteen patients with borderline hypertension, 
nine of whom 
suggest that 
hypertensive 
appears to 
treatment. 
responses to 
double-blind 
continuing their previous antihypertensive medication, 
calcium may lower blood pressure in a minority of 
subjects.(129) Calcium supplementation in this study 
have no additive effect to antihypertensive drug 
Also, young subjects showed greater blood pressure 
an increase in calcium intake. we performed a 
randomized controlled trial of calcium supplementation 
with one gram daily in ninety young subjects with persistently 
elevated blood pressure levels.(l30) Increased calcium intake for a 
period of twelve weeks resulted in a significant decrease in 
diastolic blood presure, in particular in youngsters with low serum 
total calcium and/or high plasma parathyroid hormone levels. These 
findings suggest that a subgroup of hypertensive individuals exists, 
susceptible to calcium supplementation, and characterized by 
alterations in calcium metabolism indicative of a relative calcium 
need. Future studies in subjects selected on the basis of these 
characteristics may provide further 
involved and establish the efficacy 
insight in the 
and feasibility 
mechanisms 
of calcium 
supplementation as a means of intervention on high blood pressure. 
4.5.6 Conclusion. 
Ultimately, intracellular calcium determines the state of tonic 
contraction of the vascular smooth muscle cell. { 131) Thus, 
irrespective of 
forms the final 
pathophysiological mechanisms involved, calcium 
common denominator of increased peripheral 
resistance and hypertension. 
Several disturbances in cellular and general calcium metabolism 
have been observed in hypertensive subjects and spontaneously 
hypertensive rats. The main findings regard elevations in 
intracellular calcium concentration, reduced ATP-dependent 
transmembrane calcium transport, reduced intracellular calcium 
binding capacity, reduced extracellular binding capacity, reductions 
in serum total- andjor ionized-calcium levels, increased renal 
calcium loss, reduced dietary calcium intake, and increased plasma 
parathyroid hormone concentrations. Either of these factors might 
play a part in one or more pathways leading to elevations in 
intracellular calcium as summarized in Figure 4.5.7. These findings, 
be it in combination or apart may account for elevation of blood 
pressure in same, or all, hypertensive patients. 
Ca binding 
intracelL 
Ca intake ~ 
PTH 
Natriuretic 
Na excretion ~ 
Ca ++ intracell t 
Ca excretion t 
membrane permeability 
to Ca++ t 
vascular peripheral 
resistance t 
BLOOD PRESSURE 
Figure 4.5.7. Hypothetical flaw-chart representing potential 
mechanisms involved in elevation of peripheral resistance and blood 
pressure by alterations in calcium and sodium metabolism. 
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It is as yet not sufficiently clear to what extent changes in 
calcium homeostasis are of aetiological significance, whether they 
result from the hypertensive proces itself, or perhaps enforce other 
mechanisms involved in hypertension. It appears that calcium 
supplementation could be beneficial in hypertensive subjects, in 
particular when a relative calcium deficiency, as judged by serum 
calcium and 
intervention 
moni taring of 
establish the 
parathyroid hormone levels, is present. Further 
studies in subgroups of hypertensive patients with 
determinants of calcium metabolism are needed to 
value of increases in calcium intake as a means of 
lowering blood pressure in hypertension. Moreover, this approach may 
elucidate the role played by calcium in the aetiology of high blood 
pressure. 
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DETERMINANTS OF ELEVATED BLOOD PRESSURE 
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5.1 INCREASED PLASMA DOPAMINE, NORADRENALINE AND ADRENALINE 
CONCENTRATIONS IN YOUNG PEOPLE WITH PRIMARY HYPERTENSION 
5.1.1 Introduction. 
The discovery and experimental use of the potent hypotensive action 
of specific dopamine receptor agonists has renewed the interest in 
the role of endogenous dopamine in the development of primary 
hypertension in man.(l) There are several lines of evidence 
suggesting that central dopaminergic mechanisms play an important 
part in the development of hypertension in animal models as well as 
in humans.(2,3) Studies on the peripheral action of endogenous 
dopamine are scarce but there is considerable evidence that dopamine 
may act as a neurotransmitter in peripheral tissue in addition to 
being a precursor of noradrenaline.(4) A pivotal role for dopamine 
in renal sodium handling appears to be well established.(S) Although 
methodological problems complicate the measurement of peripheral 
sympathetic nervous activity, the development of sensitive 
radioenzymatic assays enables catecholaminergic characterisation of 
hypertensive and normotensive subjects. Previous reports of 
increased levels of plasma noradrenaline in 
hypertensive subjects support the hypothesis 
relatively young 
that essential 
hypertension in its early phase is associated with an altered state 
of the autonomous nervous system.(6) However, the evidence for an 
increased release of adrenaline in essential hypertension is less 
conclusive.(7) The same holds true for dopamine, as no study has 
reported significant differences in plasma dopamine concentrations 
between normotensive and primary hypertensive subjects. 
To investigate the levels of peripheral catecholamines in early 
primary hypertension and to study their interrelationships we 
measured plasma dopamine, adrenaline and noradrenaline levels in 40 
untreated young people with stable mild hypertension and in 40 
age- and gender-matched normotensive controls from the same open 
population. Also, plasma renin and cardiac output were measured in 
these groups. 
5.1.2 Subjects and methods. 
Population 
Between 1975 and 1980 blood pressure was measured in 4,649 subjects 
out of 5,670 eligible {82%) in a study of blood pressure and other 
risk indicators for cardiovascular disease. They were 5 to 19 years 
of age and residents of two districts of a Dutch town. Of the 
initially examined subjects 1,597 were selected for yearly follow 
l12 
up, as described previously.(9) Youngsters were designated as stable 
mild hypertensive if they had at least three blood pressure readings 
of 140 and/or 90 mmHg or over, during seven to nine years of follow 
up. A control group, matched for age and gender was randomly 
selected from the remainder of the same population. Fourty 
hypertensive and 40 normotensive subjects were selected for this 
study. 
Methods 
All hypertensive and normotensive subjects were examined between 
14.00 and 20.00 hours according to a rigorously standardised 
protocol. 
Blood pressure was measured on the left arm using a random zero 
sphygmomanometer after 10 minutes of rest and before venipuncture by 
two trained paramedical observers. For the present analysis the mean 
of three readings in sitting position was used. The beginning of the 
fifth Korotkoff phase was taken as diastolic pressure. 
A blood sample was obtained using 
after 20 minutes recumbency. The blood 
an indwelling venous catheter 
sample was placed in ice-cold 
tubes, centrifuged, and 
catecholamines were 
stored 
measured 
at -70° c 
using the 
until assayed. Plasma 
COMT radioenzymatic 
method.(10) Plasma renin was determined by radioimmunoassay as the 
concentration of active enzyme.(ll) Average urinary electrolyte 
excretion was estimated from one 24-hour urine specimen. From one 
subject in the normotensive group no plasma and urine sample was 
obtained. 
Two-dimensional echocardiography was performed in supine left 
lateral decubitus position. Subsequent quantitative analysis was 
based on the parasternal short axis, apical long axis and four 
chamber views. The modified Simpson-rule formula was used for the 
calculation of end-systolic and end-diastolic left ventricular 
volumes from three consecutive cardiac cycles.(l2) End-diastolic 
minus end-systolic volume yielded stroke volume and cardiac output 
was obtained by multiplying stroke volume 
index was calculated by dividing cardiac 
area.(13) 
Data-analysis 
by heart rate. Cardiac 
output by body surface 
The data analytic approach aimed both at the analysis of differences 
between variables in hypertensive and normotensive subjects, and at 
differences in associations between variables within the 
hypertensive and the normotensive group. For each variable a t-test 
for unpaired observations was used. Only complete matched pairs were 
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taken in the analysis. P values corresponding to a two tailed test 
of significance are given. Relations between catecholamines and 
blood pressure were analysed in two ways. First, subjects were 
categorized according to the median of either of the catecholamines 
within the hypertensive and normotensive group and differences in 
blood pressure between 
quantitative analysis 
these subgroups were studied. second, 
of associations within hypertensive 
a 
and 
normotensive groups was performed by multiple linear regression 
analysis with 
appropriate. 
Results 
adjustments for confounding variables, when 
Anthropometric characteristics and blood pressures of the 
hypertensive and normotensive youngsters are shown in table 5.1.1. 
Plasma noradrenaline, adrenaline and dopamine levels were all 
substantially and significantly higher in hypertensive than in 
normotensive subjects (Table 5.1.2). Plasma renin was higher, though 
not significantly, in the hypertensive group. There were no 
differences in mean serum sodium and potassium values, nor in 24 
hour sodium and potassium excretion. The mean values of cardiac 
output and cardiac index did not differ between the groups (Table 
5.1.2 I. 
Multiple regression analysis revealed several relationships 
between variables measured and these are summarized in table 5.1.3. 
TABLE 5.1.1. Blood pressure and anthropometric characteristics in 
young subjects with and without mild hypertension. 
Age (y) 
Body weight (kg) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Sitting pulse rate (beats/min) 
Results are given as mean ± SD. 
* matching variable. 
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Hypertensives 
(n = 40) 
24+3 
77;11 
142+11 
82±11 
72±10 
Normotensives 
In • 40) 
24+3 
74+9 
125+11 
74+8 
72±10 
p value 
* 
0.18 
<0.001 
<0.001 
TABLE 5.1.2. 
excretion and 
hypertension. 
Plasma catecholamines, renin, urinary electrolyte 
haemodynamics in young subjects with and without mild 
Hypertensives Normotensives p value 
(n=40) (n=-39) 
Plasma noradrenaline (pg/ml) 
Plasma adrenaline (pg/ml) 
Plasma dopamine (pg/ml) 
Noradrenaline/dopamine ra·tio 
Plasma renL1 (u-uni ts/ml) 
24 h urinary sodium (mmol) 
24 h urinary potassium (mmol) 
24 h urinary creatinine (mmol) 
cardiac output (1/min) 
cardiac index (l/min/m2) 
Results are given as mean ±SEM. 
302+23 
91+13 
72+7 
5.2±0.6 
12.6±1.1 
136+8 
68+4 
17.0±0.7 
4.8±0.3 
2.7±0.2 
157±9 
37+4 
46+4 
4.2±0.6 
10 .1±1. 2 
141+14 
71+7 
18.0±0.6 
4.9±0.3 
2.6±0.1 
<0.001 
<0.001 
<0.01 
0.18 
0.13 
0.76 
0.70 
0.48 
0.81 
0.48 
TABLE 5 .1. 3. 
associations 
separately. 
variables. 
Coefficients of multiple linear regression of 
observed in hypertensive and normotensive groups 
Each coefficient is adjusted for differences in other 
Normotensive subjects 
Dependent variable Independent b SEM p 
Systolic BP Body weight 0.52 10.17) nunHg/pg.ml-1 0.01 
Systolic BP Noradrenaline 0.08 I 0. 03 l mmHg/pg.ml-1 0.01 
Systolic BP Adrenaline -0.07 I o. 07) mmHg/pg.ml-1 0.37 
Systolic BP Dopamine -0.11 I o. 06) mmHg/pg.m1-1 0.09 
Noradrenaline Dopamine 0.24 10.37) pg.ml-1/pg.ml-1 0.53 
Adrenaline Body weight 0.33 I 0. 43 l pg.ml-1/kg 0.39 
Renin Body weight 0.13 I 0.15 l units/kg 0.41 
Hypertensive subjects 
Dependent variable Independent b SEM p 
Systolic BP Body weight 0.12 10.19) mmHg/pg.ml-1 0.55 
Systolic BP Noradrenaline -0.01 I o. 01 l mmHg/pg.m1-1 0.91 
Systolic BP Adrenaline -0.05 I o .02) mmHg/pg.ml-1 0.06 
Systolic BP Dopamine -0.02 I 0. OS) mmHg/pg.ml-1 0.74 
Noradrenaline Dopamine 1.11 I 0.61 l pg.ml-1/pg.ml-1 0.08 
Adrenaline Body weight 2.67 11.38) pg.ml-1/kg 0.05 
Renin Body weight 0.24 I o .11) units/kg 0.04 
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Body weight was positively related to plasma renin and adrenaline. 
This association was observed in the hypertensive group and also 
when the group was analysed as a whole, but not in the normotensive 
subjects. Dopamine was positively related to noradrenaline in the 
total group and, to a lesser extent, in hypertensive and 
normotensive subjects separately. Systolic blood pressure was 
positively associated with body weight in the normotensive group but 
not in the hypertensive group. Also, a strong relation between 
noradrenaline and systolic blood pressure was observed in the 
normotensive group and in the groups combined, but not in the 
hypertensive group. This is illustrated in figure 5.1.1, showing 
differences in systolic blood pressure in hypertensive and 
normotensive subgroups based on a higher or lower than median plasma 
noradrenaline. Dopamine showed a weak negative association with 
systolic blood pressure in the normotensive group. In hypertensives 
systolic blood pressure was inversely related to adrenaline, on the 
average resulting in a lower systolic blood pressure in those with a 
higher plasma adrenaline (Figure 5.1.2). 
Systolic blood 
pressure 
(mmHg) 
160 
150 
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130 
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110 
100 
90 
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<MED ~MED 
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nn 
<MED ~MED 
D 
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Figure 5.1.1. Systolic blood pressure in subgroups of 
normotensive and hypertensive subjects according to the median of 
the distribution of plasma noradrenaline (* p < 0.05). 
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Figure 5.1.2. Systolic blood pressure in subgroups of 
normotensive and hypertensive subjects according to the median of 
the distribution of plasma adrenaline (* p < 0.05). 
Discussion 
Our findings of raised plasma catecholamine levels in young 
hypertensive subjects confirm previous 
noradrenaline and adrenaline levels in 
reports of elevated plasma 
primary hypertension and 
extend these findings to dopamine, thereby providing evidence that 
an altered state of the autonomous nervous system may be implicated 
in the early phase of primary hypertension.(14) In the hypertensive 
subjects the distribution of plasma catecholamines is skewed, 
indicating an increased 
catecholamine levels in 
proportion of individuals with high 
this group without a clear bimodality 
(Figure 
The 
source 
5.1. 3 I. 
importance 
population, 
of degree and stability of hypertension, age, 
sampling technique, and assay used in studying 
differences in catecholarnines between hypertensive and normotensive 
subjects, and the impact of differences in methods on the outcome of 
studies, have been repeatedly stressed.(8) Therefore, in the present 
study the normotensive youngsters included in the reference group 
were individually matched for age and gender with the hypertensive 
subjects, and drawn from the same population. 
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0 100 200 300 (pg/ml) 
Figure 5.1.3. Distributions of plasma noradrenaline, adrenaline 
and dopamine concentration in normotensive and hypertensive 
subjects. 
under physiological circumstances noradrenaline must be 
considered predominantly as a neurotransmittor.(15,16) Although 
several methodological comments have been made concerning the 
interpretation of plasma noradrenaline levels, it appears justified 
to conclude that plasma catecholamine levels provide a good index of 
overall sympathetic nervous system activity.(17) Moreover, studying 
physiological interrelations of catecholamines does not permit 
infusion techniques and thus excludes several other approaches. 
Contrary to noradrenaline, adrenaline is a hormone in the 
traditional sense. Infusion of adrenaline to plasma levels within 
the range we observed in the hypertensive group may have direct 
metabolic effects and plasma concentrations as low as 80 pg/ml 
impair glucose tolerance in normal subjects.(l8,19) 
The finding that both plasma adrenaline and renin were related 
to body weight, partially confirms previous reports based on urinary 
liS 
excretion of metabolites of catecholamines.(20,21) Due to these 
findings body weight must be regarded as a confounding variable when 
comparing differences in plasma renin and adrenalin and blood 
pressure within groups of hypertensive subjects. It appears that the 
relation between body weight and these hormones is less clear in 
normotensive subjects. The physiological mechanism underlying these 
findings needs further consideration. 
we observed a significant 
noradrenaline and systolic blood 
Other studies have shown that 
positive relation between plasma 
pressure in the normotensive group. 
plasma noradrenaline levels tend to 
increase with age.(22) A different association between blood 
pressure and noradrenaline may exist in different age groups. This 
might provide an explanation for the inconclusive findings regarding 
plasma noradrenaline and blood pressure by other investigators.(23) 
The lack of an association in hypertensive subjects may indicate an 
altered response of blood pressure to noradrenaline in this group. 
It may also be the result of a negative feedback, suppressing the 
physiological association. 
A positive association was found between noradrenaline and 
dopamine in the groups combined, in hypertensive subjects and, 
although less clear, in normotensive subjects. Until recently 
dopamine was regarded primarily as a precursor for noradrenaline, 
but evidence is accumulating for an independent role of dopamine in 
peripheral neurotransmission.(S) The observed positive association 
is compatible with either of these possibilities. The biological 
effects of dopamine on kidney and peripheral vasculature are 
counteracting the effects of noradrenaline, as it causes 
natriuresis, and vasodilation in 
beds.(1,4,5,24-27) The observed 
renal, mese-nteric, and coronary 
negative association between 
dopamine and systolic blood pressure in normotensive subjects 
suggests that dopamine and noradrenaline may have antagonistic roles 
in blood pressure regulation. A failing counterregulation of 
dopamine in response to elevated noradrenaline levels might result 
in an elevated blood pressure, but although in our groups the 
noradrenaline/dopamine ratio was higher in the hypertensive group 
this difference failed to reach statistical significance. 
An puzzling finding is the slight inverse relation between 
systolic blood pressure and plasma adrenaline in hypertensives. This 
observation is in conflict with an hypothesis regarding the role of 
adrenaline in hypertension by Brown and Macquin, but confirms a 
recent report by the same group.(28,29} It may be that in patients 
in which the blood pressure in not maintained by sympathetic 
activity, adrenaline is actually a weak vasodilator as a result of 
peripheral b 2 stimulation (M.J. Brown, personal communication). 
In conclusion our findings of increased levels of plasma 
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noradrenaline, adrenaline and dopamine provide evidence for enhanced 
autonomous nervous system activity in the early phase of primary 
hypertension. We did not observe an increase in cardiac output in 
the hypertensive group, indicating that no apparent "hyperkinetic" 
circulatory state is present in these subjects. In normotensive 
youngsters systolic blood pressure is positively associated with 
plasma noradrenaline and negatively with plasma dopamine, in 
hypertensive subjects these relationships are altered. 
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Chapter 5 
DETERMINANTS OF ELEVATED BLOOD PRESSURE 
5.2 INTACT PARATHYROID HORMONE (1-84] IN PRIMARY HYPERTENSION 
Introduction 
Altered calcium metabolism has been implicated in the aetiology of 
primary hypertension.(1,2) Increased levels of circulating 
parathyroid hormone have been interpreted as supporting this view. 
common finding in primary Hypertension is a 
hyperparathyroidism,(3,4) and the prevalence of hyperparathyroidism 
is considerably higher in subjects with primary hypertension than in 
normotensive subjects.(5) Two studies comparing hypertensive and 
normotensive subjects have shown higher levels of serum parathyroid 
hormone (PTH) concentrations.(6,7) The concentrations of PTH given 
in these reports concern total concentrations of the intact-PTH 
molecule as well as part of its metabolites. Recently a new two-step 
immunochemical method for estimating serum intact-PTH has been 
developed.(8,9) We measured serum intact-PTH levels in 83 
hypertensive patients aged 20 to 69 years, and in 83 normotensive 
subjects selected from the same open population and matched for age 
and gender. 
subjects, materials and methods 
Between 1975 and 1978, 10,532 out of 13,462 (78%) inhabitants aged 5 
years and over of two districts of the town Zoetermeer, near the 
Hague in the Netherlands, participated in a survey of cardiovascular 
risk indicators as described previous1y.(10,11) In all subjects 
blood pressure was measured with a random zero sphygmomanometer.(l2) 
The readings were made in sitting subjects on the left arm, by eight 
trained paramedical observers. Two readings were obtained in time 
separated by a count of the pulse rate and their mean was used in 
the analysis. Diastolic pressure was based on the fifth Korotkoff 
sound. A history of high blood pressure was taken and information 
was obtained about the use of anti-hypertensive and o~her drugs. 
Serum samples were drawn and stored frozen (-20°C). 
For the present study 83 subjects (48 men) aged 20-69 years with 
a mean arterial blood pressure (MAP = diastolic blood pressure + 
pulse pressure I 3) of 120 mmHg or more were selected, and 
designated as hypertensive. From the subjects below the 25th 
percentile of the overall blood pressure distribution of MAP (i.e. 
MAP <90 mmHg) 83 normotensive subjects matched for age and gender 
(according to 5-year strata), were randomly selected using 
computer-generated random numbers within sex specific five-year age 
strata. (13) subjects on antihypertensive or other drugs that might 
affect blood pressure were excluded from this study. 
Se~um intact-PTH concentration was measured by a two-step 
immunochemical method.(8,9) The first step involves extraction and 
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concentration of plasma PTH moieties with solid phase linked 
amino-terminal PTH antibodies. In the second step, the initial PTH 
irnmunoextract is analysed 
radioimmunoassay. 
Due to technical reasons 
determined. 
Data analyses 
with a sensitive midregion 
no serum calcium values were 
The data analytic approach was two-fold. Firstly, for group mean 
observations with pooled comparisons the t-test for unpaired 
variances was used. The p values correspond to a two-tailed test of 
significance. Secondly, weight adjusted values of intact-PTH were 
calculated by entering weight as an independent variable in a model 
for multiple linear regression with intact-PTH as the oucome 
variable. All analyses were performed for the total group, and for 
three age groups separately: < 40 years, 40-54 years and > 54 years 
respectively. 
Results 
The anthropometric characteristics of the total group are shown in 
table 5.2.1. and for the subgroups for different age strata in table 
5.2 .2 •• 
Serum creatinine levels were 1.00 mgjdl (SE 0.02) in 
hypertensive and 0.96 mg/dl (0.02) in normotensive subjects (p 
0.19). Within the three age strata a significant higher mean serum 
creatinine level was observed in those aged 40 to 55 years, 1.04 
mg/dl (0.04) in hypertensive and 0.95 mg/dl (0.02) in normotensive 
subjects (p = 0.05). 
Table 5.2.1. Anthropometric Characteristics and Mean Blood Pressure 
values of the Two Study Groups. 
Age (years) 
Body weight (kg) 
Height (em) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure {mmHg) 
Mean arterial pressure (mmHg) 
Hypertensive 
subjects 
49 I 11 
79 I 21 
171 I 11 
175 I 21 
110 I 1 I 
131 Ill 
Results are given with SEM between parentheses. 
** p < 0.001 
Normotensive 
subjects 
49 11 I 
67 I 1 I ** 171 I 1 I 
117 I 1 I ** 
68 11 I ** 84 I 1 I •• 
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Table 5.2.2. Anthropometric Characteristics and Mean Arterial Blood 
Pressure of the Two Study Groups Stratified by Age. 
Age group: < 40 year 
Age (years) 
Body weight (kg) 
Height (em) 
Mean arterial pressure (mmHg) 
Age group: 40-54 year 
Age (years) 
Body weight (kg) 
Height (em) 
MeaD arterial pressure (mmHg) 
Age group: >54 year 
Age (years) 
Body weight (kg) 
Height (em) 
Mean arterial pressure (mmHg) 
Hypertensive 
subjects 
ln=221 
30 11) 
83 I 31 
174 I 2) 
122 121 
ln=351 
49 I 1 I 
80 I 2 I 
171 12 I 
135 11 I 
ln=26) 
62 I 1 I 
75 I 2 l 
168 I 2 I 
134 I 2 I 
Results are given with SEM between parentheses. 
* p < 0-01 
** p < 0.001 
No statistically 
levels between the 
coefficients of MAP on 
significant differences in 
two groups were found. 
PTH in the hypertensive 
Normotensive 
subjects 
ln=221 
30 I 11 
67 I 21 ** 
173 (21 
80 I 1 I ** 
ln=35) 
49 11 I 
69 I 2 I ** 
171 I 21 
85 I 1 I ** 
(n=26) 
61 I 1 I 
66 I 1 I * 
168 I 1 I 
85 I 1) ** 
serum intact-PTH 
The regression 
and normotensive 
gr~ups separately and combined, were not significantly different 
from zero. However, multiple linear regression of PTH on age, body 
height and weight yielded a negative association between PTH and 
body weight (b=-1.26 pmol.l-l.kg, SE = 0.7). This finding and the 
observed differences in body weight between the hypertensive and 
normotensive groups prompted us to adjust the intact-PTH levels for 
these differences in body weight, using a model for multiple linear 
regression. After adjustment for differences in body weight a 
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significant difference in PTH was found between hypertensive and 
normotensive subjects in those aged 20-39 years, but not in older 
subjects (Table 5.2.3.). 
Table 5.2.3. Mean Values of Serum Intact-PTH (pmoljl): Observed 
Values and Values Adjusted for Differences in Body Weight. 
Unadjusted Adjusted 
Age (years) HT NT HT NT 
20-39 1. 72(0.211 1.49(0.201 1.94(0.201 1.28(0.18)* 
40-54 1.42(0.181 1.59(0.191 1.46(0.161 1.64(0.201 
55-69 1.45(0.261 1.33(0.161 1.46(0.241 1.28(0.141 
Total 1.51(0.141 1.48(0.121 1.58(0.101 1.42(0.101 
Results are given with SEM between parentheses. HT = Hypertensive 
subjects, NT = Normotensive subjects. 
*p<O.OS 
Discussion 
No differences in intact-PTH concentrations between hypertensive and 
normotensive subjects were observed when the data were analysed 
without other differences between the two groups taken into account. 
However, body weight appears to be related to both blood pressure 
and intact-PTH level and must therefore be considered a confounding 
variable in studying the association between PTH and blood pressure. 
When adjustments were made for differences in body weight, 
significantly elevated levels of intact-PTH were found in a subgroup 
of young primary hypertensive subjects. Although these findings must 
be interpreted with caution, this may give further evidence that 
increased parathyroid gland activity might play a part in the early 
pathogenesis of primary hypertension. Further studies are required 
to assess whether the potential role of PTH in hypertension has 
aetiological significance. 
some methodological comments must be made. There are two 
previous reports 
hypertension and 
on 
both 
enhanced parathyroid function in primary 
studies were based on patients attending 
hypertension clinics.(6,7) Control groups were blood donors and 
healthy volunteers. Selecting patients and controls from different 
populations may induce differences in PTH levels, or any other 
variable for that matter, that are unrelated to the difference in 
blood pressure. We removed known hypertensives from the study groups 
and selected normotensive controls from the same source population. 
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Besides, we were able to create a relatively large contrast in blood 
pressure between the two study groups. 
Contrary to the approach in previous studies, we used a combined 
biochemical and radioimmunochemical method that selectively isolates 
and estimates levels of the circulating intact-PTH [1-84]. 
Intact-PTH comprises less than 10% of total midregion or c-terminal 
PTH immunoreactivity. Most of the circulating PTH metabolites 
contain the M- and C-terminal regions of the intact hormone. 
Bioactivity, however, resides in the N-tecminal sequence.(14) 
Reduced renal clearance of nonbioactive PTH fragments may result in 
increased serum total-PTH levels without alteration of 
intact-PTH.(S) Reduction of glomerular filtration rate is present in 
most patients with severe hypertension. There is less evidence of 
renal impairment in milder forms of hypertension. However, reduction 
of renal clearance of P~H metabolites may be of relevance in chronic 
hypertensive subjects. This can in part be responsible foe reported 
increa.sed levels of total immunoreactive PTH in hypertension and 
stresses the advantages of the use of 
determine the intact fraction of serum 
more selective methods to 
total-PTH. The observed 
relation between body weight and PTH needs further elucidation 
regarding the mechanisms involved. There are no previous reports 
describing this phenomenon although the same has been observed for 
plasma catecholamines.(15) Moreover, the observed relation between 
body weight and intact-PTH is not necessarily also existing between 
total-PTH levels and body weight. As an hypothetical explanation it 
might be suggested that heavier subjects eat more, and have 
therefore a higher calcium intake and subsequent lower plasma PTH 
levels. 
The serum-samples used in our analysis are comparatively old, 
and this may have influenced the results. There are no studies on 
the reproducibility of the assay we used in serum-samples that were 
stored frozen for some time. However, if there is any effect of time 
on the serum intact-PTH levels, it is likely that this would tend to 
reduce immunoreactivity to the same extent in serum derived from 
hypertensive as from normotensive subjects. Besides, the values 
observed in the samples used are in agreement with the range of 
serum intact-PTH levels found in fresh samples.(9) 
There are several possible explanations for raised levels of 
serum PTH in hypertensive subjects. McCarron et al.(6) have raised 
the possibility that a urinary calcium leak is responsible for an 
enhanced activity of the parathyroid gland. An increase in serum PTH 
secundary to renal calcium loss 
to the early phase of primary 
would not necessarily be restricted 
hypertension. schleiffer et al. 
performed parathyroidectomy in young spontaneously hypertensive 
rats, keeping a normal serum calcium.(l6) This resulted in a delay 
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of the rise in systolic blood pressure for 42 weeks. These findings 
support the hypothesis that alterations in PTH homeostasis may be of 
special relevance in the early stages of primary hypertension. Serum 
PTH levels in hypertensive subjects may be influenced by calcium 
intake, increased sympathetic nervous system activity and several 
other mechanisms. Recent evidence has related higher intakes of 
calcium with lower systolic bloodpressure.(17) When plasma 
noradrenaline levels in young hypertensive and normotensive subjects 
are compared, the former show significantly higher plasma 
noradrenaline levels.(18) 
As there are several lines of evidence relating PTH to 
hypertension, the question arises wether PTH itself contributes to 
the elevation of blood pressure. 
concentration is known to be the most 
The intracellular calcium 
important determinant of the 
state of tonic contraction of the vascular smooth musle cell.(19} A 
known effect of PTH is an increase of the cytosolic free calcium 
concentration.(20) Circulating natriuretic substances have been 
implicated in the aetiology of primary hypertension.(21) PTH has 
natriuretic properties. The exact nature of the relation between PTH 
and arterial pressure, however, cannot be determined from our data 
and remains to be elucidated. 
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5.3 RAISED PLASMA INTACT PARATHYROID HORMONE LEVELS IN EARLY 
PRIMARY HYPERTENSION 
5.3.1 Introduction. 
An association between parathyroid gland activity and blood pressure 
was first suggested by Helstrom and coworkers, who reported an 
increased prevalence of hypertension in primary 
hyperparathyroidism. ( 1 l Furthermore, the prevalence of 
hyperparathyroidism in primary hypertensive subjects is considerably 
higher than in the general population.(2) The hypertension appears 
not to be secondary to renal damage resulting from hypercalcemia in 
hyperparathyroidism.(3,4) Whether or not blood pressure falls after 
parathyroidectomy in patients with primary hyperparathyroidism is 
still subject to debate.(4,5) Two studies have shown increased 
circulating total immunoreactive parathyroid hormone (PTH) levels in 
hypertensive patients.(6,7) Preliminary data suggest that serum 
intact para~yroid hormone (PTH [1-84]) may be elevated in young 
hypertensive subjects.(8) The level of PTH [1-84} gives a more 
accurate index of parathyroid gland activity than total PTH, because 
PTH [1-84] is unaffected by alterations in renal clearance of PTH 
metabolites as may result from chronic hypertension.(9,10) We 
studied plasma PTE [1-84] levels in a group of young subjects with 
blood pressure levels persistently in the upper range of the blo.od 
pressure distribution, and a group of normotensive reference 
subjects selected from the same population. 
Materials and methods 
Population 
From 1975 to 1979 all 5 tc 19 years residents of two districts of 
the Dutch town of Zoetermeer, were invited to take part in a survey 
of risk-indicators for cardiovascular disease and 4,649 of them 
participated (82%). Of the initially examined children, 1,597 were 
selected for annual follow-up as described previously.(!!) None of 
the subjects received any specific intervention during the 
follow-up. From this cohort the participants for the present study 
were selected. Stable mild hypertension was defined as at least 
three blood pressure readings of 140 mmHg systolic and/or 90 mmHg 
diastolic or over at yearly examinations during seven to nine years 
of follow-up, without identified secondary hypertension. Of 130 
eligible, 90 subjects (77 males) agreed to participate in the study, 
which formed part of an intervention study following shortly 
thereafter. Fourty normotensive reference subjects of the same ages, 
who had participated in a previous study,(12) were selected from the 
remainder of the follow-up cohort. 
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Measurements 
Blood pressure was measured with a random-zero sphygmomanometer, 
between 4 and 8 pm, after 10 minutes of rest and before 
venipuncture, by two trained paramedical observers. Three readings 
were obtained on the left arm with the subject sitting, and the mean 
was used in the analysis. 
A plasma sample was obtained in chilled EDTA-tubes and stored 
frozen until assayed. All subjects collected one 24-hour urine 
sample. Serum and urinary total calcium and creatinine were measured 
by standard methods. The plasma PTH [1-84] concentration was 
determined 
method. (10) 
by a recently developed two-step immunochemical 
Data analysis 
For group mean comparisons t-tests for unpaired observations with 
pooled variances were used. To assess relations between variables, 
simple linear regression analysis was performed, separately for 
hypertensive and normotensive subjects. The p values correspond to a 
two-tailed test of significance. 
Results 
The results are summarized in table 5.3. Plasma PTH [1-84] levels 
were 2.34 pmol/1 (0.11) in hypertensive subjects and 1.47 pmol/1 
(0.13) in controls (p < 0.0001, Figure 5.3). The distribution of PTH 
[1-84] was shifted as a whole to higher levels in the hypertensive 
subjects. Serum total calcium concentration was lower in 
hypertensive youngsters than in normotensive reference subjects. 
There were no differences in 24-hour urinary calcium excretion or in 
serum creatinine bet·,.;reen the groups. 
Table 5.3. Characteristics of the study subjects. 
Hypertensive group Normotensive group 
Variable (n = 90) (n = 40) p value 
Age (years) 24.3 I 0. 3 I 24.4 ( 0. 5) 0.44 
Blood pressure (rnmHg) 
systolic 143.2 I 1.11 125.0 (1.81 < 0.0001 
Diastolic 83.0 11.1 I 74.3 I 1.21 < 0.0001 
Body weight (kg) 77.9 I 1. 3 I 73.5 11.5 I 0.03 
PTH [1-84] (pmol/1 I 2.34 I 0.11 I 1.47 I 0.13 I < 0.0001 
Serum calcium (mmo1/1) 2.36 I 0. 01 I 2.42 I o .01 I 0.002 
Serum creatinine (umol/1) 73.8 I 1.51 74.0 ( 1. 7) 0. 91 
Urinary calcium (rnmol/24 h) 4.17 (0.281 3.89 I o .39 I 0.27 
values are means. SEM between brackets. 
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Figure 5.3. Means (± SE) and distributions of plasma PTH [1-84] 
in young hypertensive subjects and normotensive controls. 
Within the hypertensive group, both systolic and diastolic blood 
pressure increased with plasma PTH [1-84]: b = 2.3 mmHg/pmol/1 (SE-
1.1, p = 0.05) and b 2.2 mmHg/pmol/1 (SE 1.1, p"" 0.05) 
respectively. In the normotensive group 
the same magnitude were found (b 4.6 
systolic and b = 2.5 mmHg;pmol;l (SE = 
associations of essentially 
mmHg/pmol/1 (SE = 2.9) for 
1.9) for diastolic blood 
pressure), 
statistical 
calcium and 
but the regression coefficients failed to reach 
significance. No direct relationship between serum 
blood pressure was observed. Moreover, PTH [1-84] was 
not significantly associated with serum total calcium, either in the 
separate or combined groups. 
Discussion 
our findings of raised levels of plasma PTH [1-84] provide evidence 
that circulating intact parathyroid hormone may be increased in 
mildly hypertensive youngsters. Furthermore, in hypertensive 
subjects both systolic and diastolic blood pressure appear to be 
positively related to plasma PTH [1-84]. These observations support 
the hypothesis that enhanced parathyroid gland activity is 
implicated in the early phase of primary hypertension. This may 
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consist of autonomous hyperfunctioning of parathyroid tissue or 
result from other causes (secondary hyperparathyroidism).(l3) These 
possible causal processes include increased renal calcium loss or 
reduced dietary calcium intake. Both have been reported in 
hypertensive subjects.(6,7,14) The effects on parathyroid gland 
activity may be mediated by a slight reduction in serum calcium 
levels as observed in this and previous studies.(lS) We did not 
observe differences in urinary calcium excretion. However, it is 
difficult, if not impossible, to characterize the calcium excretion 
of an individual with a single urine specimen. 
Basal parathyroid gland activity may also be influenced by 
sympathetic nervous system activity.{16) This view is consistent 
with findings in a previous study based on a similar group of 
hypertensive youngsters selected from the same population, in which 
increased levels of plasma noradrenaline, adrenaline and dopamine 
were observed.(l2) 
The question remains whether PTH itself contributes to the 
elevation of blood pressure or whether increased parathyroid gland 
activity is merely a result of alterations in calcium metabolism 
associated with hypertension.(!?) Long-term administration of PTH 
increases blood pressure in humans 
the calcium concentration in the 
and rats.(l8,19) PTH may raise 
smooth muscle cell, thereby 
increasing contractility and consequently peripheral resistance.(20) 
Studies in spontaneously hypertensive rats suggest that parathyroid 
gland activity may affect blood pressure predominantly in the early 
phase of the development of hypertension.(21) In humans, studies on 
calcium metabolism in the onset of primary hY9ertension are clearly 
indicated, and in particular the possible role of the parathyroid 
gland in early hypertension merits further evaluation. 
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Chapter 6 
DIETARY INTERVENTION ON ELEVATED BLOOD PRESSURE 
Il9 
6.1 SODIUM RESTRICTION AND POTASSIUM SUPPLEMENTATION IN YOUNG 
PEOPLE WITH MILDLY ELEVATED BLOOD PRESSURE 
Introduction 
Electrolytes have been implicated in the aetiology and treatment of 
hypertension. The possibility of reducing high blood pressure by 
rigorous sodium restriction, to levels 
demonstrated by several workers.(l,2) 
sodium intake extent 
below 30 rnmol/day, has been 
Studies restricting daily 
have yielded conflicting 
results.(3-8) 
to 
In 
a 
1928 
lesser 
Addison was the first to suggest that 
potassium salts may reduce blood pressure.(9) The role of potassium 
supplementation in blood pressure control is now explored with 
renewed interest, since both epidemiologic and animal model studies 
have suggested potassium as a depressor.(lO,ll) 
Dietary intervention in the management of high blood pressure is 
of special importance in young people. There is a tendency of 
lowering the threshold values for treating hypertension over the 
last few decades and this means that a growing number of younger 
subjects is regarded as requiring treatment. Nonpharmacologic 
intervention by changing dietary habits might be a valuable 
alternative to life-long medication, of which the benefit-risk ratio 
is not clear.(12) 
To study the effect of moderate sodium restriction and the 
combination of sodium restriction and potassium supplementation in 
young people with high blood pressure, we conducted a double-blind 
randomised three-period crossover trial in 40 untreated young adults 
with mildly elevated blood pressure. 
Materials and methods 
Population 
Between 1975 and 1980 all persons who were 5-19 years of age and 
residents of two districts of Zoetermeer, a suburban residential 
area near the Hague in the Netherlands, were invited to participate 
in a study of blood pressure and other risk-indicators for 
cardiovascular disease (EPOZ-study).{l3) Blood pressure was measured 
in 4,649 subjects out of 5,670 eligible (82%). Of the initially 
examined subjects, 1,597 were selected for annual follow-up. This 
group comprised all children in the upper decile of the distribution 
of one or more of the cardiovascular risk-indicato~s, plus a control 
group randomly selected f~om the same population. Tthe study g~oup 
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for this trial was selected from this cohort on the basis of at 
least three blood pressure readings of 140 and;or 90 mmHg or over, 
at annual examinations during seven to nine years of follow-up and 
no evidence of secondary hypertension. In this population the 
subjects thus selected match the norm for childhood hypertension as 
reported by the Task Force on Blood Pressure Control in 
Children.(14) Of 80 eligible, 42 young people with mildly elevated 
blood pressure, as previously defined, agreed to take part in this 
study. Two subjects were excluded because they refused to continue, 
once they were confronted with the diet. All other fourty completed 
the trial, 34 males and 6 females, age 18 to 28 years. 
Protocol 
During a two week lead-in period, blood pressure was measured at 
three occasions, two at the examination center and one at home. The 
subjects collected two 24-hour 
was taken at the end of the 
entered into a randomised 
urine specimens and a blood sample 
lead-in period. The study group then 
double-blind crossover study with 
"slow-sodium" tablets for six weeks (CIBA, 10 mmol sodium per 
tablet), six weeks with "slow-potassium" tablets (CIBA, 8 mmol 
potassium per tablet), and six weeks with matched placebos (CIBA), 
with a fixed dose of nine tablets a day. The subjects were randomly 
assigned to one of six possible sequences. All participants 
restricted their dietary 
the trial (18 weeks). 
food-diary, and at the 
sodium intake during the whole period of 
During the lead-in period they kept a 
end of this period everyone received 
individual dietary 
three weeks by the 
advice. They were also visited at home every 
provided for study dietician. Tablets were 
periods of three weeks and the number of tablets left over after 
these periods was recorded as an index of compliance. A local baker 
provided bread with 35% less salt for the normal price, and low-salt 
meat products and cheese were provided for free. 
Measurements 
Blood pressure was measured on the left arm with a random zero 
sphygmomanometer after 10 minutes of rest and before venipuncture. 
At each occasion six readings were made, three sitting and three 
supine, in time separated by a count of the pulse rate. The average 
of three subsequent readings was used in the analysis. During the 
trial the patients were seen at the examination center for blood 
pressure measurement every three weeks. Every si~th week a blood 
sample v.ras obtained using an indwelling venous catheter with the 
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patient supine for 20 minutes. Two-dimensional echocardiograms were 
performed in supine left lateral decubitus position. The parasternal 
short axis, apical long axis and four chamber views were recorded 
for subsequent quantitative analysis. The modified Simpson-rule 
formula was used for the calculation of end-diastolic and 
end-systolic left ventricular volumes from three consecutive cardiac 
cycles.(l5) End-diastolic minus end-systolic volume yielded stroke 
volume and cardiac output was obtained by multiplying stroke volume 
by heart rate. Serum and plasma samples were stored at -70°C. Plasma 
renin was determined by radioimmunoassay as the concentration of 
active enzyme,(l6) and plasma catecholamines were measured using the 
COMT radioenzymatic method.(17) Mean urinary sodium, potassium and 
creatinine excretion was estimated from four 24-hour urine 
collections in each six-week period. 
Data-analysis 
The data were analysed in two ways. First, the effect of changes in 
sodium and potassium intake on the blood pressure were examined by 
comparing blood pressure at the end of the placebo period and at the 
end of the slow-potassium period with blood pressure at the end of 
the slow-sodium period. Second, changes in blood pressure were 
related to characteristics of the patients at baseline in order to 
identify subgroups of patients specifically susceptible to sodium 
restriction and potassium supplementation. The differences were 
tested using a t-test for paired observations. The results of this 
procedure are expressed as a one-tailed p-value (pl) for changes in 
blood pressure and a two-tailed p-value (p2J for other variables. A 
separate analysis revealed no treatment order effects. 
Results 
Baseline characteristics 
These are summarized in table 6.1.1. 
Electrolytes and body weight 
Mean sodium excretion was 129 mmol/24h during the slow-sodium 
period, and fell to 57 mmol/24h during placebo, and to 69 mmol/24h 
during slow-potassium. The urinary sodium/potassium ratio was 1.7 in 
the slow-sodium period, and fell to 0.5 during slow-potassium. Serum 
sodium was unchanged during the intervention periods. Serum 
potassium was 0.23 mmol/1 higher during high potassium/low sodium 
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intake than in the other periods (p2 < 0.05). Body weight remained 
stable during the intervention periods (Table 6.1.2). 
Table 6.1.1. Baseline characteristics. 
Age (yrs) 
Body weight (kg) 
Supine systolic BP (mmHg) 
Supine diastolic BP (mmHg) 
Pulse rate {beats/min) 
24 h urinary sodium (mmol) 
24 h urinary potassium (mmol) 
24 h urinary creatinine (g) 
Plasma noradrenaline (pg/ml) 
Plasma adrenaline (pg/ml) 
Plasma dopamine (pg/ml) 
Plasma renin (u-units;ml) 
Cardiac output (ljmin) 
Cardiac index (l/minjm2BSAJ 
Mean SD 
24 
77 
143 
78 
68 
141 
71 
1. 67 
302 
91 
72 
12.1 
4.8 
2.7 
3 
11 
14 
10 
10 
46 
22 
0.38 
140 
77 
42 
6.5 
2.0 
1.1 
Table 6.1.2. Effects of sodium restriction with slow-sodium, placebo 
or slow-potassium on urinary electrolyte excretion, body weight, 
pulse rate, plasma catecholamines, plasma renin, cardiac output and 
cardiac index. 
INTERVENTION PERIODS 
Slow-sodium Placebo 
(normal sodium) (low sodium) 
Slow-potassium 
(low sodium; 
high potassium) 
24 h urinary sodium (mmol) 
24 h urinary potassium {mmol) 
Body weight {kg} 
Pulse rate (beatsjmin) 
Plasma noradrenaline (pg/ml) 
Plasma adrenaline (pg/ml) 
Plasma dopamine (pg/ml) 
Plasma renin (u-units;ml) 
Serum sodium (mmol/1) 
Serum potassium (mmol/1) 
Serum creatinine (mg/dl) 
Serum cholesterol (mgj100ml) 
Serum uric acid (mg/dl) 
Cardiac output (ljmin) 
Cardiac index (l/min/m2BSA) 
129+5 
77+4 
74.7+1.6 
70+2 
220+18 
62+5 
112+13 
14.5+1.3 
143.3+0.5 
3.77±0.04 
1. 05:t:O. 02 
184+6 
5.9+0.2 
4.9±0.3 
2.6±0.1 
57±4 ** 
74±3 
74.4±1.6 
68+2 
239+19 
77±9 
98:t:16 
17 .0±1.4 
142.6±0.5 
3.76±0.03 
1.06±0.02 
184+5 
6.0±0.2 
4.6±0.3 
2.4±0.1 
69+6 ** 
131+6 ** 
74 .8±1. 6 
70+2 
225+21 
67+7 
89+12 
17.oj).6 
142.8±0.6 
4.00±0.05 * 
1.07±0.02 
183+5 
5.9±0.2 
4.2+0.2 * 
2.2±0.1 * 
Results are given as mean +SEM. 
* p2 < 0.05, ** p2 < 0.001-with reference to the slow-sodium period. 
Blood pressure 
At the end of the sixth week of the slow-potassium period supine 
systolic pressure was 3.3 mmHg lower than after six weeks of 
slow-sodium (p1 = 0.025). There was no significant change in blood 
143 
pressure after six weeks of sodium restriction alone {Figure 6.1, 
Table 6.1.3). During the slow-potassium period the fall in blood 
pressure was already apparent, although not significant, at the 
third week. Diastolic pressure did not change significantly. Changes 
in sitting blood pressure followed the same pattern but failed to 
reach statistical significance. 
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Figure 6.1. Mean systolic and diastolic blood pressure and 24 
hour urinary electrolyte excretion on slow-sodium, placebo and 
slow-potassium. 
* pl ,.. 0.025. 
Table 6.1.3. Effects of sodium restriction with slow-sodium, placebo or 
slow-potassium on supine blood pressure. 
INTERVENTION PERIODS 
Body weight (kg) 
Supine systolic BP (mmHg) 
Supine diastolic BP (mmHgl 
Supine mean pressure (mmHg) 
Slow-sodium Placebo 
normal sodium) (low sodium) 
74. 7±1.6 
136.5±2.0 
73.3±1.5 
94.3±1.3 
74.4±1.6 
135. 7±1.5 
72. 5±1. 6 
93. 5±1.2 
Results are given as mean ±SEM. 
* pl - 0.025 with reference to the slow-sodium period. 
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Slow-potassium 
(low sodium/ 
high potassium) 
74 .8±1. 6 
133. 2±1. 9 * 
71. 9±1. 5 
92.3±1.2 
Renin and catecholamines 
Plasma renin and catecholamines did not differ significantly between 
the three periods (Table 6.1.2). Baseline dopamine was inversely 
associated with the change in systolic blood pressure during placebo 
(coefficient of linear regression b: -0.4 pg;ml/mmHg, p2 = 0.001), 
and baseline plasma renin was positively associated with changes in 
diastolic pressure in this period of sodium restriction (b - 0.3 
u-units/ml/mmHg, p2 0.12). Baseline plasma renin and 
catecholamines did not correlate significantly with changes in blood 
pressure during high potassium/low sodium intake. 
Haemodynamic changes 
cardiac index was 0.4 l/min/rn2BSA (p2 ~ 0.03) lower after the 
slow-potassium period as compared with the slow sodium period (Table 
6.1.2). Differences in cardiac index between the slow-sodium and the 
placebo periods and between the slow-potassium and the placebo 
periods were not significant. 
Discussion 
The main findings of this study in young people with mildly elevated 
blood pressure are that moderate sodium restriction alone had no 
significant effect on blood pressure, but that blood pressure was 
reduced by a combination of sodium restriction and potassium 
supplementation, 
index. Although 
moderate sodium 
and that this was accompanied by a fall in cardiac 
an overall blood pressure lowering effect of 
restriction was not observed, the greater fall in 
pressure in subjects with low baseline dopamine than in those with 
high dopamine may indicate a characteristic of sodium sensitivity. 
Changes in blood pressure during the intervention periods were not 
significantly related to baseline plasma renin, adrenaline or 
noradrenaline levels. Also, blood pressure changes during sodium 
restriction were not related to changes in plasma renin or 
catecholamines. This is at variance with previous findings 
plasma 
that a 
pressure reducing effect of sodium restriction is associated with a 
concomitant stimulation of renin release.(l8) 
Although the antihypertensive effect of extreme sodium 
restriction are well documented, evidence for a pressure lowering 
action of moderate sodium restriction is equivocal.(3-8) Studies in 
which a blood pressure lowering effect of sodium restriction was 
observed included patients that were more hypertensive and had a 
higher salt intake to begin with, than negative studies. 
Recently two controlled trials on potassium supplementation in 
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hypertensive patients were reported. One study showed no additive 
effect of potassium when combined With sodium r'estriction, whereas 
in a second one a significant fall iri blood 'pressure ·was· .observed 
when potassium was supplied to diuretics treated hypokalemic 
hypertensive subjects.(l9,20) 
There is evidence for an antagonistic role for sodium and 
potassium in blood pressure regulation. Studies in rats showed 
potassium not only to lower blood pressure but to have an additional 
protective eff.ect resulting in a longer life.(21) Several mechanisms 
have been postulated to account for the antihypertensiVe action of 
potassium. The diuretic properties of potassium are well 
established.(9) However, from our data we cannot demonstrate a 
marked diuretic effect as judged by ,changes in .body weight. Also·, 
potassium may modify the neural mechanisms that regulate blood 
pressure, or influence plasma renin concentration. We found no 
significant change in plasma renin and 'catecholatnines, nor was the 
change in blood pressure related to a change in th,ese hormones 
during potassium supplementation. Potassium may also affect 
peripheral resistance· by changing intracellular ion 'concentrations, 
either directly or by alteration of sodium/potassium pump 
aCtivities.(22) The fall in blood pressure during the per~od of high 
potassium/low sodium intake in our. study was· accompanied b,Y a fall 
in cardiac index and an increase .. in serum potassium, whereas mean 
pulse rate and catecholamine levels remained unchanged. This 
observation is compatible with a direct effect of potassium on 
cardiac muscle cells. 
The question whether the fall in blood pressure is the result of 
the increase of potassium intake solely, or of the combined sodium 
restriction/potassium supplementation cannot be answered on the 
basis of our data. Several studies have shown an inverse relation 
between the dietarf'" sodium/potassium ratio and blood 
pressure.(23,24) The rice-fruit diet advocated by Kempner in 1944 as 
treatment of hypertension is known as a rather 
low-sodium diet. Often overlooked, however, is 
unpalatable rigid 
the relatively high 
potassium content of this diet, and th~ resulting considerable 
reduction of the sodium/potassium ratio. we found a difference in 
respon~e to potassium supplementation between those' showing a fall 
in systolic pressure on sodium restriction alone (n = 20), and those 
showing a rise (n = 20). The first group had a mean fall of 5.8 mmHg 
during combined sodium restriction/potassium supplementation, the 
second group a ,fall of 0.8 mrnHg (p2 = ,0.15). This appears to support 
the view: that sodium and potassium should be considered together 
when studying their role in blood pressure regulation. 
Treating high blood pressure by altering dietary intake of 
sodium and potassium is of special importance in young people. 
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"Tracking" studies of blood pressure in children and adolescents 
have shown that the predictive value of blood pressure increases 
with age and stabilizes at about 18 years of age.(25) Since 
hypertension may influence 
and blood pressure by 
vessels or adaptation 
the relation between sodium, potassium 
secundary structural alterations of the 
of pressure regulating mechanisms,(26) 
studying this relation in an early stage, i.e. in young 
hypertensives, might elucidate mechanisms involved in the aetiology 
of hypertension. 
In conclusion, our observations suggest that moderate 
restriction of dietary sodium intake has little effect on the blood 
pressure of young subjects with mildly elevated blood pressure 
levels, but that the combination of moderate sodium restriction with 
high potassium intake may have an antihypertensive effect. This may, 
in part, be due to reduction of the cardiac index. Decreasing the 
dietary sodium/potassium ratio may prove to have a place in the 
early prevention of hypertension. 
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6.2 CALCIUM SUFPLEMENTATION LOWERS DIASTOLIC BLOOD PRESSURE IN 
YOUNG PEOPLE WITH MILD HYPERTENSION 
Introduction 
There is evidence that alterations in calcium metabolism may be 
implicated in the early etiology of primary hypertension.(l,2) 
Recent Studies have suggested that a low dietary calcium intake is 
associated with high blood pressure levels.(3-8) Hypertensive 
subjects appear to have elevated urinary calcium excretion,(9,10) 
and may have reduced serum ionized calcium levels.(l1,12) An 
increased prevalence of hypertension 
with primary hyperparathyroidism.(13) 
has been observed in patients 
There is also evidence that 
levels of plasma parathyroid hormone may be elevated in hypertensive 
patients, thereby suggesting enhanced parathyroid gland function in 
primary hypertension.(10,14,15) A controlled intervention study of 
calciUm versus placebo by Belizan and coworkers showed a blood 
pressure lowering ef,fect of calcium in normotensive students.(16) In 
a randomized crossover study by McCarron and coworkers, 
supplementation with one gram of calcium for eight weeks resulted in 
a fall in blood pressure in hypertensive, but not in normotensive 
subjects.(17) The potential hypotensive action of calcium 
supplementation is of special importance in young subjects and 
patients with mildly elevated blood pressure levels, in whom the 
pharmacological approach to lower blood pressure is relatively 
unattractive.(18,19) 
We conducted a double-blind randomized trial on the effect of 
supplementation with one gram calcium daily during a period of 
twelve weeks in 90 young people with mildly elevated blood pressure. 
We also studied the predictive value of a number of biochemical 
indicators of calcium metabolism for a blood pressure response to 
calcium supplementation. 
METHODS 
Population 
From 1975 to 1980 all 5-19 year old residents of two districts of 
the Dutch town of Zoetermeer were invited to participate in a study 
of blood pressure and other cardiovascular risk indicators (the EPOZ 
study) .(20) Blood pressure was measured in 4,649 out of 5,670 
eligible subjects (82%). Of those ihitially examined, the children 
in the upper decile of the distribution of one or more 
cardiovascular risk indicators were selected for annual follow-up 
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together with a control group randomly drawn from the same 
population. (21) From this cohort of 1,597 children, subj.ects were 
' selected when they had at least. three annual blood pressure readings 
of 140 and/or 90 mmHg ·or over .d~ring seven to , nine years of 
follow-up. Of 130 eligible, 90 yo.ungsters" ,(77 males) aged 16 to 29 
years, agreed to participate in the present study. None of them had 
diagnosed 
medication. 
secondary hypertensiOn or was on antihypertenSive 
Protocol 
After a three week lead-in period during which blood pressure was 
measured twice and two 24 hour urine specimens were collected, the 
study. group attended the exam.in~tion center for baseline 
measurements. The subjects were randomly assigned to one of two 
groups, receiving either 4.17 g c'alcium-ci trate, representing 1 g 
calcium, or a matched placebo containing cellulose, for a period of 
twelve weeks. All participants entered the trial within three weeks. 
Calcium and placebo were provided by way of three times three 
water-soluble powders a day·. No dietary advice was given to the 
participants. During this period blood pressure was measured after 
six and twelve weeks, and four 24 hour urine specimens were 
collected at three week intervals. A venous blood sample was 
obtained at baseline and after twelve weeks. 
Measurements 
Blood pressure was measured on the left arm with a random zero 
sphygmomanometer,(21) by two trained paramedical observers who did 
not know what group the subjects were in. At each occasion a series 
of three readings was made, with the subject sitting, and the mean 
of these readings was used in the analysis. Before the three week 
lead-in period an estimate of dietary calcium intake was obtained by 
A dietitian using a standardized questionnaire. From this 
questio~naire, mean daily calcium intake was calculated using a 
computerized food composition table.(22l Compliance to intervention 
was evaluated by personal contact between staff and participants at 
three week intervals, and by monitoring of the number of powders 
used. Non-compliance was defined 
a period of more then seven 
as cess~tion o~ use of powders for 
consecutive days: five subjects 
receiving placebo fulfilled this receiving calcium and five 
criterion. Serum total calcium, magnesium, total protein, total 
cholesterol and creatinine, and urinary calcium, 
creatinine were measured by standard laboratory 
magnesium 
methods. 
and 
Serum 
ionized calcium was determined by use of a calcium-selective 
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electrode, with adjustments made for differences in serum pH 
(Radiometer) .(23) Intracellular sodium and potassium levels were 
measured in erythrocytes by flame-spectrophotometry as described by 
Lijnen et al.(24) Plasma intact parathyroid hormone 1-84 (PTH) was 
determined with a recently developed two-step immunochemical 
method.(25} Plasma noradrenaline, adrenaline and dopamine were 
measured with a COMT radioenzymatic assay.(26) 
Data analysis 
Our data-analytic approach was threefold. First, the overall effect 
of calcium on blood pressure was examined by comparing the change in 
blood pressure from baseline levels after six and twelve weeks, 
between the calcium and the placebo group. Second, separate analyses 
were performed for the compliers, and for subgroups based on higher 
or lower than median plasma PTH, serum total calcium level and body 
weight at baseline. The latter analyses included all participants in 
the trial. Third, the relation between indices of calcium metabolism 
and· blood pressure, at baseline and during calcium supplementation, 
were studied by linear regression of blood pressure on these 
variables. P~values for the effects of calcium on blood pressure are 
based on a one-tailed test of significance (pl), using at-test for 
unpaired observations. The results of other statistical tests are 
expressed as two-tailed p-values (p2). 
Results 
Baseline characteristics 
The baseline characteristics by treatment group are given in table 
6.2.1. Within the total group both systolic and diastolic blood 
pressure at baseline increased with baseline plasma PTH: b = 2.3 
mmHg/pmol/1 (SE = 1.1, p2 = 0.05), and b = 2.2 mmHg/pmol/1 (SE 
1.1, p2 = 0.05), respectively. PTH showed a significant decrease 
with serum ionized calcium (b = -8.2 pmol/mmol/1, SE = 3.0, p2 
0.02), but not with serum total calcium (b ~ -1.1 pmol/mmol/1, SE = 
0.9, p2- 0.21). Blood pressure was not significantly related to 
serum ionized calcium, nor to serum total calcium. 
Intervention effects on body weight and biochemical variables 
Body weight after six and twelve weeks did not differ from baseline 
values in either group. Also, serum and intracellular electrolytes 
were not significantly different within and between treatment groups 
after twelve weeks of intervention {Table 6.2.2). Although plasma 
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PTH tended to fall more in the calcium treated group, this 
difference failed to reach statistical significance. 24 hour urinary 
calcium excretion during calcium supplementation was on the average 
0.96 mmol/24 hour higher in the calcium treated group (SE ~ 0.35, p2 
0.008). The urinary excretion of other electrolytes remained 
stable during the study. No serious adverse effects of the calcium 
powders were reported. Five participants had short periods of 
diarrhoea, two in the calcium and three in the placebo group. 
Table 6.2.1 Baseline characteristics by treatment group. 
Age (years) 
Male:female (nr) 
Body weight (kg) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Mean arterial pressure (mmHgl 
Pulse rate (beats/min) 
Calcium intake (mgj24h) 
Serum total calcium (mmol/1) 
Serum ionized calcium (mmol/1) 
Serum magnesium (mmol/1) 
Serum total protein (gjl) 
Intracellular sodium (mmol/1) 
Intracellular potassium (mmol/1) 
Plasma PTH (pmol/1) 
Plasma noradrenaline (pg/ml) 
Plasma adrenaline (pg/ml) 
Plasma dopamine (pg/ml) 
Urinary calcium (mmol/24h) 
Urinary magnesium (mmolj24h) 
Urinary creatinine (g/24h) 
Placebo 
In = 44) 
24.6 13.2) 
38,6 
77.5 111.4) 
143.2 110.1) 
82.8 19.71 
103.0 17.71 
77 I 14 I 
1267 15851 
2.36 10.121 
1.26 10.031 
0.88 10.071 
78 17 I 
5.91 10.931 
91.9 13.81 
2.38 11.141 
311 11391 
64 I 46 I 
92 1801 
3.87 12.041 
4.56 12.431 
1.86 10.751 
Standard deviations between brackets. 
calcium 
In - 46) 
23.9 13.11 
39 '7 
78.4 113.31 
143.2 111.01 
83.3 110.61 
103.2 18.61 
78 I 12 I 
1411 1883 I 
2.37 10.121 
1.27 10.031 
0.88 10.061 
77 I 6 I 
6.21 10.931 
92.3 13.31 
2.32 10.831 
354 11631 
68 40 I 
89 871 
4.50 2.051 
4.86 2.211 
1.79 0.671 
Table 6.2.2 Body weight and biochemical variables after twelve weeks 
of intervention in the placebo and in the calcium group. 
Body weight (kg) 
Pulse rate (beatsjmin) 
Serum total calcium (mmol/1) 
Serum ionized calcium (mmoljl) 
Serum magnesium (mmol/1) 
Intracellular sodium (mmoljl) 
Intracellular potassium (mmol/ll 
Plasma PTH (pmoljl) 
Plasma noradrenaline (pgjml) 
Plasma adrenaline (pg/ml) 
Plasma dopamine (pg/ml) 
Urinary calcium (mmolj24h) 
Placebo 
77.7 
78 
2.40 
1.26 
0.85 
6.28 
89.3 
2.08 
289 
54 
101 
3. 71 
I 1. 71 
12 I 
10.021 
0.011 
0.011 
0.16 I 
0.51 
0.111 
I 151 
I 51 
I 121 
I o .25 I 
standard error of the mean between brackets. 
Calcium 
78.8 12.01 
78 12 I 
2.43 10.021 
1.28 10.011 
0.83 10.011 
6.51 10.161 
89.6 10.571 
1.84 10.121 
283 1121 
47 14 I 
117 1121 
4.67 10.241 
p2 
0.67 
0.76 
0.47 
0.07 
0.18 
0.31 
0. 70 
0.15 
0.75 
0.25 
0.34 
0.008 
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Intervention effects on blood pressure 
For the groups as a whole diastolic blood pressure was 3.1 mmHg (SE 
1.7) lower in the calcium treated group than in the placebo 
treated group after six weeks of calcium supplementation, and 2.3 
mmHg (1.9) after twelve weeks (Table 6.2.3). Only small differences 
in systolic blood pressure were observed. When compliers were 
analysed separately, differences in diastolic blood pressure between 
the groups were 5.1 mmHg (1.8) after six, and 3.9 mmHg (2.0) after 
twelve weeks (Table 6.2.4). When all subjects were categorized 
according to baseline PTH levels, those with a higher than median 
plasma PTH level .showed a 6.1 mmHg (2.5) greater fall in diastolic 
blood pressure after six weeks and 5.4 mmHg (2.3) after twelve 
weeks, compared to placebo, while there was no effect on blood 
pressure in the group with a lower than median PTH (Figure 6.2.1). 
When subjects were categorized according to their baseline serum 
total calcium levels, those with a lower than ffiedian serum total 
calcium had a fall in diastolic blood pressure of 6.5 mmHg (2.4) 
after six, and 4.8 mmHg (2.5) after twelve weeks, and no such 
changes were found in those with a higher than median baseline serum 
total calcium (Figure 6.2.2). Finally, the subjects were divided 
according to the median of body weight. In the group with a 
relatively large body weight the difference in systolic blood 
Table 6.2.3 Blood pressure levels at baseline and after six and 
twelve weeks of intervention for the total group (n : 90). 
Baseline 6th week 12th week 
Systolic BP lmmHgl 
Placebo 143.2 I 10.1 I 139.8 19.5 I 139.3 I 10.0 I 
Calcium 143.2 I 11.0 I 138.8 I 13.6 I 138.9 113.51 
P1* 0.29 0.43 
Diastolic BP (mmHg) 
Placebo 82.8 19.71 81.1 18.21 80.7 I 9. 5 I 
Calcium 83.3 110.61 78.5 112.31 78.8 I 9.9 I 
P1 0.04 0.11 
Values are means, standard deviations between brackets. 
* pl values are given for differences from baseline between groups. 
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Table 6.2.4 Blood pressure levels at baseline and after six and 
twelve weeks of intervention for the compliant group (n ~ 80). 
Baseline 6th week 12th week 
Systolic BP (mmHg) 
Placebo 143.7 I 10.3 I 140.3 I 9. 5 I 140.3 19 .a I 
Calcium 143.3 I 11. OJ 138.5 I 13 .a I 138.0 113. 7) 
pl• 0.23 0.17 
Diastolic BP lmmHg) 
Placebo 82.3 19.9 I 81.6 I 8. 0 I 81.0 I 9 .a I 
Calcium 83.3 110.2) 77.5 111. 7) 78.2 I 9.9 I 
p1 0.003 0.03 
Values are means, standard deviations between brackets. 
* pl values are given for differences from baseline between groups. 
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pressure was 5.3 mmHg (2.3) after six weeks, and 1.9 mmHg (2.7) 
after twelve, and in diastolic blood pressure 3.1 mmHg (2.5) and 6.5 
mmHg (2.3), respectively (Figure 6.2.3). The change in plasma PTH 
during calcium supplementation was associated with the change in 
diastolic blood pressure during the trial in the calcium treated 
group (b = 5.3 mrnHg/pmol.l-1, SE = 2.0, p2 = 0.01), but not in the 
placebo group (b = 0.2, SE = 1.1, p2 = 0.84). The difference between 
these 
0. 04 I . 
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regression coefficients was statistically significant lp2 
Discussion 
These observations suggest that calcium supplementation may lower 
diastolic blood pressure in young people with persistently mildly 
elevated blood pressure levels, in particular in youngsters with low 
serum total calcium and/or high plasma PTH levels. Before we quote 
this as support for the hypothesis that altered calcium metabolism 
is implicated in early primary hypertension, some methodological 
issues have to be addressed. 
The level of blood pressure in the study group is relatively low 
by clinical criteria for hypertension. 
much younger than the average patient 
These subjects are, however, 
attending a hypertension 
at multiple clinic. Moreover, blood pressure was assessed 
measurements in different years and the blood pressure levels in 
these youngsters were persistently in the upper range. In 
combination, these findings imply that these young subjects are at 
increased risk of developing severe hypertension in the future.27 
The effect on diastolic blood pressure was greater in those 
compliant to the intervention than in the total group, and 
reductions in blood pressure tended to be larger after six than 
after twelve weeks. This is compatible with a reduced overall 
compliance towards the end of the intervention period. In our 
experience, the use of nine powders a day is an inconvenient way of 
supplying calcium. oral calcium supplementation by one tablet a day 
would have been more appropriate, but it turned out to be impossible 
to obtain well matched placebos. Calcium in a dosage of one gram 
daily did not lead to any demonstrable side effects in this group. 
The individual increase in calcium intake in the calcium treated 
group cannot be determined reliably on the basis of urinary calcium 
excretion. This makes a dose response analysis of the effect of 
calcium supplementation impossible. In this study average daily 
calcium intake was increased by approximately 60%. Whether a greater 
or lesser increase in intake would result in similar blood pressure 
changes remains to be clarified. 
The observation that calcium lowers diastolic blood pressure to 
a greater extent than systolic blood pressure is in agreement with 
the findings of Belizan et 
Carron and coworkers,{17) 
systolic blood pressure 
normotensive subjects. 
al.{16) in normotensive subjects. Me 
however, observed a significant fall in 
in hypertensive patients but not in 
The effect of calcium supplementation 
appears to be restricted to subjects with a higher than median 
plasma PTH and;or a lower than median serum total calcium 
concentration. Furthermore, the change in diastolic blood presscre 
during the trial is positively associated with the change in PTH in 
the calcium treated group. This finding supports the view that 
!57 
enhanced parathyroid 
hypertension.{9,14,15) 
gland activity may be implicated in primary 
A puzling finding is the apparent relation 
between 
cannot 
body 
be 
weight and response to 
readily explained 
calcium, an observation that 
by factors involved in 
obesity-associated hypertension.(28) 
Several mechanisms may explain the effect of calcium on blood 
pressure. Intracellular calcium is the final determinant of the 
excitation contraction coupling and tonic contraction of the smooth 
muscle cell.(29) In hypertensive patients transcellular membrane 
calcium transport and binding kinetics may be changed and 
intracellular calcium may be higher as compared to normotensive 
controls.(7,30,31) Furthermore, in a study by Erne and coworkers a 
strong positive association was observed between intra-platelet 
calcium concentration and mean arterial pressure, in both 
normotensive and hypertensive subjects.{12) This links calcium 
directly to increased peripheral resistance and thereby to the main 
hemodynamic characteristic of primary hypertension.(32) 
Intracellular calcium may be controlled in part by the serum calcium 
concentration and by circulating PTH.(l8,20) In this study no clear 
effects of increased calcium intake on the levels of serum total 
calcium and ionized calcium were observed. Although plasma PTH was 
not significantly reduced in the calcium treated group, the change 
in blood pressure within this group appeared to be related to the 
change in PTH. This suggests that PTH may mediate the effect of 
calcium on blood pressure. Whether the individual change in PTH on 
hypertensive subjects can be used to calcium supplementation 
detect susceptibility to 
in 
calcium merits further evaluation. 
In conclusion, our findings are compatible with the view that a 
subgroup of hypertensive individuals exists, which is susceptible to 
calciu~ supplementation and is characterized by alterations in 
calcium metabolism indicative of a relative calcium need. An 
increase in daily calcium intake may be beneficial in young people 
with mild primary hypertension, in particular in subjects with 
increased plasma PTH and/or reduced serum total calcium levels. 
·~ 
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Chapter 7 
NON-PHARMOCOLOGICAL INTERVENTION ON BLOOD PRESSURE IN THE YOUNG 
161 
7.1 Introduction 
The concept that the roots of primary 
in childhood has become increasingly 
hypertension are to be 
popular.{1,2) It has 
found 
been 
recommended to measure an individual's blood pressure from the age 
of three on.{3) Although this recommendation may seem somewhat 
overenthousiastic, more and more children's blood pressures will be 
measured, and the finding of elevated blood pressure levels in a 
particular child or adolescent will inevitably lead to the question 
how to continue. During the past decades our understanding of the 
natural history of high blood pressure and its determinants has 
greatly expanded. Knowledge of the mechanisms involved is still 
limited, but there are some indications for rational ways of 
influencing blood pressure at an early stage. The question remains, 
whether intervention programs in children with elevated blood 
pressure will prevent the development of future hypertension. At 
present there is much debate regarding this question and the answer 
is likely to be dependent on the level of blood pressure and the age 
of the children involved.(4) In this chapter we will briefly discuss 
strategies of 
hypettension. 
identifying children 
Several approaches to 
with potential 
intervention and 
primary 
studies 
investigating their efficacy will be teviewed. Finally, we will come 
to some conclusion about the current status and directions for 
future research. 
7.2 Blood pressure in children: Approaches and attitudes 
Blood pressure rises in children from birth to after puberty, in 
virtually all populations in all parts of the world.{l,5,6) This 
rise in pressure is closely related to normal growth.{?) The 
question arises whether this rise is perhaps an inevitable 
consequence of maturation and therefore not susceptible to 
intervention at all. Although available data are scarce, it appears 
that at least part of the rise is determined by factors other than 
biological maturation.(8,9) 
When it is accepted 
influenced, two approaches 
approach, aiming primarily 
that children's blood 
may be followed.{lO) 
at certain identified 
pressure may be 
The "high risk" 
individuals with 
actual or potential 
increased risk for 
elevated blood pressure and therefore with an 
cardiovascular morbidity and mortality, or the 
"mass" or "whole population" approach aiming at a general shift of 
the distribution of blood pressure to lower levels. Moreover, as in 
adults, both strategies are not necessarily alternatives, but may 
form complementary means of preventing high blood pressure. In 
children and young adults, the lack of firm evidence relating blood 
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pressure levels to future hypertension and cardiovascular disease 
favours the mass strategy. However, in selected cases of subjects 
consistently in the highest percentiles of the distribution for 
their age and sex, individual treatment may be considered, depending 
on the possibilities of intervention. 
The observation that blood pressure levels in childhood rise 
substantially, adds an attractive perspective to both of these two 
approaches. Apart from aiming at a reduction of the actual blood 
pressure level, the purpose of intervention in children and 
adolescents might be to prevent the blood pressure from rising in 
the future. To summarize the different approaches towards 
non-pharmacologic intervention on blood pressure in the young, four 
patterns may be discriminated. 
1. The "high risk" approach, aiming at a lowering of actual blood 
pressure levels in young subjects at increased risk. 
2. The "high risk" appraoch, aiming at preventing or limiting the 
rise in blood pressure with age in young subjects at increased 
risk. 
3. The "whole population" approach, aiming at an overall shift of 
the blood pressure distribution in the young to lower levels. 
4. The "whole population" approach, aiming at limiting the rise in 
blood pressure during growth and maturation. 
In practice these different appraoches may not be as clearly 
separated, but as a 
this distinction may 
will follow this 
means of delineating strategies of intervention 
be profitable. In the following paragraphs we 
classification 
non-pharmacologic 
young adults. 
intervention on 
when 
blood 
discussing studies on 
pressure in children and 
7.3 The "high riskw approach aiming at a reduction of blood pressure 
level 
7.3.1 Who should be treated? 
Since there is only sparce evidence available 
cardiovascular end organ damage or mortality resulting 
concerning 
from high 
blood pressure in children, the rationale for intervention on blood 
pressure levels in children is based on the concept that the level 
of blood pressure in childhood is related to the level of blood 
pressure later an in life. This view is known as the "tracking" 
phenomenon.(2,11) Tracking describes the stability of rank of an 
individual in the blood pressure distribution over time and may be 
expressed as a "tracking coefficient". There is considerable 
controversy about the magnitude of blood pressure tracking in 
childhood, although the degree of tracking in a series of studies 
I~ 
appears to be moderate.(l2-17) This may be due to methodological 
difficulties in establishing tracking coefficients in populations, 
resulting in random error and an underestimation of the phenomenon. 
Several determinants of future blood pressure levels in children 
have been studied, but the actual blood pressure level appears to be 
the best, though relatively weak, predictor of future blood 
pressure. The predictive value is higher for systolic than for 
diastolic blood pressure and increases with age. Moreover, it has 
been suggested that the predictive value increases when based on 
multiple blood pressure readings on different occasions although 
this has not consistently been observed in different studies. 
In measuring blood pressure 
may be considered. As a rule, 
interpreted relative to the 
in children the following guidelines 
a child's blood pressure must be 
blood pressure distribution of a 
reference group of the same age. Furthermore, the method of blood 
pressure measurement used, and the cirumstances under which the 
readings take place, should closely resemble those applied to the 
reference population.(l8) At present there are no strong arguments 
to ~ay more attention to elevated diastolic than to elevated 
systolic blood pressure levels.(l9) In general the increase in blood 
pressure with age is more pronounced for the systolic blood pressure 
and takes place to a greater extent in boys. 
One may propose an algorithm as a means of selecting those at 
>95<1to 
>950, 
!';.95<1to ______ / 
>950, >95<1to 
6P·M0NITORING + 
NORMAL NON-PHARMACOLOGICAL EFFECTIVE 
MEASURES 
ABNORMAL NON-EFFECTIVE 
NORMAL !sTEpWISE DRUG TREATMENT~ 
ABNORMAL 
I SECONDARY HYPERTENSION C> SPECIFIC TREATMENT 
Figure 7.1. Algor~thm indicating 
detectlon and management of children and 
blood pressure levels. 
the various steps in the 
young adults with elevated 
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risk and eligible for intervention. A schematic and rather arbitrary 
representation is presented in figure 7.1. The scheme is based on a 
relative measure of elevated blood pressure, i.e., a blood pressure 
level equal to or higher than the 95th percentile of the age and sex 
specific blood pressure distribution. In our view there is no 
rationale for the use of an absolute blood pressure level somewhere 
in this scheme above which further action is indicated, apart from 
confirmation to common clinical practice in adults. It can, however, 
be argued that an absolute blood pressure level as a cut-off point 
for increased risk is of value in practice and should therefore be 
used. For reasons of clarity of presentation we have refrained from 
this option in the algorithm. The use of multiple (3) readings to 
assess an elevated pressure not only may increase the predictive 
value, but also substantially reduces the number of subjects 
eligible for further evaluation. 
7.3.2 How should be treated? 
As stated by Oliver,(20) there is a great difference between 
removing a risk factor and introducing a new one such as prescribing 
a drug, and this is especially true for children. Since the 
risk-benefit ratio for drug treatment of hypertension in young 
subjects with mildly elevated blood pressure levels is unknown, the 
primary goal should be to find, and test, means of nonpharmacologic 
intervention.(21) Moreover, the mere existence of an elevated blood 
pressure in a child may constitute increased risk on cardiovascular 
disease half a decade later, but the identification of a young 
individual as a patient may have a serious impact on the rest of his 
or her life.{22) Therefore, when possible, intervention must form an 
integral part of a normal life style, including dietary habits. The 
objectives of any intervention in children can be either to lower an 
already elevated blood pressure level, or to prevent blood pressure 
from rising any further. In this review we will focus on the former, 
since experimental information on the latter in children with 
elevated blood pressure is virtually lacking. Furthermore, we may 
expect these two aspects to go together to some extent. There are 
several factors, related to the level of blood pressure, that may be 
changed in order to evoke changes in blood pressure. Evidence is 
accumulating that body mass and dietary factors are related to blood 
pressure levels, and there are some reports indicating a putative 
role of (lack of) physical activity, noise, the use of oral 
contraceptives and psychosocial stress.{23-28) There is, however, 
only limited information from trials in children and youngsters, in 
which the effect of changes in these factors is tested, thus some 
evidence needs to be inferred from studies in adults.{29l 
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Weight reduction 
Evidence on the effect of reductions in body weight in 
hypertensive adults is inconclusive.(30-32) Moreover, methodological 
problems limit the possibilities of dissociating the effect of 
weight reduction per se from changes in other factors, like salt 
intake, that might affect blood pressure.(33,34) The feasibility of 
weight reduction programs in children was studied by Brownell and 
associates in 42 obese adolescents, normotensive as well as with 
elevated blood pressure.(35) From this study it appeared that 
reductions in weight were larger when the mothers of the children 
studied were involved in the program. Also, significant falls in 
blood pressure were observed, although the lack of a control group 
makes the interpretation of this finding difficult. Future studies 
are needed to establish the value of weight reduction programs in 
children with elevated blood pressure. Until then it appears to be 
justified to pay attention to dietary habits and/or physical 
activity in overweight children with high blood pressure. 
Dietary changes: Sodium and potassium 
A multitude of dietary factors may affect blood pressure and 
they provide a number of ways for single or multiple intervention in 
subjects with elevated blood pressure.(36) Reduction of sodium 
intake to reduce high blood pressure is by far the most 
studied of these factors. While the antihypertensive 
extensively 
effects of 
extreme sodium restriction in severe hypertension are well 
documented, the effects on blood pressure of a more moderate 
reduction of sodium intake, to about 3 to 4 gram NaCl daily, are 
much debated.(37,38) In an analysis of thirteen randomized trials 
the hypotensive effect of a reduction in sodium intake appeared to 
be restricted to older patients with high blood pressure levels.(39) 
This may suggest that sodium restriction per se, is of limited use 
in young subjects with mildly elevated blood pressures. However, a 
subgroup of children and adolescents which is susceptible to sodium 
may exist. As this "sodium sensitivity" may be genetically 
determined, Watt and coworkers studied susceptibility to sodium 
restriction in youngsters from hypertensive parents.(40) No effects 
on blood pressure were observed after fou~ weeks on a low sodium 
diet. Contrary to this, an open study by Skrabal et al. suggests the 
opposite.(41) There are some indications that the intracellular 
sodium concentration may relate to sodium sensitivity.(42) In 
addition, plasma catecholamine levels, and in particular dopamine, 
may give a lead to the efficacy of sodium restriction in an 
individual.(43) To provide a definite answer to the question who 
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will respond to sodium restriction and who will not, clearly more 
studies are needed. Alternatively, not the sodium intake by itself 
but the dietary sodium to potassium ratio may determine the fall in 
blood pressure on intervention.(44) The effect of sodium restriction 
in combination with potassium supplementation was studied in fourty 
young people with persistent mildly elevated blood pressure 
levels.(43) Blood pressure fell significantly after six weeks of 
intervention and was accompanied by a fall in cardiac output. This 
finding is in agreement with an earlier study by Khaw and Thorn in 
twenty young normotensive males.(45) Moreover, on the basis of 
analyses of the relationship between total body sodium and potassium 
with blood pressure levels, Lever and coworkers have suggested that 
potassium is particularly implicated in the early stage of primary 
hypertension, whereas sodium may play a part later on in life.(46) 
These observations look promising, but further studies are needed to 
assess the safety and efficacy of increases in potassium intake, 
whether or not in combination with sodium restriction.(47,48) 
Furthermore, one has to be aware of the risk that changes in one 
dietary constituent result in concurrent changes in other components 
as well. For example, a sodium restricted diet may also reduce 
calcium and vitamin B intake as an unintended consequence.(49) 
Dietary changes: Calcium 
Another component of the diet 
the diet has been associated 
calcium.(50) In a study by 
of which a relative shortage in 
with blood pressure level, is 
Belizan and collaborators, 
calcium daily resulted in a 
significant fall in mean diastolic blood pressure of normotensive 
young adults.(Sl) In a study in ninety young subjects with mildly 
elevated blood pressure levels, a fall in diastolic blood pressure 
was observed after twelve weeks of calcium supplementation.(52) This 
effect appeared to be most prominent in subjects with relatively low 
serum calcium and/or high plasma parathyroid hormone levels. The 
latter finding may provide a way to identify subjects who are 
sensitive to increases in dietary calcium. In a recent study which 
compared hypertensive and normotensive youngsters from the same 
population, raised plasma parathyroid hormone levels were observed 
in hypertensive subjects.(53) Although further experimental evidence 
for a beneficial effect of calcium in children and young adults with 
supplementation with one gram 
elevated blood pressure needs 
investigations look promising.(54) 
to be awaited, these first 
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other dietary factors 
Although several other dietary constituents, like magnesium,(SS) 
poly-unsaturated fatty (PUFA),(56) alcohol,(57) coffee,(58) and 
trace elements,(59) have been implicated in the aetiology of 
hypertension, very limited experimental evidence, in particular in 
young subjects, is available on the blood pressure lowering 
potential of these factors. Studies on the effect on blood pressure 
of magnesium supplementation are equivocal and have only been 
conducted in middle-aged hypertensive patients.(60,61) In a study by 
stern and associates in adolescents with elevated blood pressures, a 
diet rich in PUFA resulted in a fall in systolic and diastolic blood 
pressure.(62) The same was reported in studies in adults.(63,64) The 
use of alcoholic drinks to a total amount of more than 40 grams of 
alcohol per 
sufficient 
day may induce elevation 
data are available to 
of blood pressure in adults. No 
estimate the contribution of 
alcohol to blood pressure in youngsters, nor on the effects of 
lowering alcohol intake on blood pressure levels. The same holds 
true for coffee use. Although trace elements may affect blood 
pressure at very high doses, this appears to be of little relevance 
under physiological circumstances.(59) 
Increasing physical activity 
Both physical fitness and physical activity may be associated 
with blood pressure level.(23) From studies in adults, it appears 
that isotonic excercise may reduce blood pressure in hypertensive 
subjects.(65) A program of excercise training in hypertensive 
adolescents significantly lowered systolic and diastolic blood 
pressure during the study.(66) The effect, however, was not 
sustained after the program had stopped. In a study by Duncan and 
coworkers aerobic excercise for 
and diastolic blood pressure in 
action of the 
sixteen weeks reduced both systolic 
mildly hypertensive patients.(67) 
The hypotensive 
subjects with elevated 
program was 
plasma adrenaline 
be elevated in 
most pronounced in 
levels. As plasma 
catecholamine levels may a 
hypertensive subjects,(68) this may indicate a 
youngsters with elevated blood pressure in 
increases in physical activity might be expected. 
Behavioural modification 
subgroup 
way of 
whom a 
of young 
selecting 
benefit of 
Irrespective of the exact part played by psychological stress in 
the aetiology of high blood pressure,(69) behavioural factors may be 
used to reduce elevated blood pressure levels.(70) In particular, 
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relaxation therapy by biofeedback and yoga techniques have gained 
substantial interest and evidence from studies in humans is 
suggestive that this approach may show favourable results in 
hypertensive subjects.(71,72) However, studies in children and 
adolescents are lacking. As with physical activity, it might be 
suggested that sympathetic nervous system activity is associated 
with a response to behavioural intervention.(73) In this area, more 
studies in younger subjects are clearly indicated. 
7.4 The "high" risk approach aiming at reducing the rise in blood 
pressure 
No studies have been conducted thus far that specifically addressed 
the question whether a further rise in blood 
in children at increased risk, i.e., with 
pressure may be limited 
persistently elevated 
blood pressure levels. As has been mentioned, it is often very 
difficult to clearly discriminate between an effect on the actual 
level and the potential change of blood pressure on intervention. In 
particular, when a given intervention shows to reduce blood pressure 
levels, this implies an effect on blood pressure slope at the same 
time. The reverse, however, may not be true. When a particular 
measure fails to affect blood pressure levels, an effect of the same 
intervention on the change in blood pressure over time can not be 
ruled out unless the groups under study are followed up for a 
considerable period. The latter has, for obvious practical reasons, 
seldomly been accomplished. Because a significant reduction in blood 
pressure rise in high risk youngsters may have a beneficial effect 
on blood pressure levels later on in life, this potential of 
non-pharmacologic intervention clearly merits further investigation. 
7.5 Shifting the distribution of blood pressure levels: The "whole 
population" approach 
The whole population approach is of great interest when aiming at 
prevention of cardiovascular disease by influencing blood pressure 
in childhood. As indicated by Blackburn et al. the distribution of 
risk factors, like hypertension, and their associate lifestyles 
suggests that an unfavorable environment encourages the maximal 
exhibition of susceptible phenotypes in the population.(74) A 
preventive strategy based on this concept attempts to create the 
most favourable environment possible. Thus, the concept that 
"nurture", much as in combination with "nature", influences blood 
pressure, means by definition that intervention is applied at best 
as early as possible, i.e., in childhood. Although some would favor 
a more selective appraoch to achieve an effective control of 
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cardiovascular disease,(75) at least it appears justified to 
stimulate a healthy lifestyle at an early age. Which factors may be 
succesfully influenced to reduce blood pressure levels in children 
is, however, not yet very clear. 
The efficacy of the whole population approach in intervening on 
risk factors for cardiovascular disease is in general evaluated in 
groups of subjects without increased risk, e.g. in normotensive 
intervention studies in individuals. There are limited data from 
normotensive children and adolescents. Some investigators have 
single factor on blood pressure in 
agreement with studies in adults,(76) 
studied the effect 
normotensive children. 
of a 
In 
intervention trials on a reduction in sodium intake in normotensive 
children and adolescents show virtually no effect on blood 
pressure.(41,77,78) It may, however, be that a low sodium intake may 
show an effect only after a prolongued period of time. As discussed 
in the previous paragraphs, there are some indications that 
increased intake of dietary calcium or potassium may reduce blood 
pressure in normotensive adolescents.(46,51) In addition, a 
reduction of body weight may affect blood pressure also in children 
with normal blood pressures.(36) Intuitively, a mass approach to 
blood pressure reduction calls for multiple intervention aiming at 
the combined effect of several changes in lifestyle and dietary 
habits that may be integrated in normal (school-) children's lifes. 
Data on multiple intervention in children, as in adults, are 
inconclusive. Puska and associates did not observe an average fall 
in blood pressure due to intervention after two years, while in New 
York Walter and associates reported significantly lower blood 
pressure levels after one year of multifactorial 
intervention.(79,80) 
7.6 The ~whole population approach aiming at shifting the 
distribution of blood pressure rates of increase 
In children, more than in adults, the whole population approach has 
an interesting additional perspective, namely to prevent the blood 
pressure from rising, or to limit its rate of increase. Partly 
because of logistic and methodological difficulties, studies on this 
subject are very scarce. In the Netherlands Hofman and coworkers 
studied the role of sodium intake in the developement of blood 
pressure during the first six month of life in a double blind 
randomised trial.(81) This observation not only provides a rationale 
for intervention aiming at a reduction of rise, but also offers 
experimental evidence for an aetiological role of dietary sodium in 
the development of elevated blood pressure. The effects of changes 
170 
in other determinants of blood pressure rise have not been formally 
tested. 
7.7 Conclusion and directions for future research 
The measurement of blood pressure levels in children is becoming 
increasingly common. It is, however, still insufficiently clear to 
what extent children's blood pressures are related to blood pressure 
later on in life and in particular to hypertension. Nevertheless, it 
appears to be justified to pay extra attention to those children and 
adolescents persistently in the upper part of their age and sex 
specific blood pressure distribution ("high risk" approach). In 
addition, it may show to be beneficial to encourage a 
"non-hypertensiogenic" lifestyle, including dietary advices, for the 
young population at large ("whole population" approach). However, it 
has to be noted that this benefit, albeit plausible, is not yet 
firmly established. Therefore, there is little justification for 
agressive strategies to achieve this goal. 
Several means of non-pharmacological intervention may be used in 
young mildly hypertensive subjects. Unfortunately, the intervention 
that is the most studied, restriction of sodium intake, appears to 
be of little merit in the young.(40) A number of other factors have 
been less extensively studied and, therefore, still have the benefit 
of the doubt. 
Promising effects of dietary changes have been suggested for 
increases in potassium and/or calcium intake, and an increase in the 
proportion of polyunsaturated fatty acids in the diet. Calcium 
supplementation may show to be most effective in those expressing a 
relative calcium need, as indicated by indices of calcium 
metabolism. The excessive use of alcoholic drinks, and perhaps of 
coffee, should be disencouraged. The efficacy of sodium restriction 
appears to be limited. Future studies 
significance of certain characteristics 
with sodium sensitivity. 
may, however, clarify the 
suggested to be associated 
Weight reduction and increase in physical activity may be aimed 
for in obese children and adolescents with elevated blood 
Relaxation procedures and behavioural modification 
pressure. 
have shown 
promising results in hypertensive adults. It is conceivable that 
this type of intervention is most effective in youngsters with 
elevated plasma catecholamines indicative of raised sympathetic 
nervous system activity. These children and young adults may also be 
susceptible 
programs. 
for the hypotensive action of physical activity 
When non-pharmacological treatment is applied to evaluate its 
efficacy or to clarify mechanisms involved, the modification of only 
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one factor is generally pursued. However, in medical practice the 
before mentioned approaches may well go in combination. 
Approaches to shift the blood pressure distribution in children 
to lower levels may follow the same lines of intervention as in 
children at increased risk. However, even more than in children and 
young adults with 
dietary habits 
elevated blood presssure, changes in lifestyle and 
should be easily integrated in normal life. 
Therefore, these advices will presumably result in a so-called 
"prudent" diet, low in saturated fatty acids and with sufficient 
amounts of potassium and calcium, with moderate use of sodium, 
alcohol and coffee. Furthermore, in obese subjects weight reduction 
is advisable, as is regular physical activity in these and 0ther 
children. There are indications that a limited sodium intake may 
reduce the rise in blood pressure early in life. This observation 
argues against the addition of extra sodium salts to baby food. 
From this review it may be clear that further studies are needed 
in a number of ways. Firstly, the relative contribution of dietary 
and other factors to blood pressure levels is still insufficiently 
established. secondly, there are only limited data on the efficacy 
of changes in diet, body weight, physical activity and psychological 
and social factors in children and young adults with or without 
elevated blood pressure. Thirdly, apart from the blood pressure 
lowering potential of a certain intervention, attention should be 
given to its effect on the rate of change of blood pressure over 
time. 
Future studies should aim at longer periods of intervention and 
evaluate the predictive value of genetic and other factors for a 
blood pressure response to a specific intervention. Moreover, the 
use of double blind procedures to increase validity of results 
should be encouraged. Also, because ultimately the purpose of 
intervention on blood pressure is to reduce cardiovascular risk, the 
effect of non-pharmacological treatment on other risk indicators, 
like serum cholesterol levels, should be monitored. It should be 
noted that, in particular in children, modifaction of a dietary 
factor may result in imbalances in the intake of other, valuable, 
dietary constituents. Finally, still more information is needed on 
determinants of future blood pressure levels in children, other than 
the actual level of blood pressure. In addition, long term follow-up 
of children and young adults may assess and quantify the risk 
associated with high blood pressure at a young age. 
To summarize, data are needed for a more adequate selection of 
young subjects at increased risk, for fu~ther clarification of the 
efficacy of non-pharmacological intervention both for the young 
population as a whole and for individuals at increased risk, and 
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finally for assessment of the predictive value of certain 
characteristics for a specific means of intervention. 
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SUMMARY 
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The studies presented in this thesis were conducted in a population 
of young, non-hospitalized subjects. This opportunity was presented 
by the availability of a large cohort of children and young adults 
that had been followed up for more than seven years as part of the 
Epidemiologic Preventive Organization zoetermeer {EPOZ study), and 
of which a large body of data on blood pressure and other 
characteristics could be used. The basic theme of the studies was to 
elucidate mechanisms involved 
hypertension, with special 
electrolytes. (chapter 1) 
in the early pa~hogenesis 
emphasis on the role 
of 
of 
primary 
dietary 
The effect of changes in electrolyte intake in youngsters 
elevated blood pressure was studied in two randomized trials. 
with 
The 
scientific concept 
in evaluating the 
of the randomized trial is of primary importance 
effect of a certain characteristic, like 
electrolyte intake, on another characteristic, like blood 
Randomization garantuees internal validity of a study with 
pressure. 
regard to 
potential sources of bias. In addition, blinding of participants and 
investigators for the type of intervention during the trial reduces 
the possibility of distortion of the results by information bias. 
Randomization may be accomplished by random assignment of 
individuals to a certain treatment, the parallel-group design, or by 
randomization of treatment periods within an individual, the 
crossover design. Both methods were applied in studies presented in 
this thesis. (chapter 2) 
The main haemodynamic characteristic of hypertension in adults 
is an increase total peripheral resistance. In early hypertension, 
the situation is less clear. Several investigators have suggested 
that a high cardiac output state exists in young subjects with 
elevated blood pressure. 
number of other studies, 
This, however, could not be confirmed by a 
including the one presented in this thesis. 
A major discrepancy between the former and the latter studies is 
that the latter used non-invasive methods to assess cardiac output, 
whereas the former studies used invasive techniques. This could 
account for a difference in stress response between hypertensive and 
normotensive subjects within the various studies leading ot the 
inconclusive findings. In our view, elevated blood pressure at all 
ages is asociated with elevated peripheral resistance. Furthermore, 
significantly elevated plasma catecholamine levels may be present in 
a subgroup of young primary hypertensive subjects. This would 
indicate altered sympathetic nervous system activity in the early 
phase of hypertension. (chapter 3) 
Of all dietary factors related to blood pressure, electrolytes 
have gained major interest. In particular a putative role of sodium 
intake in the aetiology of high blood pressure has bee~ the subject 
of many studies. The magnitude of an effect of sodium on blood 
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pressure is, however, still unclear. Moderate reduction of sodium 
intake appears to be of limited use in those most eligible for 
non-pharmacologic treatment, 
elevated blood pressure. Data 
namely young subjects with mildly 
on the relationships between potassium 
intake of and calcium and blood pressure are more limited. Increased 
potassium and calcium may be associated with lower levels of blood 
pressure. Moreover, supplementation of these electrolytes may have 
an hypotensive effect in both subjects with normal or elevated blood 
pressure. The mechanism by which electrolytes exe~t their effect on 
blood pressure is likely to reside, in part, on a cellular level. 
The final consequence of alterations in cellular electrolyte 
homeostasis would then be an increase in the contractile state of 
vascular smooth muscle cells, leading to a raised circulatory 
resistance and consequently to elevated blood pressure. (chapter 4) 
Plasma levels of catecholamines, plasma renin and cardiac output 
were studied in fourty young hypertensive individuals and an equal 
numbe~ of normotensive subjects, matched for age and gender. To 
eliminate selection bias both groups were drawn from the same 
population. A strictly standardized protocol of measurements assured 
that hypertensive and normotensive 
during the study. The findings 
groups 
in this 
were treated similarly 
study indicate that 
hypertensive and normotensive subjects de not differ significantly 
with regard to plasma renin levels, or cardiac output and cardiac 
index. Also, pulse rates were similar between the groups. However, 
mean plasma noradrenaline, adrenaline and dopamine were all 
significantly higher in the hypertensive group. Furthermore, the 
"normal" interrelation between noradrenaline, adrenaline and blood 
pressure appeared to be altered in hypertensive subjects. 
In two additional studies in groups of hypertensive and 
normotensive individuals, increased levels of plasma intact 
parathyroid hormone, and reduced serum total calcium concntration 
were observed in hypertensive groups, 
reference groups. These findings support 
compared to normotensive 
the hypothesis that altered 
calcium metabolism may be implicated in early primary hypertension. 
(chapter 5) 
The main investigations of this thesis are formed by two 
intervention studies on changes in electrolyte intake and blood 
pressure. (chapter 6) 
In a double blind randomized crossover trial, the effect on 
blood pressure was studied of moderate sodium restriction and 
combined sodium restriction and potassium supplementation in fourty 
young subjects with mildly elevated blood pressure. In this study, 
six weeks of reduced sodium intake showed no significant effect on 
blood pressure. 
supplementation, 
However, when combined with potassium 
a significant fall in systolic blood pressure was 
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observed. The change in blood pressure in the high potassium/low 
sodium period was accompanied by a fall in cardiac index. The latter 
finding may indicate a mechanism where by alterations in dietary 
sodium/potassium ratio may affect blood pressure. 
In a subsequent double blind randomized trial the effect of 
calcium supplementation versus placebo was evaluated in two groups 
of hypertensive youngsters. Supplementation 
daily significantly lowered diastoiliC 
with one gram of calcium 
blood pressure. The 
hypotensive action of calcium was most prominent in subjects with 
relatively high plasma parathyroid hormone levels and/or relatively 
low serum total calcium levels. This observation is compatible with 
the view that a subgroup of hypertensive individuals exists, 
susceptible to calcium supplementation characterized by biochemical 
indications of a relative calcium need. 
In the final chapter of this thesis, ways of non-pharmacological 
intervention in young subjects are discussed. Several approaches may 
be followed. The "whole population" approach, aims at either a 
downward shift of the distribution of blood pressure levels, or an 
average reduction in the rate of increase of blood pressure at an 
early age. Alternati-vely OI" in combination, one might attempt to 
identify those individuals at increased risk for cardiovascular 
disease, as judged by their blood pressure, and lower either their 
blood pressure level or their blood pressure rate of increase, the 
"high risk" approach. Non-pharmacological intervention in youngstei"s 
as well as in older age groups may act by changing body weight, 
dietary habits, or physical activity, OI" by behavioural 
modification. Expei"imental evidence on the efficacy of these 
interventions in the young is, 
studies are needed, with special 
non-pharmacological intei"vention 
however, 
emphasis 
on blood 
in the whole young population as well as 
addition, the predictive value of certain 
characteristics for a specific means 
very limited. Further 
on long-term effects of 
pressure charactei"istics 
in high risk groups. In 
biochemical and other 
of intervention in an 
individual needs to be further clarified. {chapter 7) 
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Chapter 9 
SAMENVATTING 
!83 
De onderzoekingen die in dit proefschrift beschreven worden werden 
uitgevoerd in een populatie van jongeren 
opgenomen waren. Deze mogelijkheid 
beschikbaarheid van een cohort kinderen 
die niet in een ziekenhuis 
werd geboden door de 
en jong volwassenen die 
sinds meer dan zeven jaar deelnamen in een vervolgonderzoek als 
onderdeel van het Epidemiologisch Preventief Onderzoek Zoetermeer 
{EPOZ). Van 
ondermeer de 
deze jongeren was een 
bloeddruk beschikbaar. 
groat 
Het 
aantal gegevens over 
voornaamste doel van de 
onderzoekingen was het inzicht te vergroten in de mechanismen die 
een rol spelen in de vroege pathogenese van primaire hypertensie, 
met speciale aandacht voor electrolyten in de voeding. (hoofdstuk 1) 
In twee interventie onderzoekingen werd de invloed van 
verandering in electrolyt inname op de bloeddruk nagegaan bij 
jongeren met een verhoogde bloeddruk. Bet gerandomiseerde onderzoek, 
de "randomized 
ondubbelzinnige 
zeals electrolyt 
trial", vormt een belangrijke manier om op 
wijze het effect van veranderingen in een factor, 
inname, op een andere factor, zeals de bloeddruk, 
vast te leggen. Bet aselect toewijzen van de deelnemers in een 
onderzoek aan de onderzoeksgroepen (randomiseren) waarborgt de 
interne validiteit van een onderzoek. Daarnaast wordt door het 
dubbel blind uitvoeren van het onderzoek het optreden van inforrnatie 
bias voorkomen. Aselecte toewijzing kan plaatsvinden tussen twee 
groepen, parallele groepen onderzoek of tussen verschillende 
elkaar opvolgende interventie perioden, het cross-over onderzoek. 
Beide methoden werden toegepast bij onderzoekingen beschreven in dit 
proefschrift. {hoofdstuk 2) 
Hypertensie bij volwassenen wordt hemodynamisch gekenmerkt door 
een toegenomen totale perifere weerstand. Bij vroege primaire 
hypertensie is de situatie minder duidelijk. Door verscheidene 
onderzoekers is verondersteld dat bij jongeren met een verhoogde 
bloeddruk sprake is van een toegenomen hartminuut volume. Dit is 
echter door ander onderzoek, waaronder onderzoek beschreven in dit 
proefschrift, niet bevestigd. Een belangrijk verschil tussen deze 
twee waarnemingen wordt gevormd door de toepassing van invasieve 
methoden om het hartminuut volume te bepalen in de eerste groep 
onderzoekingen, terwijl in de tweede groep gebruik werd gemaakt van 
niet invasieve technieken. Een verschil in reactie op invasief 
onderzoek, stress-respons, tussen hypertensieve en normotensieve 
jongeren zou het verschil in bevindingen geheel of ten dele kunnen 
verklaren. waarschijnlijk hangt hoge bloeddruk op elke leeftijd 
samen 
jonge 
met een verhoogde perifere 
leeftijd, sprake van 
weerstand. Tevens is, met name op 
significant verhoogde plasma 
catecholamine spiegels. Dit zou kunnen wijzen op een veranderde 
activiteit van het sympatisch zenuwstelsel in de vroege fase van 
primaire hypertensie. (hoofdstuk 3) 
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Van de 
bloeddruk 
elementen van de voeding waarvan 
verondersteld is hebben met name 
een verband met de 
electrolyten veel 
aandacbt gekregen. Vooral de rol van natrium in de ontwikkeling van 
hypertensie is het onderwerp van veel onderzoek geweest. De mate van 
bet effect van natrium op de bloeddruk is echter nag onvoldoede 
duidelijk. Matige natrium beperking als maatregel ter verlaging van 
een verhoogde bloeddruk blijkt van beperkt belang juist in die 
gevallen waar niet medicamenteuze bebandeling aangewezen lijkt, 
namelijk bij jongeren en patienten met een matig verhoogde 
bloeddruk. Veel minder gegevens zijn voorhanden aangaande bet 
verband tussen kalium en calcium en de bloeddruk. Een verhoogde 
inname van deze electrolyten lijkt echter samen te gaan met een 
lagere bloeddruk. Daarnaast leidt verhoging van de inname van kalium 
en calcium mogelijk tot verlaging van de bloeddruk zowel bij 
normotensieve als hypertensieve personen. 
De wijze waarop electrolyten de bloeddruk kunnen beinvloeden 
lijkt onder andere te verlopen via mechanismen op cellulair niveau. 
Het uiteindelijke gevolg van veranderingen in electrolythuishouding 
zou dan een toename van de 
in de vaatwand zijn, met 
weerstand en verhoging van 
Plasma spiegels van 
contractietoestand van de gladde 
als gevolg een toename van de 
de bloeddruk. (hoofdstuk 4) 
catecholaminen en renine 
spiercel 
perifere 
en bet 
hartminuutvolume werden onderzocht bij veertig jongeren met een 
verboogde bloeddruk en veertig normotensieve jongeren van gelijke 
leeftijd en geslacht. Beide groepen jongeren waren afkomstig uit 
dezelfde bronpopulatie en werden onderzocht volgens eenzelfde 
protocol om de invloed van verstorende variabelen zoveel mogelijk te 
beperken. 
hebben en 
De twee groepen bleken gelijke plasma 
oak het hartminuut volume verschilde 
renine spiegels te 
niet. Er werden 
echter grate verschillen gevonden in de gemiddelde plasma 
noradrenaline, adrenaline en dopamine concentraties die allen hager 
waren in de hypertensieve groep. Daarnaast leek bet "normale" 
verband tussen deze catecholaminen en de bloeddruk veranderd bij de 
jongeren met een verhoogde bloeddruk. 
In twee 
normotensieve 
volgende onderzoekingen in 
en hypertensieve personen 
vergelijkbare groepen 
werden verhoogde plasma 
bijschildklierhormoon en verlaagde serum totaal calcium spiegels 
gevonden in de hypertensieve groep. Deze bevindingen ondersteunen de 
veronderstelling dat veranderingen in de calciumhuishouding een rol 
spelen in vroege primaire hypertensie. (hoofdstuk 5) 
De voornaamste deel van dit proefschrift wordt gevormd door twee 
interventie onderzoekingen naar de invloed van veranderingen in 
electrolyt inname op de bloeddruk. (hoofdstuk 6) 
In een dubbelblind gerandomiseerd cross-over onderzoek werd het 
effect van een verlaging van de natrium inname, al dan niet 
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gecombineerd met een verhoging van de kalium inname, nagegaan bij 
veertig jongeren met een matig verhoogde bloeddruk. In dit onderzoek 
bleek zes weken natriurnbeperking geen significante verlaging van de 
bloeddruk te veroorzaken. De combinatie van een !age natrium inname 
en een verhoogde kalium inname leidde echter tot een verlaging van 
de bloeddruk die samen bleek te gaan met een verlaging van het 
hartminuutvolume. Deze bevinding vormt een aanwijzing over de wijze 
waarop veranderingen in dietaire natrium/kalium ratio de bloeddruk 
kunnen beinvloeden. 
Vervolgens werd een dubbelblind gerandomiseerd onderzoek 
uitgevoerd, waarbij het effect van extra calcium versus een placebo 
werd vergeleken in twee groepen hypertensieve jongeren. Dagelijkse 
inname van een extra hoeveelheid van een gram calcium bleek de 
diastolische bloeddruk te verlagen. 
uitgesproken bij diegenen met 
bijschildklierhorrnoon spiegels en;of een 
calcium concentratie. 
hypothese dat een deel 
Deze bevinding is 
van de personen 
Dit effect was het meest 
relatief lage plasma 
relatief hoge serum totaal 
in overeenstemrning met de 
met verhoogde bloeddruk 
geveolig is voor een verhoging van de calcium inname en dat deze 
groep gekenmerkt wordt door biochemische aanwijzingen van een 
relatief calcium tekort. 
Het laatste hoofdstuk van dit proefschrift bespreekt de 
mogelijkheden van niet medicaroenteuze beinvloeding van de bloeddruk 
op jonge leeftijd. Hierbij kunnen verschillende benaderingen gekozen 
worden. De "bevolkings" aanpak streeft ernaar de bloeddruk verdeling 
in een bevolking in z'n geheel naar lagere waarden te verschuiven of 
de toename van de bloeddruk met de leeftijd in een bevolking 
gemiddeld te verlagen. Daarnaast kan, al of niet in combinatie met 
de eerste aanpak, gekozen worden tot het opsporen van personen met 
een verhoogd risico op hartvaatziekten op basis van een verhoogde 
bloeddruk en kan geprobeerd worden deze bloeddruk te verlagen. De 
tweede aanpak wordt de "hoog risico" benadering genoemd. Niet 
medicamenteuze beinvloeding van de bloeddruk kan plaatsvinden via 
een verlaging van het lichaarnsgewicht, verandering van 
voedingsgewoonten, toename van de lichamelijke activiteit of 
beinvloeding van het gedrag. Experimenteel onderzoek naar de 
effectiviteit van deze vormen van bloeddrukverlaging is echter neg 
maar zeer beperkt verricht. Verder onderzoek, met speciale aandacht 
voor de lange termijn gevolgen van niet medicamenteuze beinvloeding 
van de bloeddruk op jonge leeftijd, is noodzakelijk zowel voor de 
"bevolkings" als de "hoog risico" aanpak. Daarnaast verdient de 
voorspellende waarde van biochemische en andere karakteristieken 
nader aandacht. (hoofdstuk 7) 
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If therefore some may apt to think that I have sometimes too far 
indulged conjecture, in the inferences I have drawn from the events 
of some experiments; they ought to consider that it is from these 
kinds of conjectures that fresh discoveries first take their rise; for 
tho' some of them may prove false, yet they often lead to further 
and new discoveries. 
Stephen Hales 
Haemastatics (1733) 
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